1. A compound of Formula I: (Formula Removed) where: R1 is hydrogen, R2, R3, and R4 are each hydrogen; R5 is hydrogen; R6 is-NR10R11; R7 is halo; R8 is hydrogen; R is hydrogen; R10 is Ph2-methyl or Ar1- methyl; R1 is hydrogen; Ph1 is phenyl optionally substituted with 1 to 5 independently selected halo substituents, or with 1 to 3 substituents independently selected from the group consisting of halo, cyano, -SCF3, (C1-C6)alkyl optionally further substituted with 1 to 6 fluoro substituents, and (C1-C6)alkoxy optionally further substituted with 1 to 6 fluoro substituents; Ph2 is phenyl substituted with R12 and optionally further substituted with 1 or 2 substituents independently selected from the group consisting of halo, cyano, -SCF3, methyl, -CF3, methoxy, -OCF3, nitro, and hydroxy; Ar1 is 5-R13-pyridin-2-yl or 6-R13-pyridin-3-yl optionally further substituted with one or two substituents independently selected from the group consisting of halo, cyano, methyl, -CF3, hydroxy, and methoxy; R12 is a substituent selected from the group consisting of: a) Het1-(Co-C5)alkyl optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; b) Het2-(Co-C3)alkyl optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; c) Het3-(Co-C3)alkyl optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; d) Ar2-(Co-C3)alkyl optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; e) (C1-C6)alkyl-C(R14)=C(R14)- optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; f) (R14)2C=C[(Ci-C6)alkyl]- optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; g) (C3-C7)cycloalkyl-(Co-C3)alkyl-C(R14)-C(R15)- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; h) (R15)CH=C[(C3-C7)cycIoalkyl-(Co-C3)alkyl]- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; i) (C1-C6)alkyl-C≡C- optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; j) (C3-C7)cycloalkyl-(Co-C3)alkyl-C=C- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; k) (C3-C7)cycloalkyl-(Co-C3)alkyl-C(O)-(C1-C5)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; 1) Ph1-(Co-C3)alkyl-C(O)-(C1-C5)alkyl optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; m) pyridyl-(Co-C3)alkyl-C(O)-(C1-C5)alkyl, optionally substituted on the pyridyl moiety with 1 to 3 substituents independently selected from the group consisting of halo, (C1-C3)alkyl, (C1-C3)alkoxy, -CF3, -O-CF3, nitro, cyano, and trifluoromethylthio, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; n) (C1-C6)alkyl-O-(C1-C3)alkyl-C(O)- optionally substituted on the (C1-C6)alkyl moiety with 1 to 6 fluoro substituents and independently optionally substituted on the (C1-C3)alkyl moiety with 1 to 4 fluoro substituents; o) (C3-C7)cycloalkyl-(C0-C3)alkyl-O-(C1-C3)alkyl-C(O)- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; p) Ph1-(Co-C3)alkyl-O-(C1-C3)alkyl-C(O)- optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; q) (C1-C6)alkyl-S-(C1-C3)alkyl-C(O)- optionally substituted on the (C1-C6)alkyl moiety with 1 to 6 fluoro substituents and independently optionally substituted on the (C1-C3)alkyl moiety with 1 to 4 fluoro substituents; r) (C3-C7)cycloalkyl-(Co-C3)alkyl-S-(C1-C3)alkyl-C(O)- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; s) Ph1-(C0-C3)alkyl-S-(C1-C3)alkyl-C(O)- optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; t) (C1-C6)alkyl-NR16-(C1-C3)alkyl-C(O)- optionally substituted on the (C1-C6)alkyl moiety with 1 to 6 fluoro substituents and independently optionally substituted on the (C1- C3)alkyl moiety with 1 to 4 fluoro substituents; u) (C3-C7)cycloalkyl-(Co-C3)alkyl-NR16-(C1-C3)alkyl-C(O)- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; v) Ph1-(Co-C3)alkyl-NR16-(C1-C3)alkyl-C(O)- optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; w) (C1-C6)alkyl-O-(C1-C3)alkyl-SO2- optionally substituted on the (C1-C6) alkyl moiety with 1 to 6 fluoro substituents and independently optionally substituted on the (C1-C3)alkyl moiety with 1 to 4 fluoro substituents; x) (C3-C7)cycloalkyl-(C0-C3)alkyl-O-(C1-C3)alkyl-SO2- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; y) Ph1-(C0-C3)alkyl-O-(C1-C3)alkyl-SO2- optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; z) (C1-C6)alkyl-S-(C1-C3)alkyl-SO2- optionally substituted on the (C1-C6)alkyl moiety with 1 to 6 fluoro substituents and independently optionally substituted on the (C1-C3)alkyl moiety with 1 to 4 fluoro substituents; k) (C3-C7)cycloalkyl-(Co-C3)alkyl-S-(C1-C3)alkyl-SO2- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; l) Ph'(Co-C3)alkyl-S-(C1-C3)alkyl-SO2- optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; ac) (C1-C6)alkyl-NR16-(C1-C3)alkyl-SO2- optionally substituted on the (C1-C6)alkyl moiety with 1 to 6 fluoro substituents and independently optionally substituted on the (C1-C3)alkyl moiety with 1 to 4 fluoro substituents; n) (C3-C7)cycloalkyl-(Co-C3)alkyl-NR16-(C1-C3)alkyl-SO2- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; o) Ph1-(Co-C3)alkyl-NR16-(C1-C3)alkyl-SO2- optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; p) R17R18-N-C(O)-(C1-C5)alkyl optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; q) RI7Rl8-N-C(S)-(C1-C5)alkyl optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; ah) (C3-C7)cycloalkyl-(Co-C3)alkyl-S- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; ai) (C3-C7)cycloalkyl-(Co-C3)alkyl-S-(C1-C5)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; aj) Ph'-(Co-C3)alkyl-S-(C1-C5)alkyl optionally substituted on the (C1-C5)alkyl moiety with 1 to 6 fluoro substituents and independently optionally substituted on the -(Co-C3)alkyl moiety with 1 to 4 fluoro substituents; ak) Ar3-(Co-C3)alkyl-S-(C1-C5)alkyl optionally substituted on the (C1 -C5) alkyl moiety with 1 to 6 fluoro substituents and independently optionally substituted on the -(Co-C3)alkyl moiety with 1 to 4 fluoro substituents; al) Ar3-(Co-C3)alkyl-O-(C1-C5)alkyl optionally substituted on the (C1-C5)alkyl moiety with 1 to 6 fluoro substituents and independently optionally substituted on the -(Co- C3)alkyl moiety with 1 to 4 fluoro substituents; am) Het1-(Co-C3)alkyl-S-(Co-Cs)alkyl wherein Het1 is linked through any carbon atom of Het and wherein the (Co-C5)alkyl moiety is optionally substituted with 1 to 6 fluoro substituents and independently optionally substituted on the -(Co-C3)alkyl moiety with 1 to 4 fluoro substituents; an) Het1-(Co-C3)alkyl-O-(Co-C5)alkyl wherein Het1 is linked through any carbon . atom of Het1 and wherein the (Co-C5)alkyl moiety is optionally substituted with 1 to 6 fluoro substituents and independently optionally substituted on the -(C0-C3)alkyl moiety with 1 to 4 fluoro substituents; ao) Het2-(C0-C3)alkyl-S-(Co-C5)alkyl optionally substituted on the (C0-C5)alkyl moiety with 1 to 6 fluoro substituents and independently optionally substituted on the -(Co-C3)alkyl moiety with 1 to 4 fluoro substituents; ap) R16R19-N-C(O)-S-(Co-C5)alkyl optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; aq) R16Rl9-N-C(O)-O-(C0-C5)alkyl optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; ar) R16R19-N-C(O)-NRl6-(C0-C5)alkyl optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; as) (C1-C6)alkyl-C(O)-(C1-C3)alkyl-S- optionally substituted on the (C1-C6)alkyl moiety with 1 to 6 fluoro substituents and independently optionally substituted on the (C1-C3)alkyl moiety with 1 to 4 fluoro substituents; at) (C1-C6)alkyl-SO2-(C1-C3)alkyl-S- optionally substituted on the (C1-C6)alkyl moiety with 1 to 6 fluoro substituents and independently optionally substituted on the (C1-C3)alkyl moiety with 1 to 4 fluoro substituents; au) (C3-C7)cycloalkyl-(C0-C3)alkyl-C(O)-(C1-C3)alkyl-O- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; av) (C3-C7)cycloalkyl-(C0-C3)alkyl-SO2-(C1-C3)alkyl-O- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; aw) (C3-C7)cycloalkyl-(Co-C3)alkyl-C(O)-(C1-C3)alkyl-S- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; ax) (C3-C7)cycloalkyl-(Co-C3)alkyl-SO2-(C1-C3)alkyl-S- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; ay) Ph1-(Co-C3)alkyl-SO2-(C1-C3)alkyl-O- optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; az) Ph1-(Co-C3)alkyl-C(O)-(C1-C3)alkyl-S- optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; u) Ph'-(Co-C3)alkyl-SO2-(C1-C3)alkyl-S- optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; v) Rl7Rl8N-C(O)-(C1-C3)alkyl-S- optionally substituted on the alkyl moiety with l to 4 fluoro substituents; be) R17RlsN-C(S)-(C1-C3)alkyl-S- optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; x) R17R18N-C(S)-(C 1-C3)alkyl-O- optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; y) (C3-C7)cycloalkyl-(Co-C3)alkyl-SO2-(C1-C5)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents and further optionally substituted on the (C1-C5)alkyl moiety with 1 to 6 fluoro substituents; bf) Ph1-(Co-C3)alkyl-SO2-(C1-C5)alkyl optionally substituted on the (C0-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (CrC5)alkyl moiety with 1 to 6 fluoro substituents; bg) Ar3-(Co-C3)alkyl-SO2-(C1-C5)alkyl optionally substituted on the (C0-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (C1- C5) alkyl moiety with 1 to 6 fluoro substituents; bh) Het2-(Co-C3)alkyl-SO2-(C0-C5)alkyl optionally substituted on the (C0-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (C1- C5)alkyl moiety with 1 to 6 fluoro substituents; bi) R17R18N-(C1-C3)alkyl optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; bj) (C1-C6)alkyl-C(O)-N(R16)-(C0-C5)alkyl optionally substituted on either or both alkyl moieties independently with 1 to 6 fluoro substituents; bk) (C3-C7)cycIoaIkyl-C(O)-N(R16)-(Co-C5)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; bl) Ph1-(Co-C3)alkyl-C(O)-N(R16)-(Co-C5)alkyl optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Co-C5)alkyl moiety with 1 to 6 fluoro substituents; bm) Ar3-(Co-C3)alkyl-C(O)-N(R16)-(C0-C5)alkyl optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Co-Cs)alkyl moiety with 1 to 6 fluoro substituents; bn) (C1-C6)alkyl-C(S)-N(R16)-(Co-C5)alkyl optionally substituted on either or both alkyl moieties independently with 1 to 6 fluoro substituents; bo) (C3-C7)cycloalkyl-C(S)-N(R16)-(Co-C5)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; bp) Ph1-(Co-C3)alkyl-C(S)-N(R16)-(C0-C5)alkyl optionally substituted on the (Co- C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Co-C5)alkyl moiety with 1 to 6 fluoro substituents; bq) Ar3-(Co-C3)alkyl-C(S)-N(R16)-(C0-C5)alkyl optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Co-Cs)alkyl moiety with 1 to 6 fluoro substituents; br) (Ci-C6)alkyl-O-N=C(CH3)- optionally substituted on the (Ci-C6)alkyl moiety with 1 to 6 fluoro substituents; bs) (C0-C3)alkyl-O-N=C[(C1-C6)alkyl]- optionally substituted on the (C0-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (C1-C6)alkyl moiety with 1 to 6 fluoro substituents; bt) HO-N=C[(C0-C1)alkyl-(C3-C7)cycloalkyl]- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 2 fluoro substituents; bu) CH3-O-N=C[(C0-C1)alkyl-(C3-C7)cycloalkyl]- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 2 fluoro substituents; R13 is a substituent selected from the group consisting of: a) Het -(Co-C3)alkyl optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; b) Het3-(Co-C3)alkyl optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; c) Ar -(Co-C3)alkyl optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; d) (C1-C6)alkyl-C(Rl4)=C(R14)- optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; e) (R14)2C=C[(C1-C6)alkyl]- optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; f) (C3-C7)cycloalkyl-(C0-C3)alkyl-C(R14)=C(R15)- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; g) (R15)CH=C[(C3-C7)cycloalkyl-(Co-C3)alkyl]- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; h) (C1-C6)alkyl-C=C- optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; i) (C3-C7)cycloalkyl-(Co-COalkyl-C≡C- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the alkyl moiety with 1 to 2 fluoro substituents; j) (C1-C6)HIlCyI-O-(C i-CsAlkyl optionally optionally substituted on either or both alkyl moieties independently with 1 to 6 fluoro substituents; k) (C3-C7)cycloalkyl-(Co-C3)aIkyl-O-(Co-C5)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents and further optionally substituted on the (Co-C5)alkyl moiety with 1 to 6 fluoro substituents; 1) Ph1-(Co-C3)alkyl-O-(C0-C5)alkyl optionally substituted on the (C0-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Co- C5)alkyl moiety with 1 to 6 fluoro substituents; m) Ar3-(Co-C3)alkyl-O-(Co-C5)alkyl optionally substituted on the (C0-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Co-C5)alkyl moiety with 1 to 6 fluoro substituents; n) Het2-(Co-C3)alkyl-O-(C0-C5)alkyl optionally substituted on the (C0-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Co-C5)alkyl moiety with 1 to 6 fluoro substituents; o) (C3-C7)cycloalk;yl-(C0-C3)alkyl-C(O)-(C1-C5)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents and further optionally substituted on the (C1-C5)alkyl moiety with 1 to 6 fluoro substituents; p) Phl-(C0-C3)alkyl-C(O)-(C1-C5)alkyl optionally substituted on the (C0-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (C1-C5)alkyl moiety with 1 to 6 fluoro substituents; q) pyridyl-(Co-C3)alkyl-C(O)-(C1-C5)alkyl optionally be substituted on the pyridyl moiety with 1 to 3 substituents independently selected from the group consisting of halo, (C1-C3)alkyl, (C1-C3)alkoxy, -CF3, -O-CF3, nitro, cyano, and trifluoromethylthio, and independently optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents, and independently optionally substituted on the (C1-C5)alkyl moiety with 1 to 6 fluoro substituents; r) (C1-C6)alkyl-C(O)-(C1-C3)alkyl-O- optionally substituted on the (C1-C6)alkyl moiety with 1 to 6 fluoro substituents and independently optionally substituted on the (C1-C3)alkyl moiety with 1 to 4 fluoro substituents; s) (C3-C7)cycloalkyl-(C0-C3)alkyl-C(O)-(C1-C3)alkyl-O- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both of the alkyl moieties independently with 1 to 4 fluoro substituents; t) Ph1-(C0-C3)alkyl-C(O)-(C1-C3)alkyl-O- optionally substituted on either or both of the alkyl moieties independently with 1 to 4 fluoro substituents; u) pyridyl-(Co-C3)alkyl-C(O)-(C1-C3)alkyl-O- optionally be substituted on the pyridyl moiety with 1 to 3 substituents independently selected from the group consisting of halo, (C1-C3)alkyl, (CrC3)alkoxy, -CF3, -O-CF3, nitro, cyano, and trifluoromethylthio, and independently optionally substituted on either or both of the alkyl moieties independently with 1 to 4 fluoro substituents; v) R17R18N-C(O)-(C1-C3)alkyl-O- optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; w) R17R18N-C(S)-(C1-C3)alkyl-O- optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; x) (C3-C7)cycloalkyl-(Co-C3)alkyl-S- substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both of the alkyl moieties independently with 1 to 4 fluoro substituents; y) (C1-C6)ahcyl-S-(C1-C5)alkyl optionally substituted on either or both alkyl moieties independently with 1 to 6 fluoro substituents; z) (C3-C7)cycloalkyl-(C0-C3)alkyl-S-(C1-C5)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents, and independently optionally substituted on the (C1-C5)aDcyl moiety with 1 to 6 fluoro substituents; k) Ph1-(Co-C3)alkyl-S-(C1-C5)alkyl optionally substituted on the (C0-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (C1-C5)alkyl moiety with 1 to 6 fluoro substituents; l) Ar3-(Co-C3)alkyl-S-(C1-C5)alkyl optionally substituted on the (C0-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (C1-C5)alkyl moiety with 1 to 6 fluoro substituents; m) (C1-C6)alkyl-C(O)-(C1-C3)alkyl-S- optionally substituted on the (C1-C6)alkyl moiety with 1 to 6 fluoro substituents and independently optionally substituted on the (C1-C3)alkyl moiety with 1 to 4 fluoro substituents; n) (C3-C7)cycloalkyl-(Co-C3)alkyl-C(O)-(C1-C3)alkyl-S- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both of the alkyl moieties independently with 1 to 4 fluoro substituents; ae) Ph1-(C0-C3)alkyl-C(O)-(C1-C3)alkyl-S- optionally substituted on either or both of the alkyl moieties independently with 1 to 4 fluoro substituents; p) pyridyl-(C0-C3)alkyl-C(O)-(C1-C3)alkyl-S- optionally be substituted on the pyridyl moiety with 1 to 3 substituents independently selected from the group consisting of halo, (C1-C3)alkyl, (C1 -C3) alkoxy, -CF3, -0-CF3, nitro, cyano, and trifiuorometliylthio, and independently optionally substituted on either or both of the alkyl moieties independently with 1 to 4 fluoro substituents; q) R17R18N-C(O)-(C1-C3)alkyl-S- optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; ah) R17Rl8N-C(S)-(C1-C3)alkyl-S- optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; ai) (C1-Co)alkyl-SO2-(C0-C5)alkyl optionally substituted on either or both of the alkyl moieties independently with 1 to 6 fluoro substituents; aj) (C3-C7)cycloalkyl-(C0-C3)alkyl-SO2-(C0-C5)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents, and independently optionally substituted on the (Co-Cs)alkyl moiety with 1 to 6 fluoro substituents; ak) Ph1-(Co-C3)alkyl-SO2-(C0-C5)alkyl optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Co-C5)alkyl moiety with 1 to 6 fluoro substituents; al) Ar3-(Co-C3)alkyl-SO2-(C0-C5)alkyl optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Co-C5)alkyl moiety with 1 to 6 fluoro substituents; am) Het2-(Co-C3)alkyl-SO2-(C0-C5)alkyl optionally substituted on the (C0-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Co-C5)alkyl moiety with 1 to 6 fluoro substituents; an) R17R18-N-C(O)-(C1-C5)alkyl optionally substituted on the (C1-C5)alkyl moiety with 1 to 6 fluoro substituents; ao) R17R18-N-C(S)-(C1-C5)alkyl optionally substituted on the (C1-C5)alkyl moiety with 1 to 6 fluoro substituents; ap) R17R18N-(C1-C3)alkyl optionally substituted on the (C1-C3)alkyl moiety with 1 to 4 fluoro substituents; aq) (C1-C6)alkyl-C(O)-N(R16)-(C0-C5)alkyl optionally substituted on either or both of the alkyl moieties independently with 1 to 6 fluoro substituents; ar) (C3-C7)cycloalkyl-C(O)-N(R16)-(C0-C5)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the (C0-C5)alkyl moiety with 1 to 6 fluoro substituents; as) Ph,-(C0-C3)alkyl-C(O)-N(Rl6)-(C0-C5)alkyl optionally substituted on the (C0-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Co-C5)alkyl moiety with 1 to 6 fluoro substituents; at) Ar3-(C0-C3)alkyl-C(O)-N(R16)-(C0-C5)alkyl optionally substituted on the (C0-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Co-C5)alkyl moiety with 1 to 6 fluoro substituents; au) (C1-C6)alkyl-C(S)-N(R16)-(C0-C5)alkyl optionally substituted on either or both of the alkyl moieties independently with 1 to 6 fluoro substituents; av) (C3-C7)cycloalkyl-C(S)-N(R16)-(C0-C5)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the (C0-C5)alkyl moiety with 1 to 6 fluoro substituents; aw) Ph1-(C0-C3)alkyl-C(S)-N(R16)-(C0-C5)alkyl optionally substituted on the (C0-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (C0-C5)alkyl moiety with 1 to 6 fluoro substituents; ax) Ar3-(C0-C3)alkyl-C(S)-N(R16)-(C0-C5)alkyl optionally substituted on the (C0-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Co-Cs)alkyl moiety with 1 to 6 fluoro substituents; R14 is hydro gen or (C1- C2)alkyl optionally substituted with 1 to 5 fluoro substituents; R15 is hydrogen or methyl optionally substituted with 1 to 3 fluoro substituents; R16 is hydrogen or (C1-C3)a!kyl optionally substituted with 1 to 5 fluoro substituents; R17 is (C1-C6)alkyl optionally substituted with 1 to 6 fluoro substituents, Ph1(C1- C3)alkyl optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents, or (C3-C7)cycloalkyl-(C0-C3)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents independently selected from methyl and fluoro and independently optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; R18 is hydrogen or (C1-C3)alkyl, or R17 and R18 taken together with the nitrogen atom to which they are attached, form Het1, imidazolidin-2-onyl, imidazolidin-2,4-dionyl, or tetrahydropyrimidin-2-onyl optionally substituted with 1 or 2 methyl substituents; R19 is (C1-C3)alkyl optionally substituted with 1 to 5 fluoro substituents; Ar is an aromatic heterocycle substituent selected from the group consisting of pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, 1,2,3-oxadiazolyl, 1,2,4- oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, thiophenyl, thiazolyl, isothiazolyl, and 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,2,3- triazolyl, 1,2,4-triazolyl, wherein the heterocycle is substituted with R15R17N-, wherein R15 is hydrogen and R17 is (C1- C6) alkyl or (C3-C7) cycloalkyl or (C0- C3 ) alkyl R17NH-C(O)-, R17C(O)NH-, R17O-C(O)NH-, (d-C6)alkyl-C(O)-, (C3- C7)cycloalkyl-(C0-C3)alkyl-C(O)-, (C3-C7)cycloalkyl-(C0-C3)alkyl, N-linked Het1, and N-linked Het1-C(O)-, and which is optionally further substituted with a substituent selected from the group consisting of methyl, cyano, halo, and trifluoromethyl; Ar3 is an aromatic heterocycle substituent selected from the group consisting of pyrrolyl, furanyl, thiophenyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, and pyridyl, any of which may optionally be substituted with 1 to 3 substituents independently selected from the group consisting of halo, (C1-C3)alkyl, (C1- C3)alkoxy, -CF3, -O-CF3, nitro, cyano, and trifluoromethylthio; Het is a saturated, nitrogen-containing heterocycle substituent selected from the group consisting of pyrrolidinyl, piperidinyl, homopipei'idinyl, morpholinyl, thiomorpholinyl, homomorpholinyl, and homothiomorpholinyl, any of which may optionally be substituted with (C1-C6) alkyl or with 2 methyl substituents; Het2 is a saturated, oxygen-containing heterocycle substituent selected from the group consisting of tetrahydrofuranyl and tetrahydropyranyl, any of which may optionally be substituted with (C1-C6)alkyl or with 2 methyl substituents; Het3 is a nitrogen containing heterocycle selected from the group consisting of pyrrolidin- 2-onyl, piperidin-2-onyl, oxazolidin-2-onyl, pyrrolin-2-onyl, and dihydropyridin-2- onyl; or a pharmaceutically acceptable salt or solvate thereof.

2. The compound as claimed in claim 1, which is selected from: 7-Chloro-6-[4-(l-methoxyimino-ethyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(l-ethoxyimino-ethyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(l-iso-butoxyimino-ethyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo [d]azepine; 7-Chloro-6-[4-(l-hydroxyimino-3-methyl-butyl)-benzyIamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(l-methoxyimino-3-methyl-butyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(2-methylamino-thiazol-4-yl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(2-ethylamino-thiazol-4-yl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo [d] azepine; 7-Chloro-6-[4-(2-iso-propylamino-thiazol-4-yl)-benzylamino]-2,3.4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(2-n-propylamino-thiazol-4-yl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(2-piperidin-l-yl-thiazol-4-yl)-benzylamino]-2,3,4,5-tetrahydro- 1H-benzo[d]azepine; 7-Chloro-6-[4-(2-cyclopropylmethylamino-thiazol-4-yl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d] azepine; 7-Chloro-6-[4-(2-iso-butylamino-thiazol-4-yl)-benzylamino]-2,3,4,5-tetrahydro- 1H-benzo[d]azepine; 7-Chloro-6-[4-(2-methylamino-oxazol-4-yl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(cyclopentylthiomethyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(cyclohexylthiomethyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[(5-cyclopentylthiomethyl-pyridin-2-ylmethyl)-amino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[(5-cyclohexylthio-methyl-pyridin-2-ylmethyl)-amino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[(5-iso-propylthio-methyl-pyridin-2-ylmethyl)-amino]-2,3,4,5-tetrahydro- 1H-benzo[d]azepine; 7-Chloro-6-[(5-iso-butylthio-methyl-pyridin-2-ylmethyl)-amino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{6-[(2,2-dimethyl-propylthiotnethyl)-pyridin-3-ylmethyl]-amino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(3,3-dimethyl-cyclohexylthiomethyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[ d]azepine; 7-Chloro-6-[4-(3,3-dimethyl-cyclohexylthio)-benzylamino]-2,3,4,5-tetrahydro-1H- benzo[d] azepine; 7-ChIoro-6-{6-[(3,3-dimethyl-cyclohexyIthio)-pyridin-3-ylmethyl]-amino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 6-[(6-tert-Butylthiomethyl-pyridin-3-ylmethyl)-amino]-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{6-[(3,3-dimethyl-cyclohexyloxy)-pyridin-3-ylmethyl]-amino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[(6-cyclopentylthiomethyl-pyridin-3-ylmethyl)-amino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[(6-cyclohexylthiomethyl-pyridin-3-ylmethyl)-amino]-2,3,4,5-tetrahydro-1H-bcnzo[d]azepine; 7-Chloro-6-[(6-cyclohexyloxy-pyridin-3-ylmethyl)-amino]-2,3,4,5-tetrahydro- 1H-benzo[d]azepine; 7-Chloro-6-{6-[(4,4-dimethyl-cyclohexyloxy)-pyridin-3-ylmethyl]-amino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[6-(2-methyl-2-propane-sulfonylmethyl)-pyridin-3-ylmethyl]-amino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[(6-iso-propoxymethyl-pyridin-3-ylmethyl)-amino]-2,3,4,5-tetrahydro- 1H-benzo[d]azepine; 7-Chloro-6-[(2,2-dimethylpropoxymethyl-pyridin-3-ylmethyl)-amino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[(cyclopentyloxymethyl-pyridin-3-ylmethyl)-amino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[(cyclohexyloxymethyl-pyridin-3-ylmethyl)-amino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[(5-cyclohexyloxy-pyridin-2-ylmethyl)-amino]-2,3,4,5-tetrahydro-1H-benzo [d] azepine; 7-Chloro-6-[(5-cycloheptyloxy-pyridin-2-ylmethyl)-amino]-2,3,4,5-tetrahydro-1H-benzo[d] azepine; 7-Chloro-6-{5-[(3,3-dimethylcyclohexyloxy)-pyridin-2-ylmethyl]-amino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; (E)-7-Chloro-6-{6-[(2-cyclohexyl-vinyl)-pyridin-3-ylmethyl]-amino}-2,3,4,5-tetrahydro-1H-benzo[of]azepine; (E)-7-ChIoro-6-{5-[(2-cyclohexyl-vinyl)-pyridin-2-ylmethyl]-amino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; (Z)-7-Chloro-6-{6-[(2-cyclohexyl-vinyl)-pyridin-3-ylmethyl]-amino}-2,3,4,5-tetrahydro- 1H-benzo[d]azepine; (Z)-7-Chloro-6-{5-[(2-cyclohexyl-vinyl)-pyridin-2-ylmethyl]-amino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; (Z)-7-Chloro-6-[4-(2-cyclohexyl-vinyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(2-cyclohexyl-2-oxo-ethyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo [d] azepine; 7-Chloro-6-[4-(morpholin-4-ylmethyl)-benzylamino]-2,3,4,5-tetrahydro-lH-benzo[d]azepine; (R)-7-Chloro-6-{4-[(l-methyl-2,2,2-trifluoro-ethylamino)-methyl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[(2,2,2-trifluoroethylamino)-methyl]-benzylamino}-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(piperidin-l-ylmethyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(pyrrolidin-l-ylmethyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(azepan-l-ylmethyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[(l-methyl-2,2,2-trifluoro-ethylamino)-methyl]-benzylamino}-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[N-(cyclohexyl)-aminomethyl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 6-{4-[N-(iso-Butyl)-aminomethyl]-benzylamino}-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[N-(iso-propyl)-aminomethyl]-benzylatnino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[(N-methyl-iso-propylamino)-methyl]-benzylamino}-2,3,4,5-tetrahydro- 1H-benzo[d]azepine; 7-Chloro-6-{5-[(N-cyclohexyl-aminomethyl)-pyridin-2-yl-methyl]-amino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{6-[(piperidin-l-ylmethyl)-pyridin-3-yl-methyl]-amino}-2,3,4,5-tetrahydro- 1H-benzo[d] azepine; 7-Chloro-6-[4-(2,2-dimethyl-propionylamino)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]-azepine; 7-Chloro-6-[4-(cyclopropanecarbonyl-amino)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]-azepine; 7-Chloro-6-{4-[(l-methyl-cyclopropanecarbonyl)-amino]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]-azepine; 7-Chloro-6-{4-[(2,2,3,3-tetramethyl-cyclopropanecarbonyl)-amino]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]-azepine; (+)-7-Chloro-6-{4-[(2-methyl-cyclopropanecarbonyl)-amino]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]-azepine; (-)-7-Chloro-6-{4-[(2-methyl-cyclopropanecarbonyl)-amino]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]-azepine; 7-Chloro-6-[4-(N-methyl-2,2-dimethyl-propionylamino)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]-azepine; 7-Chloro-6-[4-(cyclohexanecarbonyl-amino)-benzylamino]-2,3,4,5-tetrahydro-1H-benzol -azepine; 7-Chloro-6-[4-(cyclopentanecarbonyl-amino)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]-azepine; 7-Chloro-6-[4-(cycloheptanecarbonyl-amino)-benzylamino]-2,3,4,5-tetrahydro- 1H-benzo[d]-azepine; 7-Chloro-6-{4-[(2,2-dimethyl-propionylamino)-methyl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[(cyclopropanecarbonyl-amino)-methyl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d] azepine; 7-Chloro-6-{4-[2-(2,2-dimethyl-propionylamino)-ethyl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d] azepine; 7-Chloro-6-[4-(iso-propylcarbamoyl-methyl)-benzylamino]-2,3,4,5-tetrahydro- lH-benzo[d] azepine; 7-Chloro-6-{4-[(2,2-dimethylpropyl-carbamoyl)-methyl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(2-oxo-2-pyrrolidin-l-yl-ethyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; (±)-7-Chloro-6-{4-[l-(2,2-dimethylpropyl-carbamoyl)-ethyl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[(cyclohexylmethyl-carbamoyl)-methyl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[(3,3-dimethylbutyl-carbamoyl)-methyl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; (R)-7-Chloro-6-{4-[(l-methyI-2,2,2-trifluoro-ethylcarbamoyl)-methyl]-benzylamino}-2,3,4,5-tetrahydro-lH-benzo[d]azepine; 6-{4-[2-(tert-Butylcarbamoyl)-ethyl]-benzylamino}-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[2-(2,2-dimethylpropyl-carbamoyl)-ethyl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{6-[(2,2-dimethyl-propanesulfonylmethyl)-pyridin-3-ylmethyl]-amino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[(6-cyclohexanesulfonylmethyl-pyridin-3-ylmethyl)-amino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(2,2-dimethyl-propanesulfonylmethyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-(4-dimethylcarbamoylthio-benzylamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(3,3-dimethyl-2-oxobutyIthio)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[(2,2-dimethyl-propylcarbamoyl)-methylthio]-benzylamino}-2,3,4,5-tetrahydro-1 H-benzo[d]azepine; 7-Chloro-6-{[6-(3,3-dimethyl-2-oxo-butoxy)-pyridin-3-ylmethyl]-amino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-({6-[(2,2-dimethyl-propylcarbamoyl)-methoxy]-pyridin-3-ylmethyl}-amino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[5-(cycIopropylmethyl-amino)-isothiazol-3-yl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[2-(2,2,2-trifluoroethylamino-thiazol-4-yl)]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[2-(3-methyl-butylamino)-thiazol-4-yl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[2-(2,2-dimethyl-propylamino)-thiazol-4-yl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(2-cyclopentylmethylamino-thiazol-4-yl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(2-cyclohexylmethylamino-thiazol-4-yl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(2-cyclopropylmethylamino-5-methyl-thiazol-4-yl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; (R)-7-Chloro-6-{4-[2-(l-methyl-2,2,2-trifluoroethyl-amino)-thiazol-4-yl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; (S)-7-Chloro-6-{4-[2-(l-methyl-2,2,2-trifluoroethy[-amino)-thiazol-4-yl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 6-[4-(2-Benzylamino-thiazol-4-yl)-benzylamino]-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[2-(3,3,3-trifluoropropylamino)-thiazol-4-yl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{[5-(2-cyclopropylmethylamino-thiazol-4-yl)-pyridin-2-ylmethyl]-amino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{[6-(2-cyclopropylmethylamino-thiazol-4-yl)-pyridin-3-ylmethyl]-amino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[2-(cyclopropanecarbonyl-amino)-thiazol-4-yl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(l-cyclopropylmethyl-1H-pyrazol-3-yl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{[4-(3-cyclopropylmethylamino)-pyrazol-l-yl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[6-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[4-(cyclopropylmethyl-amino)-pyrimidin-2-yl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-benzylamino}-2,3,4,5-tetrahydro-lH-benzo[d]azepine; 7-Chloro-6-{4-[5-(3,3-dimethylbutyryl)-thiophen-2-yl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[of]azepine; 7-Chloro-6-{[6-(2,2-dimethylpropane-sulfonyl)-pyridin-3-yl-methyl]-amino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; and 7-Chloro-6-[4-(2,2,2-trifluoroethylthio-methylcarbonyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; or a pharmaceutically acceptable salt thereof.

3. The compound as claimed in claim 1 which is 7-Chloro-6-[4-(2-cyclopropylmethylamino-thiazol-4-yl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine, or a pharmaceutically acceptable salt thereof.

4. The compound as claimed in claim 1 which is 7-Chloro-6-{6-[(3,3-dimethyl-cyclohexyloxy)-pyridin-3-ylmethyl]-amino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine, or a pharmaceutically acceptable salt thereof. 5.The compound as claimed in claim 1 which is 7-Chloro-6-[4-(piperidin-l-ylmethyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine, or a pharmaceutically acceptable salt thereof. 6.A pharmaceutical composition comprising a compound as claimed in any one of claims 1-5, or a pharmaceutically acceptable salt thereof, as an active ingredient in association with a pharmaceutically acceptable carrier, diluent or excipient.

6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-lH-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS The neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) has a rich pharmacology arising from a heterogeneous population of at least seven receptor classes. The serotonin S-HTa class is further subdivided into at least three subtypes, designated 5-HT2A, 5-HTaB, and 5-HT2C. The 5-HT-2C receptor has been isolated and characterized (Julius, et al., U.S. Patent No. 4,985,352), and transgenic mice lacking the 5-HT2c receptor have been reported to exhibit seizure and an eating disorder resulting in increased consumption of food (Julius et al., U.S. Patent No. 5,698,766). The 5-HTac receptor has also been linked to various other neurological disorders including obesity (Vickers et al., Psychopharmacology, 167: 274-280 (2003)), hyperphagia (Tecott et al, Nature, 374: 542-546 (1995)), obsessive compulsive disorder (Martin et al, Pharmacol. Biochem. Behav., 71: 615 (2002); Chou-Green et al, Physiology & Behavior, 78: 641-649 (2003)), depression (Leysen, Kelder, Trends in Drug Research n, 29: 49-61 (1998)), anxiety (Curr. Opin. Invest Drugs 2(4), p. 317 (1993)), substance abuse, sleep disorder (Frank et al., Neuropsychopharmacology 27: 869-873 (2002)), hot flashes (EP 1213017 A2), epilepsy (Upton et al., Eur. J. Pharmacol., 359: 33 (1998); Fitzgerald, Ennis, Annual Reports in Medicinal Chemistry, 37:21-30 (2002)), and hypogonadism (Curr. Opin. Invest. Drugs 2(4), p. 317 (1993)). Certain substituted 2,3,4,5-tetrahydro-lH-benzo[d]azepine compounds have been disclosed as useful therapeutics as for example: US 4,265,890 describes certain substituted 2,3,4,5-tetrahydro-lH-benzo[d]azepine compounds as dopaminergic receptor antagonists for use as antipsychotics and antiemetics, inter alia. EP 0 285 287 describes certain substituted 2,3,4,5-tetrahydro-lH-benzo[d]azepine compounds for me as agents to treat gastrointestinal motility disorders, inter alia. WO 93/03015 and WO 93/04686 describe certain substituted 2,3,4,5-tetrahydro-lH-benzo[d]azepine compounds as alpha-adrenergic receptor antagonists for use as agents to treat hypertension and cardiovascular diseases in which changes in vascular resistance are desirable, inter alia. WO 02/074746 Al describes certain substituted 2,3,4,5-tetrahydro-lH-benzo[d]azepirie compounds as 5-HT2C agonists for the treatment of hypogonadism, obesity, hyperphagia, anxiety, depression, sleep disorder, inter alia. WO 03/006466 Al describes certain substituted tricyclic hexahydroazepinoindole and indoline compounds as 5-HT ligands and consequently their usefulness for treating diseases wherein modulation of 5-HT activity is desired. WO 05/019180 describes 6-(2,2,2-trifluoroethylamino)-7-chloro-2,3,4,5-tetrahydro-lH-benzo[d]azepine as a potent and selective 5-HTac agonist for the treatment of obesity, anxiety, depression, and obsessive-compulsive disorder. High affinity S-HTac receptor agonists would provide useful therapeutics for the treatment of the above mentioned 5-HT2C receptor-associated disorders including obesity, hyperphagia, obsessive/compulsive disorder, depression, anxiety, substance abuse, sleep disorder, hot flashes, and hypogonadism. High affinity 5-HT2C receptor agonists that are also selective for the 5-HTac receptor, would provide such therapeutic benefit without the undeskable adverse events associated with current therapies. Achieving selectivity for the 5-HT2C receptor, particularly as against the 5-HT2A and S-HTas receptors, has proven difficult in designing S-HTzc agonists. 5-HT2A receptor agonists have been associated with problematic hallucinogenic adverse events. (Nelson et al, Naunyn-Schmiedeberg's Arch. Pharm., 359:1-6 (1999)). 5-HT2B receptor agonists have been associated with cardiovascular related adverse events, such as valvulopathy. (V. Setola et al., Mol. Pharmacology, 63:1223-1229 (2003), and ref. cited therein). Previous references to substituted 2,3,4,5-tetrahydro-lH-benzo[d]azepine compounds as potential therapeutics have predominantly recited their uses as alpha adrenergic and/or dopaminergic modulators. Adrenergic modulators are often associated with, the treatment of cardiovascular diseases (Frishman, Kotob, Journal of Clinical Pharmacology, 39:7-16 (1999)). Dopaminergic receptors are primary targets in the treatment of schizophrenia and Parkinson's disease (Seeman, Van Tol, Trends in Pharmacological Sciences, 15: 264-270 (1994)). It will be appreciated by those skilled in the art that selectivity as against these and other physiologically important receptors will generally also be preferred characteristics for therapeutics for the specific treatment of 5-HTzc associated disorders as described above. The present invention provides selective 5-HT2C agonist compounds of Formula I: (Formula Removed) where: R1 is hydrogen, fluoro, or R2, R3, and R4 are each independently hydrogen, methyl, or ethyl; R5 is hydrogen, fluoro, methyl, or ethyl; R6is-NR10R"; R7 is hydrogen, halo, cyano, (Ci-Ce)alkyl optionally substituted with 1 to 6 fluoro substituents, (C2-C6)alkenyl optionally substituted with 1 to 6 fluoro substituents, (C3-C7)cycloalkyl optionally substituted with 1 to 4 fluoro substituents, optionally substituted with 1 to 6 fluoro substituents, (Ci-Q)alkylthio optionally substituted with 1 to 6 fluoro substituents, Phl-(Co-C3>alkyl optionally substituted with 1 to 6 fluoro substituents, Phl-(C(r-C3)alkyl-O- optionally substituted with 1 to 6 fluoro substituents, or Ph'-CQr-CaJalkyl-S- optionally substituted with 1 to 6 fluoro substituents; R8 is hydrogen, halo, cyano, -SCFa, or hydroxy; R9 is hydrogen, halo, cyano, -CF3, -SCFs, hydroxy, or (Ci-C3)alkoxy optionally substituted with 1 to 6 fluoro substituents; R10 is Ph2-{Ci-€3)-H-alkyl or Ar'-(Ci-C3)-n-alkyl, wherein the n-alkyl moiety is optionally substituted with (Ci-CsJalkyl, dimethyl, gem-ethano or 1 to 2 fluoro substituents; Ru is hydrogen,, (Ci-C3)alkyl optionally substituted with 1 to 6 fluoro substituents, or allyl; Phl is phenyl optionally substituted with 1 to 5 independently selected halo substituents, or with 1 to 3 substituents independently selected from the group consisting of halo, cyano, -SCFa, (Ci-Q)alkyl optionally further substituted with 1 to 6 fluoro substituents, and (Ci-C6)alkoxy optionally further substituted with 1 to 6 fluoro substituents; Ph2 is phenyl substituted with R12 and optionally further substituted with 1 or 2 substituents independently selected from the group consisting of halo, cyano, -SCF3, methyl, -CF3, methoxy, -OCFs, nitro, and hydroxy; Ar1 is 5-R13-pyridin-2-yl or 6-Rl3-pyridin-3-yl optionally further substituted with one or two substituents independently selected from the group consisting of halo, cyano, methyl, -CFs, hydroxy, and methoxy; R12 is a substituent selected from the group consisting of: a) Het'-(CcrC3)alkyl optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; b) Het2-(Co"C3)alkyl optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; c) Het3-(Co-"C3)alkyl optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; d) Ar2-(Co-(-3)alkyl optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; e) (C|-C6)alllcyl-C(RI4>=C(R14)- optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; f) (Rl4)aC=C[(Ci-C6)alkyl]- optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; g) (C3-C7)c3'cloalkyl-(Co-C3)alkyl-C(Rl4)=C(R15)- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; h) (R15)CH=C[(C3-C7)cycloalkyl-(C(r-C3)alkyl]- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; i) (Ci-Ce^yl-CsC- optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; j) (C3-C7)cycloalkyl-(Co-C3)alkyl-CsC- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the alkyl moiety with I to 4 fluoro substituents; k) (C3-C7)cycloalkyl-(Co-C3)alkyl-C(O)-(Ci-C5)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; 1) Ph'-C^^alkyl-CCOHCi-^alkyl optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; m) pyridyl-(Co-C3)alkyl-C(O)-(Ci-Cs)a]kyl, optionally substituted on the pyridyl moiety with 1 to 3 substituents independently selected from the group consisting of halo, (Ci-C3)alkyl, (C1-C3)alkoxy> -CF3, -O-CF3, nitro, cyano, and trifluoromethylthio, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; n) (Ci-Q)alkyl-O-(Ci-C3)alkyl-C(O)- optionally substituted on the (d-C6)alkyl moiety with 1 to 6 fluoro substituents and independently optionally substituted on the (Ci-C3)alkyl moiety with 1 to 4 fluoro substituents; o) (C3-C7)cycloalkyl-(Co-C3)alkyl-O-(Ci-C3)alkyl-C(O)- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; p) Ph'-(Co-C3)alkyl-O-(Ci-C3)alkyi-C(O)- optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; q) (Ci-C6)alkyl-S-(Ci-C3)alkyl-C(0)- optionally substituted on the (Ci-CeJalkyl moiety with 1 to 6 fluoro substituents and independently optionally substituted on the (Ci-C3)alkyl moiety with 1 to 4 fluoro substituents; r) (C3^7)cycloalkyHQr-C3)alkyl-S-(Ci-C3)alkyl-C(O)- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; s) Ph'-(Co-C3)alkyl-S-(Ci-€3)alkyl-C(O)- optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; t) (Ci-C6)allcyl-NR16-(Ci-C3)alkyl-C(O)- optionally substituted on the (C|-C6)alkyl moiety with 1 to 6 fluoro substituents and independently optionally substituted on the (Ci-CsJalkyl moiety with 1 to 4 fluoro substituents; u) (C3^7)cycloalkyl-(Ctf-C3)alkyl-NRl6-(Ci-C3)alkyl-C(O)- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; v) Ph'-(Ca-C3)alkyl-NR16-(Ci-C3)alkyl-C(O)- optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; w) (Ci-C6)alkyl-O-(Ci-C3)alkyl-SO2- optionally substituted on the (Ci-C6)alkyl moiety with 1 to 6 fluoro substituents and independently optionally substituted on the (Cj-C3)alkyl moiety with 1 to 4 fluoro substituents; x) (C3-C7)cycloalkyl-(Co-C3)alkyl-O-(Ci-C3)alkyl-SO2- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; y) PhI-(C0-^cloalkyl-(C(r-C3)alkyl-C(O)-(Ci-C3)alkyl-O- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; av) (C3-C7)cycloalkyl-(Co-C3)alkyl-SO2 (Ci-C3)aIkyl-O- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; aw) (C3-^7)cycloalkyl-(C(r-C3)alkyl-C(O)-(Ci-C3)alkyl-S- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; ax) (C3-C-;)cycloalkyl-(Co-C3)alkyl-SO2-(Ci-C3)alkyl-S- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; ay) Ph'-CCo-CsJalkyl-SOz-CCi-Caialkyl-O- optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; az) Ph1-(QrCj)alkyl-C(OHCi-C3)alkyl-S- optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; u) Ph^Cr-C3)alkyl-SO2-(Ci-C3)alkyl-S- optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; v) Rl7R18N-C(O)-(Ci-C3)alkyl-S- optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; be) R17R18N-C(SHCi-C3)alkyl-S- optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; x) R17R18N-C(S)-(Ci-C3)alkyl-O- optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; y) (C3-^7)cycloalkyl-(Co-C3)alkyl-SO2-(C|-C5)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the (QrC3)alkyl moiety with 1 to 4 fluoro substituents and further optionally substituted on the (Ci-Cs)alkyl moiety with 1 to 6 fluoro substituents; z) PhJ-(Co-C3)alkyl-SO2-(Ci-Cs)alkyl optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Ci-Cs)alkyl moiety with 1 to 6 fluoro substituents; aa) Ar3-(Co~C3)alkyl-SO2-(Ci-C5)alkyl optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Ci-Cs)alkyl moiety with 1 to 6 fluoro substituents; bh) Het2-(QrC3)alkyl-SO2-(C(rC5)alkyl optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Ci-Cs)alkyl moiety with 1 to 6 fluoro substituents; bi) Rl7R18N-(Ci--C3)alkyl optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; bj) (Ci-C6)alkyl-C(O)-N(Rl6)-((VCs)alkyl optionally substituted on either or both alkyl moieties independently with 1 to 6 fluoro substituents; bk) (C3-C7)cycloalkyl-C(0)-N(Rl6)-(Co-C:5)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; bl) Ph'-CCo-CaJalkyl-QO-NCR^HCo-CsJalkyl optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Co-Cs)alkyl moiety with 1 to 6 fluoro substituents; bm) Ar3-(Co~C3)alkyl-C(O)-N(Rl6)-(Co--C:5)alkyl optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Co-Cs)alkyl moiety with 1 to 6 fluoro substituents; bn) (C|-C6)aIkyl-C(S)-N(Rl6)-(Co-Cs)alk;yl optionally substituted on either or both alkyl moieties independently with 1 to 6 fluoro substituents; bo) (C3-C7)cycloalkyl-C(S)-N(RI6)-(Co-C:5)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; bp) Ph1-(CVC3)alkyl-C(S)-N(R16HCo-Cs)alkyl optionally substituted on the (Co-Q)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Co-Cj)alkyl moiety with 1 to 6 fluoro substituents; bq) Ar3-(Co-JC3)alkyl-C(S)-N(R16)-(C(K:s)alkyl optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Co-Cj)alkyl moiety with 1 to 6 fluoro substituents; br) (Ci-C«)alkyl-O-N=C(CH3)- optionally substituted on the (Ci-C«)alkyl moiety with 1 to 6 fluoro substituents; bs) (Co-C3)allkyl-O-N=C[(C[-C6)alkyl]- optionally substituted on the (C0-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Ci-C«)alkyl moiety with 1 to 6 fluoro substituents; bt) HO-N=C[(Co-Ci)alkyl-(C3-C7)cycloalkyl]- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 2 fluoro substituents; bu) CH3-O-N=C[(Co-Ci)alkyl-(C3-C7)cycloalkyl]- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 2 fluoro substituents; 13 is a substituent selected from the group consisting of: a) Het2-)alkyl-O-(C|-C5)alkyl optionally optionally substituted on either or both alkyl moieties independently with 1 to 6 fluoro substituents; k) (C3-C7)cycloalkyl-(Co-C3)alkyl-O-(Co-Cs)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents and further optionally substituted on the (Co-C5)alkyl moiety with 1 to 6 fluoro substituents; 1) Ph'-(Calkyl or with 2 methyl substituents; Het3 is a nitrogen containing heterocycle selected from the group consisting of pyrrolidin- 2-onyl, piperidin-2-onyl, oxazolidin-2-onyl, pyrrolin-2-onyl, and dihydropyridin-2- onyl; or a pharmaceuticaUy acceptable salt or solvate thereof. This invention also provides pharmaceutical compositions which comprise a compound of Formula I, or a pharmaceurtcally acceptable salt or solvate thereof, in association with a pharmaceutically acceptable carrier, diluent, or excipient. In another aspect of the present invention, there is provided a method for increasing activation of the 5-HT2C receptor in mammals comprising administering to a mammal in need of such activation an effective amount of a compound of Formula I, or a pharmaceuticaUy acceptable salt or solvate thereof. The present invention also provides a method for treating obesity in mammals comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I, or a pharmaceuticaUy acceptable salt or solvate thereof. The present invention also provides a method for treating obsessive/compulsive disorder in mammals comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof. Furthermore, the present invention provides a method for treating depression in mammals comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof. Furthermore, the present invention provides a method for treating anxiety in mammals comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof. In preferred embodiments of the above methods of treatment utilizing a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, the mammal is a human. In another aspect of the present invention, there is provided a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, for use in selectively increasing activation of the S-HTic receptor and/or for use in treating a variety of disorders associated with decreased activation of 5-HT2C receptors. Preferred embodiments of this aspect of the invention include a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of obesity, hyperphagia, obsessive/compulsive disorder, depression, anxiety, substance abuse, sleep disorder, hot flashes, and/or hypogonadism. Particularly preferred embodiments of this aspect of the invention include the treatment of obesity, obsessive/compulsive disorder, depression, and/or anxiety. In another aspect of the present invention, there is provided the use of one or more compounds of Formula I, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the activation of S-HTjc receptors in a mammal. In preferred embodiments of this aspect of the invention, there is provided the use of one or more compounds of Formula I, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment of obesity, hyperphagia, obsessive/compulsive disorder, depression, anxiety, substance abuse, sleep disorder, hot flashes, and/or hypogonadism. Particularly preferred embodiments of this aspect of the invention include the use of one or more compounds of Formula I, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of medicaments for the treatment of obesity, obsessive/compulsive disorder, depression, and/or anxiety. Additionally, the present invention provides a pharmaceutical formulation adapted for the treatment of obesity, or for the treatment of obsessive/compulsive disorder, or for the treatment of depression, or for the treatment of anxiety, each of which comprise a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, in association with a pharmaceutically acceptable carrier, diluent or excipient. In those instances where the disorders which can be treated by S-HTjc agonists are known by established and accepted classifications, their classifications can be found in various sources. For example, at present, the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV™) (1994, American Psychiatric Association, Washington, D.C.), provides a diagnostic tool for identifying many of the disorders described herein. Also, the International Classification of Diseases, Tenth Revision (ICD-10), provides classifications for many of the disorders described herein. The skilled artisan will recognize that there are alternative nomenclatures, nosologies, and classification systems for disorders described herein, including those as described in the DSM-IV and ICD-10, and that terminology and classification systems evolve with medical scientific progress. The general chemical terms used throughout have their usual meanings. For example, the term "alky!" refers to a branched or unbranched saturated hydrocarbon group. The term "n-alkyl" refers to an unbranched alkyl group. By way of illustration, but without limitation, the term "(C|-C2)alkyl" refers to methyl and ethyl. The term "(C\-C3) n-alkyl" refers to methyl, ethyl, and propyl. The term "(Ci-C3)alkyl" refers to methyl, ethyl, propyl, and isopropyl. The term "(Ci-Cj)alkyl" refers to all branched and unbranched alkyl groups having from one to five carbon atoms. The term "(C]-C6)alkyl" refers to all branched and unbranched alkyl groups having from one to six carbon atoms. The term "(Cs-C^alkyl" refers to all branched and unbranched alkyl groups having from three to six carbon atoms. The term "(Ca-CeJalkyl" refers to all branched and unbranched alkyl groups having from two to six carbon atoms. (Cx-Cy)alkyl may also be used in conjunction with other substituents to indicate a branched or unbranched saturated hydrocarbon linker for the substituent, where x and y indicate the range of carbon atoms permitted in the linker moiety. By way of illustration, but without limitation, -(Co-Ci)alkyl refers to a single bond or a methylene linker moiety; -(Co-CjJalkyl refers to a single bond, methylene, methyl-methylene, or ethylene linker moiety; -(Co-C3)alkyl further includes trimethylene, alpha- or beta-methyl ethylene, or ethyl methylene; -(Co-Cs)alkyl refers to a bond or a saturated, branched or unbranched hydrocarbon linker having from 1 to 5 carbon atoms. -(Ci-CaJalkyl, -(Ci-C3)alkyl, -(Ci-Cs)alkyl, and -(C|-C6)alkyl refer to branched or unbranched alkylene linkers having from 1 to 2,3,5, or 6 carbon atoms, respectively. The term "alkenyl" refers to a branched or unbranched hydrocarbon group having one or more carbon-carbon double bonds. By way of illustration, but without limitation, the term M(C2-Cis(diphenylphospliino)ferrocene. "EDC" means l-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride. "EDTA" means ethylenediaminetetraacetic acid, "ee" means enantiomeric excess. "EE" means energy expenditure. "EtOAc" means ethyl acetate. "EtOH" means ethanol. "GC-MS" means gas chromatography-mass spectrometry. "GDP" means guanosine diphosphate. "GTP" means guanosine triphosphate. "GTP7[33S]" means guanosine triphosphate having the terminal phosphate substituted with 35S in place of an oxygen. "HOBt" means 1-hydroxybenzotriazole hydrate. "HPLC" means high-pressure liquid chromatography. "ISPA" means immunoadsorption scintillation proximity assay. "MeOH" means methanol. "MS (APCI+)" means mass spectroscopy using atmospheric pressure chemical ionization. "MS (ES+)" means mass spectroscopy using electrospray ionization. "NBS" means /V-bromosuccmimide. "NMP" means l-methjd-2-pyrrolidinone. "Pd/C" means palladium on activated carbon, "psi" means pounds per square inch. "RQ" means respiratory quotient. "SCX chromatography" means chromatography on a SCX column or cartridge. "SCX column" or "SCX cartridge", as used herein, refers to a Varian Bond Elute® silica based strong cation exchange resin column or disposable cartridge or equivalent. "SFC" means supercritical fluid chromatography. "Tf' in a chemical structure means the trifluoromethanesulfonyl moiety (-S02CF3). "Ts" in a. chemical structure means the 4-methylbenzenesulfonyl moiety. "TFA" means trifluoroacetic acid. "THF" means tetrahydrofuran. While all of the compounds of the present invention are useful as 5-HTjc agonists, certain classes are preferred, as for example, compounds having any of the following enumerated selections of substituents: Compounds wherein 1) R7 is halo; 2) R7 is chloro; 3) R7 is fluoro; 4) R7 is (Ci-C6)alkyl optionally substituted with 1 to 6 fluoro substituents; 5) R7 is (Ci-C3)alkyl optionally substituted with 1 to 6 fluoro substituents; 6) R7 is -€F3; 7) R7 is (C3-C6)alkenyl optionally substituted with 1 to 6 fluoro substituents; 8) R7 is (C3-€«)alkenyl; 9) R7 is cyano; 10) R1"5 are each hydrogen; 11) R5 is methyl or ethyl; 12) R5 is methyl; 13) R3 is methyl; 14) R8 is hydrogen; 15) R9 is hydrogen; 16) R9 is (C|-C3)alkoxy; 17) R9 is methoxy; 18) R9 is halo; 19) R9 is chloro; 20) R9 is cyano; 21) Rs'is-CF3; 22) R11 is hydrogen; 23) R" is methyl; 24) R10isPh2-methyl-; 25) R10 is Ph2-CH(CH3)- (i.e. Ci-«-alkyl substituted with methyl); 26) R10 is Ph2-CH(CH2CH3)- (i.e. Cm-alkyl substituted with ethyl); (Formula Removed) 27) R'°is (i.e. Ci-n-alkyl substituted with gem-ethano); 28) R10 is Ar'-methyl-; 29) R10 is Ar'-CH(CH3)- (i.e. Ci-n-alkyl substituted with methyl); 30) R10 is Ar2-CH(CH2CH3)- (i.e. Q-n-alkyl substituted with ethyl); (Formula Removed) 31) Rlois ' (i.e. Ci-n-alkyl substituted with gem-ethano); 32) Ph2 is substituted in the para position; 33) Ph2 is substituted in the para position and further substituted in the meta- position with halo, hydroxy, or cyano; 34) Ph2 is substituted in the para position and further substituted in the meta- position with fluoro or chloro; 35) Ph2 is monosubstituted; 36) Ph2 is monosubstituted in the para position; 37) Ph2 is substituted with Het'-(Co-C3)alkyl optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; 38) Ph2 is substituted with Het2-{Co-C3)alkyl optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; 39) Ph2 is substituted with Het3-(Co-C3)alkyl optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; 40) Ph2 is substituted with Ar^Co-C^alkyl optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; 41) Ph2 is substituted with (C|-C6)alkyl-C(RI4)=C(R14)- optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; 42) Ph2 is substituted with (RM>2C=C[(Ci-C6)alkyl]- optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; 43) Ph2 is substituted with (C3-C7)cycloalkyl-(QrC3)alkyl-C(R14)=C(Rls)- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and further optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; 44) Ph2 is substituted with (R15)CH:=C[(C3-C7Xycloalkyl-(C(rC3)alkyl]- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and further optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; 45) Ph2 is substituted with (Ci-C6)alkyl-OC- optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; 46) Ph2 is substituted with (C3-C7)cycloalkyl-(Co-C3)alkyl-C=C- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and further optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; 47) Ph2 is substituted with (C3-C7)cycloalkyl-(Co-C3)alkyl-C(O)-(C,-C5)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and further optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; 48) Ph2 is substituted with Ph1-(Co~C3)alkyl-C(O)-(C|-Cs)alkyl optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; 49) Ph2 is substituted with pyridyl-(Co-A)alkyl-C(OMCi-C5)aikyl, optionally substituted on the pyridyl moiety with 1 to 3 substituents independently selected from the group consisting of halo, (Cj-C3)alkyl, (Ci-CsJalkoxy, - CFs, -O-CFs, nitro, cyano, and trifluoromethylthio, and optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; 50) Ph2 is substituted with (Cj-C6)alkyl-O-(C i-C3)alkyl-C(O)- optionally substituted on the (Ci-CeJalkyl moiety with 1 to 6 fluoro substituents and further optionally substituted on the (C|-C3)alkyl moiety with 1 to 4 fluoro substituents; 51) Ph2 is substituted with (C3-C7)cycloalkyl-(Co-C3)alkyl-O-(Ci-C3)alkyl- C(O)- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and further optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; 52) Ph2 is substituted with Ph^QrA)alkyl-0-(Ci^3)alkyl-C(O)- optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; 53) Ph2 is substituted with (C1-C6)alkyl-S-(Ci-C3)alkyl-C(O)- optionally substituted on the (Ci-C6)alkyl moiety with 1 to 6 fluoro substituents and further optionally substituted on the (Ci-C3)alkyl moiety with 1 to 4 fluoro substituents; 54) Ph2 is substituted with (C3-C7)cycloalkyl-(C(r-C3)alkyl-S-(Cj-C3)alkyl- C(O)- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and further optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; 55) Ph2 is substituted with Phl-(Co-C3)alkyl-S-(Ci-C3)alkyl-C(O)- optionally substituted on either or both alkyl moieties with 1 to 4 fluoro substituents; 56) Ph2 is substituted with (C,-C6)alkyl-NRl6-(Ci-C3)alkyl-C(O)- optionally substituted on the (Ci-C6)alkyl moiety with 1 to 6 fluoro substituents and further optionally substituted on the (Ci-C3)alkyl moiety with 1 to 4 fluoro substituents; 57) Ph2 is substituted with (C3^)cycloalkyHCo-C3)alkyl-NRl6-(Ci-C3)alkyl- C(O> optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and further optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; 58) Ph2 is substituted with Phl-(QrC3)alkyl-NRl6-(C,-C3)alkyl-C(O)- optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; 59) Ph2 is substituted with (C|«C6)alkyl-O-(Ci-C3)alkyl-SO2- optionally substituted on the (Q-Chalky 1 moiety with 1 to 6 fluoro substituents and further optionally substituted on the (Ci-CsJalkyl moiety with 1 to 4 fluoro substituents; 60) Ph2 is substituted with (C3-C7)cycloalkyl-(Co-C3)alkyl-O-(Ci-C3)alkyl- SC>2- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and further optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; 61) Ph2 is substituted with Ph'-(C(r-C3)alkyl-O-(Ci-C3)alkyl-SO2- optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; 62) Ph2 is substituted with (Ci-C6)alkyl-S-(Ci-€3)alkyl-SO2- optionally substituted on the (Ci-C6)alkyl moiety wirn 1 to 6 fluoro substituents and further optionally substituted on the (Cj-CsJalkyl moiety with 1 to 4 fluoro substituents; 63) Ph2 is substituted with (C3-C7)cycloalkyl-(Co-C3)alkyl-S-(Ci-C3)alkyl-SO2- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and further optionally substituted on either or both alkyl moieties uidependently with 1 to 4 fluoro substituents; 64) Ph2 is substituted with Phl-(Co-C3)alkyl-S-(Ci-C3)alkyl-SO2- optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; 65) Ph2 is substituted with (Cr€6)alkyl-NRl6-(Ci-C3)alkyl-SO2- optionally substituted on the (Ci-Q)alkyl moiety with 1 to 6 fluoro substituents and further optionally substituted on the (Ci-C3)alkyl moiety with 1 to 4 fluoro substituents; 66) Ph2 is substituted with (C3-C7)cycloalkyl-(Co-C3)alkyl-NR16-(C,-C3)alkyl- SG2- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and further optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; 67) Ph2 is substituted with Phl-(CtrC3)alkyl-NR16-(Ci-C3)alkyl-SO2- optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; 68) Ph2 is substituted with Rl7R18-N-C(O)-(Ci-Cs)alkyl optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; 69) Ph2 is substituted with (C3-C7)cycloalkyl-(Co-C3)alkyl-S- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and further optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; 70) Ph2 is substituted with (C3-C7)cycloalkyl-(C-C3)alkyl moiety with 1 to 4 fluoro substituents and further optionally substituted on the (Co-Cs)alkyl moiety with 1 to 6 fluoro substituents; 121) Ar1 is substituted with (C3-C7)cycloalkyl-(QrC3)alkyl-C(O)-(Ci-Cs)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and further optionally substituted on the (Co-CsJalkyl moiety with 1 to 4 fluoro substituents and further optionally substituted on the (CrCsJalkyl moiety with 1 to 6 fluoro substituents; 122) Ar1 is substituted with Ph'-CQrCsJalkyl-CCO^Ci-Cs)^! optionally substituted on the (Co-CsJalkyl moiety with 1 to 4 fluoro substituents and further optionally substituted on the (Ci-C5)alkyl moiety with 1 to 6 fluoro substituents; 123) Ar1 is substituted with pyridyl-(C(r-C3)alkyl-C(O)-(Ci-C5)alkyl optionally be substituted on the pyridyl moiety with 1 to 3 substituents independently selected from the group consisting of halo, (Ci-C3)alkyl, (CrC3)alkoxy, - CF3, -0-CFs, nitro, cyano, and trifluoromethylthio, and optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents and further optionally substituted on the (Ci-Cj)alkyl moiety with 1 to 6 fluoro substituents; 124) Ar1 is substituted with (C|-C6)iilkyl-C(OHCi-C3)alkyl-O- optionally substituted on the (Ci-C6)alkyl moiety with 1 to 6 fluoro substituents and further optionally substituted on the (C|-C3)alkyl moiety with 1 to 4 fluoro substituents; 125) Ar1 is substituted with (C3-C7)cycloalkyl-(C0-C3)alkyl-C(O)-(Ci-C3)alkyl- O- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and further optionally substituted on either or both of the alkyl moieties independently with 1 to 4 fluoro substituents; 126) Ar1 is substituted with Ph'-(C(r-C3)alkyl-C(O)-(Ci-C3)alkyl-O- optionally substituted on either or both of the alkyl moieties independently with 1 to 4 fluoro substituents; 127) Ar1 is substituted withpyridyl-(Ca-C3)alkyl-C(O)-(C1-C3)alkyl-O- optionally be substituted on the pyridyl moiety with 1 to 3 substituents independently selected from the group consisting of halo, (C|-C3)alkyl, (Q- C3)alkoxy, -CF3, -O-CF3, nitro, cyano, and trifluoromethylthio, and optionally substituted on either or both of the alkyl moieties independently with 1 to 4 fluoro substituents; 128) Ar1 is substituted wirnR17Rl8N-C(O)-(Ci-C3)alkyl-O- optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; 129) Ar1 is substituted with (C3-C7)cycloalkyl-(Co-C3)alkyl-S- substituted on cycloalkyl moiety with 2 to 4 methyl substituents and further optionally substituted on the the alkyl moiety with 1 to 4 fluoro substituents; 130) Ar1 is substituted with (Ci-C6)alkyl-S-(Ci-C3)alkyl optionally substituted on either or both alkyl moieties independently with 1 to 6 fluoro substituents; 131) Ar1 is substituted with (C3-C7)cycloalkyl-(Co-C3)alkyl-S-(Ci-C5)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and further optionally substituted on the (C0-C3)alkyl moiety with 1 to 4 fluoro substituents, and further optionally substituted on the (Ci-Cj)alkyl moiety with 1 to 6 fluoro substituents; 132) Ar1 is substituted with Ph1-(Co-€3)alkyl-S-(Ci-Cs)alkyl optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents and further optionally substituted on the (Ci-C5)alkyl moiety with 1 to 6 fluoro substituents; 133) Ar1 is substituted with Ar3-(Co-C3)alkyl-S-(Ci-Cs)alkyl optionally substituted on the (Q>-C3)alkyl moiety with 1 to 4 fluoro substituents and further optionally substituted on the (Ci-Cs)alkyl moiety with 1 to 6 fluoro substituents; 134) Ar1 is substituted with (Ci-C6)alkyl-C(O)-(Ci-C3)alkyl-S- optionally substituted on the (Ci-Qs)alkyl moiety with 1 to 6 fluoro substituents and further optionally substituted on the (Ci-C3)alkyl moiety with 1 to 4 fluoro substituents; 135) Ar1 is substituted with (C3-C7)cycloalkyl-(C(r-C3)alkyl-C(OKCi-C3)alkyl- S- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and further optionally substituted on either or both of the alkyl moieties independently with 1 to 4 fluoro substituents; 136) Ar1 is substituted with Ph'-CCo-Csialkyl-CCOHCi-CsJalkyl-S- optionally substituted on either or both of the alkyl moieties independently with 1 to 4 fluoro substituents; 137) Ar1 is substituted with pyridyl-(C(rA)alkyl-C(OMC|-C3)alkyl-S- optionally be substituted on the pyridyl moiety with 1 to 3 substituents independently selected from the group consisting of halo, (Ci-C3)alkyl, (Cr Cajalkoxy, -CFs, -O-CFs, nitro, cyano, and trifluoromethylthio, and optionally substituted on either or both of the alkyl moieties independently with 1 to 4 fluoro substituents; 138) Ar1 is substituted with R17Rl8N-C(O)-(Ci-C3)alkyl-S- optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; 139) Ar1 is substituted with (Ci-C6)alkyl-SO2-(Co-C5)alkyl optionally substituted on either or both of the alkyl moieties independently with 1 to 6 fluoro substituents; 140) Ar1 is substituted with (C3-C7)cycloalkyl-(Co-C3)alkyl-SO2-(Co-Cs)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and further optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents and further optionally substituted on the (Co-Cs)alkyl moiety with 1 to 6 fluoro substituents; 141) Ar1 is substituted with PhI-(Co-C3)alkyl-SO2-(Co-C5)alkyl optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents and further optionally substituted on the (Co-Cs)alkyl moiety with 1 to 6 fluoro substituents; 142) Ar1 is substituted with Ar3-(Co-C3)alkyl-SO2-(Co--C5)alkyl optionally substituted on the (CVCa)alkyl moiety with 1 to 4 fluoro substituents and further optionally substituted on the (Co-Cj)alkyl moiety with 1 to 6 fluoro substituents; 143) Ar1 is substituted with Het2-(Qr£s)alkyl-SCM(VCs)alkyl optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents and further optionally substituted on the (Co-Cs)alkyl moiety with 1 to 6 fluoro substituents; 144) Ar1 is substituted with R17R18-N-C(O)-(Ci-C5)alkyl optionally substituted on the (Ci-Cj)alkyl moiety with 1 to 6 fluoro substituents; 145) Ar1 is substituted with RI7R18N-(Ci-C3)alkyl optionally substituted on the (Q-C3)alkyl moiety with 1 to 4 fluoro substituents; 146) Ar1 is substituted with (Ci-C6)alkyl-C(O)-N(R16)-(Co-C5)alkyl optionally substituted on either or both of the alkyl moieties independently with 1 to 6 fluoro substituents; 147) Ar1 is substituted with (C3-C7)cycloalkyl-C(O)-N(Rl6)-(Co-C5)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and further optionally substituted on the (Co-C5)alkyl moiety with 1 to 6 fluoro substituents; 148) • Ar1 is substituted with Phl-(Cff-C3)alkyl-C(O)-N(R16)-(Co-Cs)alkyl optionally substituted on the (Co-CaJalkyl moiety with 1 to 4 fluoro substituents and further optionally substituted on the (C0-C5)alkyl moiety with 1 to 6 fluoro substituents; 149) AJ' is substituted with Ar^^CaJalkyl^O^NCR^MCff-CsJalkyl optionally substituted on the (Co-C3)alkyI moiety with 1 to 4 fluoro substituents and further optionally substituted on the (Co-Cs)alkyl moiety with 1 to 6 fluoro substituents; 150) Ar2 is substituted with R15R17N-, wherein R15 is hydrogen and R17 is (C,-C6)alkyl or (C3-C7)cycloalkyl-(Co-C3)alkyl; 151) Ar2 is thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, or pyrazolyl; 152) Het1 is pyrrolidinyl, piperidinyl, homopiperidinyl, or morpholinyl optionally be substituted with (Ci-Cs)alkyl or with 2 methyl substituents; 153) Het1 is pyrrolidinyl, piperidinyl, homopiperidinyl, or morpholinyl; 154) Het1 is pyrrolidinyl, piperidinyl, homopiperidinyl optionally be substituted with (C|-C6)alkyl or with 2 methyl substituents; 155) Het1 is pyrrolidinyl, piperidinyl, homopiperidinyl; It will be understood that the above classes are preferred selections for each substitutent and may be combined with preferred selections for other substitutents to form additional preferred classes. Exemplary combinations include, but are not limited to: 156) Any one of preferred embodiments 1) through 9) (the preferred selections for R7), combined with any one of preferred embodiments 24) through 155) (the preferred selections for R10 and substituents thereon); 157) Any one of preferred embodiments 24) through 155) (the preferred selections for R10 and substituents thereon), wherein R7 is halogen; 158) Any one of preferred embodiments 24) through 155) (the preferred selections for R10 and substituents thereon), wherein R7 is chloro; 159) Any one of preferred embodiments 32) through 36) (the preferred positions for substituents on Ph2), combined with any one of preferred embodiments 37) through 102) (the preferred selections for substituents on Ph2); 160) Any one of preferred embodiments 103) through 149) (the preferred selections for mono-substitutions on Arl), wherein Ar1 is further substituted with a substituent selected from the group consisting of halo, cyano, methyl, -CFa, and methoxy; 161) A preferred combination according to any .one of 156) through 160), wherein R1"5, R8, and R9 are each hydrogen; 162) A preferred combination according to any one of 156) through 161), wherein R11 is hydrogen; Generally, a methylene linker from the 6-position nitrogen atom to the phenyl or pyridyl moiety is preferred over longer or larger linkers, as hi compounds wherein R10 is Ph2-methyl- or R10 is Ar'-methyl-. Also generally, for 6-benzylamino compounds, (Le. compounds wherein R10 is Ph2) substitution at the para-position of the phenyl moiety is particularly preferred. One favored group of compounds of the present invention is that represented by formula (la), and pharmaceutically acceptable salts thereof: (Formula Removed) wherein R7* is halogen, and especially chloro; R12 is as defined in relation to formula (I); and R20 is halo, hydroxy, or cyano; or a pharmaceutically acceptable salt or solvate thereof. Preferred compounds according to formula (la) are those wherein R20 is fluoro or chloro. Another favored group of compounds of the present invention is that represented by formula (Ib), and pharmaceutically acceptable salts thereof: (Formula Removed) whereinR7" is halogen, and especially chloro; R13 is as defined in relation to formula (I); and R20 is halo, hydroxy, or cyano; or a pharmaceutically acceptable salt or solvate thereof. on Preferred compounds according to formula (Ib) are those wherein R is fluoro or chloro. Yet another favored group of compounds of the present invention is that represented by formula (Ic), and pharmaceutically acceptable salts thereof: N-H Ic wherein R7* is halogen, and especially chloro; R13 is as defined in relation to formula (I); and Rzo is halo, hydroxy, or cyano; or a pharmaceutically acceptable salt or solvate thereof. Preferred compounds according to formula (Ic) are those wherein R20 is fluoro or chloro. Generally, compounds according to formula (Ib) are preferred over compounds of formula (Ic). Specific preferred compounds of the present invention are those described in the Examples herein, including the free bases and the pharmaceutically acceptable salts and solvates thereof. It will be appreciated that the preferred definitions of the various substituents recited herein may be taken alone or in combination and, unless otherwise stated, apply to the generic formula (I) for compounds of the present invention, as well as to the preferred classes of compounds represented by formulae (la), (Ib), and/or (Ic). The compounds of the invention can be prepared according to the following synthetic schemes by methods well known and appreciated in the art. Suitable reaction conditions for the steps of these schemes are well known hi the art and appropriate substitutions of solvents and co-reagents are within the skill of the art. Likewise, it will be appreciated by those skilled in the art that synthetic intermediates may by isolated and/or purified by various well known techniques as needed or desired, and that frequently, it will be possible to use various intermediates directly in subsequent synthetic steps with little or no purification. Furthermore, the skilled artisan will appreciate that in some circumstances, the order in which moieties are introduced is not critical. The particular order of steps required to produce the compounds of Formula I is dependent upon the particular compound being synthesized, the starting compound, and the relative liability of the substituted moieties as is well appreciated by those of ordinary skill in the art. All substituents, unless otherwise indicated, are as previously defined, and all reagents are well known and appreciated in the art. The compounds of Formula I may be prepared by a variety of procedures, some of which are described below. All substituents, unless otherwise indicated, are as previously defined, and all reagents are well known and appreciated in the art. The products of each step can be recovered by conventional methods including extraction, evaporation, precipitation, chromatography, filtration, trituration, crystallization, and the like. In Scheme I, appropriately substituted 6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-///-benzo[d]azepines (a) can be converted to the compounds (c), under Buchwald's coupling conditions, by treatment with an appropriate amine (b) in the presence of an effective palladium catalyst/ligand system, and a base in a suitable solvent, typically toluene or 1,4-dioxane under an inert atmosphere. While a variety of catalysts and ligands can be used, typical catalysts include tris(dibenzyiideneacetone)-dipalladium(0), palladiumOQ) acetate or a mixture of both, and typical ligands include (±)-2,2'-bis(diphenylphosphino)-l,r-binaphthalene (BINAP). Introduction of a second substituent R", if needed, may be performed to provide compounds (d). Pg is a suitable protecting group for a secondary amine such as, but not limited to, trifluoroacetyl, tert-butoxycarbonyl, or benzyl. Compounds of Formula (la) where R3 is H, may be obtained from compounds (d) by removing the protecting group Pg under conditions well known to the skilled artisan. Compounds of Formula (la) where R is methyl or ethyl, may be either obtained from intermediates (c) where Pg is methyl or ethyl, respectively; or, alternately, compounds of Formula (la) where R3 is H, may be converted to the N-methyl or N-ethyl derivatives (la) where R3 is methyl or ethyl via alkylation conditions well known in the art. An appropriate compound of Formula (la) is one hi which variables R1, R2, R3, R4, R5, R7, R8, R9, R10 and R11 are as previously defined for Formula I. Scheme I R6 -Pg Amines (b) are either commercially available or may be prepared by a variety of methods. For example, as illustrated hi Scheme n, amines of formula (f) and (h) can be prepared from nitriles (e) and (g) in the presence of hydrogen, at atmospheric pressure or 60 psi, using Degussa-type Pd/C as catalyst in a suitable solvent, such as methanol/hydrochloric acid, ethanol/hydrochloric acid, methanol/water/acetic acid, ethanol/water/acetic acid, THF/wo-propanol and the like. Alternately, hydrogenation can be performed at atmospheric pressure or 60 psi using Raney Nickel® as catalyst in a suitable solvent, typically methanol or ethanol hi the presence of ammonia Alternately, nitriles (e) and (g) can be reduced using lithium aluminum hydride or borane (THF or dimethylsulfide complex) in a suitable solvent, typically THF. Nitriles (e) and (g) can be also reduced using cobalt(II) chloride hexahydrate or nickel(n) chloride hexahydrate and sodium borohydride hi a suitable solvent, typically methanol or ethanol. Nitriles (e) and (g) are either commercially available or may be prepared by methods well known to the skilled artisan. Scheme n Ph' .ON ^ Ph'^•Z^ ^Z" (e) (0 (g) Z: bond or alkyl linker As illustrated in Scheme EQ, nitriles (e) and (g) can be also reduced in the presence of a suitable protecting group for an amine such as, but not limited to, di-te/t-butyl-dicarbonate. Reduction of nitriles (e) and (g) can be performed by hydrogen, at atmospheric pressure or 60 psi, using Degussa-type Pd/C as catalyst in a suitable solvent, such as methanol, ethanol, THF/iso-propanol, ethyl acetate and the like in the presence of di-fcrt-butyl-dicarbonate. Alternately, other suitable reducing agents could be cobalt(n) chloride hexahydrate or nickcl(ll) chloride hexahydrate and sodium borohydride in a suitable solvent, typically methanol or ethanol in the presence of di-terf-butyl-dicarbonate. Deprotection of the nitrogen gives the desired amines (f) and (h). Nitriles.(e) and (g) are either commercially available or may be prepared by methods well known to the skilled artisan. Scheme IH Ph*. -CN Ph'v^ ^CH,-NH-Boc ^ Ph*v^ ^ CH,-NH2 (e) (0 0 ,CN ^ Aft v, ^CHj-NH-Boc ^ Ar'.x^ ^,CH,-Nt (0) (I) W Z: bond or alkyl linker Amines (fa) and (ha) can also be prepared as illustrated in Scheme IV. Bromination of compounds (k) and (n) using NBS and AIBN in a suitable solvent, typically carbon tetrachloride, chloroform or dichloromethane provides bromides (1) (o), respectively. Reaction of compounds (1) and (o) with di-tert-butyl-iminodicarboxylate in the presence of a base such as sodium hydride, potassium carbonate, cesium carbonate or potassium tert-butoxide, in a suitable solvent, typically DMF or THF, afford compounds (m) and (p). Deprotection gives the desired amines (f) and (h). Compounds (k) and (n) are either commercially available or may be prepared by methods well known to the skilled artisan. Scheme IV Ph!-CH. — (k) -•- Phz-CH2-Br — (1) Pha -CH,-N(Boc)a — (m) -*• Ph2-CH,-NH2 <«a) Ar' -CHS — (n) -*- Ar' -CH2-Br » (o) Ar' -CH.-N(Boc). — (P) -*. Ar' -CHj-NH, (ha) Amines (fb) and (hb) may be prepared from the corresponding alcohols (q) and (s), respectively, via reaction sequences well known to the skilled in the art, as illustrated in Scheme V. The alcohols are converted to intermediates (r) and (s) with a suitable leaving group, such as but not limited to chloride, bromide, or mesylate, which may be displaced by a nucleophile such as azide (N3~), using a reagent such as sodium azide, di-tert-butyl-iminodicarboxylate in the presence of a suitable base or ammonia. The intermediates obtained from displacement with azide (Ns~) or di-terf-butyl-iminodicarboxylate may be converted to the amines (fb) and (hb) via well known standard procedures. Scheme V (q) M ('b) (s) (1) Z: bond or alkyl linker L: Cl, Br, I, OSO,CH3 Amines (fc) and (he) may also be prepared as illustrated in Scheme VI via reductive amination procedures. The corresponding aldehydes (u), R = H, or ketones (u), R = alkyl, are converted to the amines by reaction with a amine reagent, such as but not limited to a ammonium salt, in the presence of a reducing agent, such as sodium triacetoxy borohydride, or sodium cyano borohydride. Scheme VI nl 7 ft ni f ' kiii R-Z-\^° ^ R-Z->>.,NHt R R (u) (fc)R'=Ph2 (he) R1 = Ar< R':Ar',Ph2 R: H. alkyl Z: bond or alkyl linker Amines (fd), (fe), (hd), (he) may also be prepared as illustrated in Scheme VH. The corresponding nitriles (va) or esters (wa) may be dialkylated in the alpha-positions according to methods well known in the art. For example, reaction of compounds (va) with ethylene dibromide or ethylene dichloride in the presence of an appropriate base and hi a suitable solvent, such as but not limited to K[NSi(CHa)2] in THF, can afford the gem-ethano compounds (vb). Reduction of the nitrile under conditions some of which have been described above may yield amines (fe) and (he). Alternately, hydrolysis of the nitrile to the primary amide under conditions well described in the literature and rearrangement of the primary amide in the presence of NaOCl or NaOBr (Hofman rerrangement of primary amides) may lead to the amines (fd) and (hd). Alternately, esters (wb) can be hydrolyzed to the corresponding carboxylic acids, which then can be converted to the amines (fd) and (hd), via a Curtius-type rearrangement in the presence of sodium azide and sulfuric acid. Gem-ethano esters (wb) may also be obtained from the corresponding unsaturated esters (we), for example by reaction with CHBra in the presence of base, such as for example NaOH under phase transfer catalysis conditions, followed by denomination for example with Mg in methanol, or by reaction with diazomethane under suitable conditions. Scheme (va) (wa> (wb) 'vs^C02alkyl |j R':Ar<. Ph* (wo) Amines (ff) and (hf) can be prepared, as illustrated in Scheme VIII, by transformation of appropriately substituted intermediates (\a.\ (\c), (x.d), (x.e) into the appropriately substituted heteroaromatic compounds (xb) according to procedures known hi the art. Transformations of the nitrile by following the procedures previously described give the desired amines (ff) and (hf). Compounds (xa), (xc), (xd), and (xe) are either commercially available or may be prepared by methods well known to the skilled artisan. A = CHorN z, z', z* = bond or alkyl linker R = H or additional substltuents as described for Ph2 or Ar1 Amines (fg) and (hg) can be also prepared, as illustrated in Scheme K, by the couling of boronic acids (ya) with an appropriately substituted heteroaromatic bromide, chloride, iodide or triflate in the presence of a suitable palladium catalyst/ligand system, and a base in a suitable solvent, typically toluene, DMF or 1,4-dioxane under an inert atmosphere. Transformations of the nitriles (yb) by following the procedures previously described gives the desired amines (fg) and (hg). Boronic acids (ya) are either commercially available or may be prepared by methods well known to the skilled artisan. Alternately, intermediates (yb) can be obtained by reaction of compounds (yc) with an appropriately activated heteroaryl derivative, under appropriate transition metal catalysis, especially in the presence of a suitable palladium reagent, as described in the literature and well known to the skilled artisan [see for example, Li and Gribble, Palladium in Heterocyclic Chemistry, Pergamon, Amsterdam (2000)]. Scheme DC AxCH orN z, 2' * bond or alkyl linker R = H or additional substltuents S 2^ zx as described for Ph2 or Ar N CN NH2 L = Br, Cl, I, 0-Trfflate (ya) (yb) (fg) A - CH . (hg) A » N (yc) As illustrated in Scheme X, compounds of Formula (fa) can be prepared alternately from 6-amino-2,3,4,5-tetrahydro-7/f-benzo[d]azepines (za) by reaction with an appropriate bromide (zb), and an appropriate base, such as sodium hydride, potassium carbonate or cesium carbonate, in a suitable solvent, typically DMF, toluene, acetonitrile and the like. Introduction of a second substituent R11, if needed, may be performed to provide compounds (d). Pg is a suitable protecting group for a secondary amine such as, but not limited to, trifluoroacetyl or tert-butoxycarbonyl. Compounds of formula (d) are deprotected to give compounds of Formula (la). An appropriate compound of Formula (la) is one in which variables R1, R2, R3, R4, Rs, R7, R8, R9, R10 and R11 are as previously defined for Formula I. Bromides (zb) are either commercially available or may be prepared by methods well known to the skilled artisan. Scheme X The appropriately substituted 6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-lH-benzo[d]azepines (a) may be prepared as described in Scheme XI starting from 1-naphthol. 1-Naphthol can be converted to 5-hydrbxy-l,4-dihydronaphthalene (aa) by Birch reduction using ammonia and lithium metal at low temperature. Methylation of the 6-hydroxy group affords the compound (ab). Ozonolysis of compound (ab) and subsequent reduction with sodium borohydride provide the diol (ac). After converting the two hydroxyl groups into two good leaving groups, for example methanesulfonates, cyclize the compound (ad) to the 6-memoxy-2,3,4,5-tetrahydro-l#-benzo[rf]azepines (ae) with aqueous ammonia under pressure. Protect the ring nitrogen by treatment with a variety of alkyl halides, acid chlorides or anhydrides such as trifluoroacetic anhydride to give compounds (af). Subsequently convert the methyl ether (af) to the phenol (ag) with BBrs in dichloromethane or other methods well known in the literature [see for example, Oreene and Wuts, Protective Groups in Organic Synthesis, 3ri Ed., John Wiley and sons, Chapter ffl, New York (1999)]. Functionalization of the aromatic ring to introduce substituents R7, R8 and R9 are well known in the art and very depending on the substitution desired. Subsequent tru%oromethanesulfonylation of the appropriately X substituted 6-hydroxy-2,3,4,5-tetrahydro-JjFf-benzo[d]azepines (ah) affords the desired 6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-JH-benzo[d]azepines(a). R4 The skilled artisan will also appreciate that not all of the substituents in the compounds of Formula I will tolerate certain reaction conditions employed to synthesize the compounds. These moieties may be introduced at a convenient point in the synthesis, or may be protected and then deprotected as necessary or desired, as is well known in the art. The skilled artisan will appreciate that the protecting groups may be removed at any convenient point in the synthesis of the compounds of the present invention. Methods for introducing and removing protecting groups used in this invention are well known in the art; see, for example, Greene and Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley and sons, New York (1999). The following Preparations and Examples are illustrative of methods useful for the synthesis of the compounds of the present invention. Exemplified compounds are also particularly preferred compounds of the present invention. X General Procedure 1-1 Dissolve 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-l#-benzo[6-trifluoromemanesiitfonyloxy-2,3,4,5-tetrahydro-lH- benzo[4]azepine OH 5-Methoxv-1,4-dihydronaphthalene: Add powdered potassium carbonate (193.1 g, 1.397 mol) to a solution of 5-hydroxy-l,4-dihydronaphthalene [68.08 g, 90% potency based on 'H-NMR, 0.4657 mol, from Societa Italiana Medicinala Scandicci, s.r.l., Reggello (Firenze), Italy] in ethanol (700 mL). Cool the solution to 0°C with ice/water and add dimethyl sulfate (88.1 g, 66.1 mL, 0.699 mol) dropwise, maintaining the temperature between 5°C and 10°C. Then heat the reaction mixture to 40°C until the TLC (10:1 hexane/EtOAc) shows the absence of starting material (about 2 h). Filter off the solids by vacuum filtration and remove the solvent in vacua. Dilute the residual brown oil with diethyl ether (500 mL), wash with 10% aqueous NHiOH (500 mL), water (500 mL), brine (500 mL), dry the organic layer over NajSOn, filter and concentrate in vacua to give the crude product as a brown oil (73 g). Purify the crude mixture by short path distillation under vacuum (bp 120-130°C/ 5 Torr) to give the desired intermediate as a clear oil (69.0 g, 92.5% potency corrected) (contains some l,2,3,4-tetrahydro-5-methoxynaphthalene as an impurity). 'H NMR (300 MHz, CDC13), $ 7.15 (t, 1H, / = 7.9), 6.72 (dd, 2H, J = 15.7, 7.9), 5.93-5.88 (m, 2H), 3.83 (s, 3H), 3.42-3.39 (m. 2H), 3.30-3.28 (m, 2 H); Rf = 0.58 eluting with 10:1 hexane/EtOAc. 2.3-Bi8-(2-hvdroxvethvl)-l-methoxvbenzene: Charge a four-neck 5 L flask equipped with an over-head mechanical stirrer, reflux condenser, thermocouple, and gas dispersion apparatus with 5-methoxy-l,4-dihydronaphthalene (264.54 g, 89.5% potency based on 'H-NMR, 1.478 mol) in DCM (1.3 L) and 2B-3 ethanol (1 L). Add Sudan ffl (10 mg) to give a faint red color. Cool the solution to -65 °C or lower, then pass Oa through the solution until the solution turns a light yellow color and the TLC (10:1 hexane/EtOAc, X KMnO4 stain) shows the absence of the starting material (about 30 h). Transfer the solution via cannula into a slurry of NaBUt (97.8 g, 2.59 mol) in 2B-3 ethanol (500 mL) cooled in ice/water. It is important that the temperature be maintained at or above 0°C, as for example between 0°C and 10°C, throughout the transfer to ensure the ozonide is completely reduced to the diol. After the transfer is complete, warm the solution to ambient temperature and stk for about 30 min. Cool the slurry to 0°C with ice/water then slowly add acetone (540 mL, 7.4 mol) to remove excess NaBR*. After all the solids dissolve, remove the solvent in vacuo. Dissolve the yellow solid in DCM (1 L) and water (1 L), separate the layers and extract the aqueous layer with DCM (750 mL). Wash the combined organic layers with brine (1.5 L), add toluene (750 mL) and remove the solvent M vacuo. Dissolve the solid in DCM (500 mL) with heating, then add toluene (750 mL) and concentrate the solution in vacuo to give the desired intermediate as a light yellow solid (283.7 g, 89% potency corrected, mp 82-83°C) (contains l,2,3,4-tetrahydro-5-methoxynaphthalene as an impurity (8.6%)). Further purify the product by vacuum drying overnight at 75°C, 5 Torr, to remove all but trace amount of the l,2,3,4-tetrahydro-5-methoxynaphthalene impurity. 'H NMR (300 MHz, CDC13), 67.16 (dd, 1H, J = 8.2, 7.6), 6.83 (s, 1H, /= 7.0), 6.76 (s, 1H, J = 8.2), 3.85-3.77 (m, 7H), 3.01-2.91 (m, 4H), 2.35 (s, 2H); 13C NMR (300 MHz, DMSO-4), 6 157.5,138.9,126.5,125.2,122.0,108.4, 62.1,60.5,55.3,36.1,29.6; IR (KBr): 3006,2960,2886,2829,1583,1461,1440,1264, 1091,1041 cm'1; MS (ES+) m/z 178 (M+H)+; Anal. Calc'd for CnH,6O3: C, 67.32; H, 8.22; N, 0. Found: C, 67.26, H, 8.10, N, 0.21; Rf = 0.23 eluting with 95:5 DCM/methanol. 2.3-Bis-(2-methanesulfonyloxvethvl)-l-methoxvbenzene: To a slurry of 2,3-bis-(2-hydroxyethylM-methoxybenzene (50.6 g, 0.258 mol, 1 equiv.) and triethylamine (78.3 g, 0.774 mol, 3 equiv.) in DCM (500 mL) at 0°C, add dropwise a solution of methanesulfonyl chloride (65.0 g, 0.567 raol, 2.2 equiv.) in DCM (100 mL) over 45 min. The addition is exothermic and the methanesulfonyl chloride is added at a rate to keep the temperature below 10°C. After the addition is complete, warm the reaction to ambient temperature. Wash the solution with water (2x500 mL), and then brine (750 mL). Dry the organic layer over Na2SO4, filter and concentrate in vacuo to obtain the desired intermediate as a dark yellow oil (87.4 g, 96.2%), which is used in the next reaction without further purification. An analytical sample is obtained by flash column chromatography eluting with 100% diethyl ether. 'H NMR (300 MHz, CDC13), 8 7.20 (t, 1H, 7= 7.9), 6.82 (s, 1H, 7=7.2), 6.80 (s, 1H, 7 = 8.2), 4.41-4.34 (m, 4H), 3.83 (s, 3H), 3.16-3.09 (m, 4H), 2.91 (s, 3H), 2.87 (s, 3H); I3C NMR (300 MHz, CDC13), 8 158.07, 136.55,128.26,123.34,122.39,109.24,69.88,69.08,55.55,37.35,37.14,32.57,26.47; 13C NMR (300 MHz, DMSO-d6), 5 157.58,136.79,127.81,122.91,122.00,109.33, 70.19,68.88,55.55, 36.49,36.47,31.56,25.72; IR (KBr): 1586.8,1469.4,1358.51, 1267.3,1173.9,1105.4,972.4,954.6,914.3 cm'1; MS (ES+) m/z 257 (M+H)+; Anal. Calc'd. for Ci3H2oO7S2: C, 44.31; H, 5.72; N, 0. Found: C, 44.22, H, 5.68, N, 0.13; Rf= 0.72 eluting with 95:5 DCM/methanol. 6-Methoxv-2.3.4.5-tetrahydro-l/f-benzofff|azepine: Dissolve 2,3-bis-(2-methanesulfonyloxyethyl)-l-methoxybenzene (474.4 g, 1.346 mol) in acetonitrile (7 L) and split the mixture into two equal lots. In two separate runs, add concentrated aqueous NHtOH (3.5 L) and charge the solution to a pressure vessel (Parr apparatus). Heat the solution in a closed reactor to 100°C over 20 min (internal pressure reaches about 100 psi), and maintain at 100°C until the reaction is complete (about 1 h, HPLC monitored). Cool the reaction mixture to ambient temperature. Combine the two lots and remove the solvent in vacua. Dissolve the residue in MTBE (3.5 L) and water (3.5 L). Adjust the pH to 6.5 using 2M aqueous NaOH or 1M aqueous HC1 as appropriate (typically the pH is about pH=5.1 and the adjustment requires about 50 mL 2M aqueous NaOH). Discard the organic layer, adjust the aqueous layer to pH=13 using 50% NaOH (about 150 mL). Extract with MTBE (2x3.5 L), wash the combined organic layers with brine (3.5 L), dry over Na2SO4, filter and concentrate in vacua to give the title compound as a crude yellow oil that solidifies upon standing (179.3 g). Use the material for the next step without further purification. Prepare an analytical sample by purification by two Kugelrohr distillations to give a clear oil that solidifies upon standing, mp 44.3-45.0°C. 13C NMR (300MHz, DMSO-de), 8156.1,144.4,130.3.126.2,121.5,108.9,55.5,48.2,47.9,39.9, 29.1; MS (ES+) m/z 163 (M+Hf; Anal. Calc'd for C,,HISNO: C, 74.54; H, 8.53; N, 7.90. Found: C, 74.28, H, 8.62, N, 7.86. 6-Methoxv-2.3A5-tetrahvdro-l/^-benzorrflazepine Hvdrochloride: Dissolve crude 6-methoxy-2,3,4,5-tetrahydro-lflr-benzo[rf]azepine (35.1 g, 0.198 mol) in 2B-3 ethanol (250 mL), heat the solution to reflux and add 2M HC1 in ethanol (108.9 mL, 0.218 mol, 1.1 equiv.). Slowly add heptane (700 mL) over 10 min, then remove the heating mantle and cool the solution to ambient temperature, and finally continue the cooling with an ice/water mixture. Collect the resulting solid by vacuum filtration and wash with cold ethanol:heptane (1:2) (3x100 mL), air-dry for 15 min under vacuum, then further dry the product in a vacuum oven at 60°C for 1 h to give the desired intermediate as a white granular solid (35.53 g, 63%): mp 246.6-246.9°C; *H NMR (300 MHz, DMSO-4j), 8 9.82 (broad s, IH), 7.12 (dd, IH, /= 7.6,7.9), 6.88 (d, IH /= 8.2), 6.78 (d, IH, /= 7.3), 3.75 (s, 3H), 3.20-3.00 (m, 8H); 13C NMR (300 MHz, DMSO-^), 8 156.2,141.3,127.4, 127.2, 121.6, 109.7, 55.7,44.9,44.7, 31.6, 21.7; MS (ES+) m/z 178 (M+H)+; Anal. Calc'd for CuHisClNO: C, 62.12; H, 7.11; N, 6.59. Found: C, 61.95, H, 7.64, N, 6.58. 6-Memoxy-3-(2.2.2-trifluoroacetvl)-2.3.4.5-tetrahvdro-lflr-benzorgnazepine: To a slurry of 6-meraoxy-2,3,4,5-tetrahydro-l#-benzo[4, filter and concentrate in vacuo to give the desired intermediate as a light yellow solid (166.3 g, 94%). Use the product for the next step without further purification. Prepare an analytical sample by chromatography on silica gel eluting with 40% diethyl ether in hexane: mp 183.0-185.2°C. 'H NMR (300 MHz, DMSO-d«j), 6 9.39 (s, 1H), 6.94-6.88 (m, 1H), 6.72-6.68 (m, 1H), 6.61-6.57 (m, 1H), 3.67-3.32 (m, 4H), 2.99-2.86 (m, 4H); I3C NMR (300 MHz, DMSO-^), $ 154.50,141.47,141.18,126.77, 126.64,125.77,125.33,120.38,120.32,118.49,114.67,113.64,113.47,47.31,47.27, 47.00, 46.96,45.83,45.49,36.17, 34.93,26.46,25.18,20.66,14.00; MS (ES+) m/z 260 (M+H)*; Anal. Calc'd. for C|2Hi2F3NO2: C, 55.60; H, 4.67; N, 5.40. Found: C, 55.51, H, 4.71,N, 5.29. 7-Chloro-6-hvdroxv-3-f2.2.2-trifluoroac»t^lV2.3.4.5-tetrahvdro-ljy-benzorgnazepine: Heat a mixture of 6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-l/fr benzo[rf)azepine (120 g, 0.4629 mol) and toluene (14.4 L) to 70°C for 45 min until most of the starting material is dissolved. Add diisobutylamine (1.197 g, 1.62 mL, 9.26 ramol) followed by addition of sulfuryl chloride (62.48 g, 37.19 mL, 0.463 mol) hi toluene (360 mL) over 20 min. Stir the reaction mixture for 50 min and then add additional sulfuryl chloride (4.536 g, 2.70 mL, 0.0336 mol) neat and stir the reaction mixture for 15 min at 70°C. Cool the reaction mixture to 24°C over 30 rain and then add IN hydrochloric acid (2 L). Separate, wash the organic layer with saturated aqueous NaHCO3 (2 L), brine (2 L) and then dry over Na2SO4. Filter and remove the solvent with a rotary evaporator at 70°C until about 672.5 g remains using the minimum effective vacuum in order to maintain a vapor phase sufficient to prevent drying above the solvent line and self-seeding, thus preventing crystallization under these conditions. Using toluene heated to 70°C, transfer the light-yellow solution to a preheated (70°C) 3-neck flask equipped with a mechanical stirrer. Lower the temperature to 58°C over 1 h. If available, seed the solution with crystals of 7-chloro-6-hydroxy-3-(2,2,2-trucluoroacetyl)-2,3,4,5-tetrahydro-ltf-benzo[d]azepine from a prior synthesis to enhance crystallization. After 30 min, reduce the temperature further to 55°C and observe the initiation of the crystallization process. Hold the temperature at 55°C for 2 h followed by 4 h at 45°C, then turn off the heat allowing the mixture to slowly reach 24°C (ambient temperature). After stirring for 8 h with the heat off, cool the mixture to 0°C for 2 h followed by 2 h at -10°C. Collect the resulting dense, white, granular crystals by vacuum filtration at -10°C. Rinse the crystals twice with cold (-10°C) toluene and vacuum dry at 50°C, 5 Torr, for 12 h., to obtain the desired intermediate as a white solid (120.7 g, 99.5% purity, 88.8%): mp 133-134°C. MS (ES+) m/z 294 (M+H)+. Anal. Calc'd for C^HuClFaNOz: C, 49.08; H, 3.78; N, 4.77; Cl, 12.07. Found: C, 49.01; H, 3.63; N, 4.72; Cl, 12.32. 7-(^oro-3-f2.2.2-triflucroacetvl)-6-trifluorom benzofJlazepine: Cool a solution of 7-chloro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-ltf-benzo[d]azepine (60 g, 0.204 mol), triethylamine (62.6 mL, 0.448 mol, 2.2 equiv.), and DCM (590 mL) hi an ice bath and add dropwise trifluoromethanesulfonic anhydride (43.5 mL, 0.258 mol, 1.26 equiv.) over 70 min. Remove the ice bath and stir the reaction mixture for 2 h. Wash the reaction mixture sequentially with water (500 mL), IN aqueous HC1 (500 mL), water (500 mL), and brine (500 mL). Dry the organic layer over Na2SO4 and concentrate in vacua to give the crude product as a brown solid (90 g). Dissolve the solid in warm toluene (200 mL). Further purify by plug filtration chromatography over silica gel (500 g) eluting sequentially with hexane (1 L), hexane/EtOAc (9:1,1L), hexane/EtOAc (4:1,1L), and hcxane/EtOAc (7:3, 9L). Pool the 1,1 eluents and evaporate the solvent to obtain the product as a yellow tan solid (86.3 g). Dissolve the solid in warm EtOAc (86 mL) and then add hexane (700 mL). If available, seed the solution with crystals of 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trffluoromethanelsulfonyloxy-2,3,4,5-tetrahydr6-lflr-benzo[benzonitrile (1.6 g, 7.9 mmol) in methanol (200 mL). Add di-te/t-butyl-dicarbonate (2.2 g, 10.3 mmol) and nickel(H) chloride hexahydrate (188 mg, 0.8 mmol). Cool the solution to 0°C under a nitrogen atmosphere. Add sodium borohydride (1.5 g, 39.7 mmol) portionwise over 5 min at 0°C under a nitrogen atmosphere. Stir the resulting black mixture for 1 h at room temperature. Concentrate the mixture in vacua, dilute the residue with EtOAc (150 mL) and wash with saturated aqueous NaHCOa (30 mL). Collect the organic phase, concentrate in vacua and purify by chromatography on silica gel (40 g) eluting with hexane/EtOAc (20:1 to 3:2 gradient) to obtain the desired intermediate (1.6 g, 67%). MS (ES+) m/z: 204.1 (M-Boc+H)+. 4-(2-Metfavlamino-oxazol-4-vl)-benzvlamine Hvdrochloride: Add 4N hydrogen chloride in dioxane (10.5 mL) to a solution of W-(tert-butoxycarbonyl)-4-(2-mernylamino-oxazol-4-yl)-benzylamine (624 mg, 1.6 mmol) in DCM (250 mL). Stir the solution at room temperature for 16 h in a sealed flask. Concentrate the mixture in vacua to a solid. Slurry the solid in excess of diethyl ether and filter. Collect the white solid to obtain the title compound (1.48 g, 95%). MS (ES+) m/z: 204.1 (M+H)+. Preparation 12 4-(Cyclopentylthiomethyl)-benzylamuie X) fsr) H2N 4-(Cvclopentylthiomethvi)-benzonitrile: Add sodium bis(trimeuiylsilyl)amide (20 mL, 40 mmol, 2M solution in THF) to a solution of cyclopentanethiol (4.3 mL, 40 mmol) in anhydrous THF (100 mL) and stir at room temperature under nitrogen for 1 h. Add 4-bromomethyl-benzonitrile (7.85 g, 40 mmol) and stir the mixture for 24 h at room temperature. Reduce solvent in vacua and wash with saturated aqueous NaHCO3. Extract with DCM (50 mL), wash organic phase with brine (50 mL) and dry over MgSO4 to obtain a light yellow oil suitable for use without additional purification. GO-MS m/z: 217 (M+ ). 4-4 and concentrate in vacuo to obtain the desired intermediate as a yellow solid (1.04 g, 71%). 3-Aminomethyl-6-cvclohexvloxv-pyridine: Dissolve 6-cyclohexyloxy-pyridine-3-carbonitrile (1 g, 5 mmol) in anhydrousTHF (7 mL) under nitrogen and cool the mixture at 0°C. Add borane-THF complex (15 mL, 15 mmol, 1M solution in THF) and stir the reaction mixture at room temperature overnight. Pour slowly the reaction mixture into an ice-cold 5N aqueous HC1 (50 mL) and stir the resulting solution for 4 h. Concentrate in vacuo, take up the resulting solid with a minimum amount of methanol and filter through a SCX-2 column eluting with methanol followed by 3N ammonia in methanol to obtain the title compound as a yellow oil (621 mg, 62%). MS (ES+) m/z: 207 (M+H)*. Preparation 26 The compound of Preparation 26 may be prepared essentially as described in Preparation 25 using 6-chloro-nicotinonitrile and 4,4-dimethyl-cyclohexanol. Overall yield and MS (ES+) data are shown hi the Table below. Prep. Structure Compound Yield MS(ES+) m/z e.e. 26 C^~ 3-Aminomethyl-6-(4,4- 40 235 - A^ dimethyl-cyclohexyloxy)- (M+H)+ y pyridine H.KT Preparations 27 and 28 3-Aminomethyl-6-(3,3-dimethyl-cyclohexyloxy)-pyridine Isomer 1 and 3-Aminomethyl-6-(3,3-dimethyl-cyclohexyloxy)-pyridine Isomer 2 CN 6-f3.3-Dimethvl-cyclohexyloxv)-pyridine-3-carbonitrile: Dissolve 3,3-dimethylcyclohexanol (6 g, 47 mmoles) in anhydrous THF (70 mL) under nitrogen atmosphere and cool at -78°C. Add sodium bis(trimethylsilyl)amide (23.4 mL, 47 mmol, 2M solution hi THF) to this solution and stir at -78°C for 30 rnin before raising to room temperature. Cool down again to -78°C and add a solution of 2-chloro-5-cyanopyridine (7. 1 g, 51.7 mmoles) in anhydrous THF (20 mL) and stir overnight while wanning to room temperature. Add saturated aqueous NaHCOs (100 mL) and extract the aqueous layer with DCM (3x100 mL). Wash the combined organic extracts with brine (200 mL). Dry over MgSO4, filter and concentrate in vacua. Purify the crude mixture by 7-2 X chromatography on silica gel eluting with cyclohexane/EtOAc (1:0 to 9:1 gradient) to afford the desired intermediate as a solid (9.14 g, 84 %). MS (ES+) m/z: 231.1 (M+H)+. (±)-3-Aminomethvl-6-(3.3-dimethvl-cvclohexvloxvVpvridine: Dissolve 6-(3,3-dimethyl-cyclohexyloxy)-pyridine-3-carbonitrile (9.14 g, 39.7 mmoles) in THF (20 mL) at 0°C under nitrogen and add borane-THF complex (119 mL, 119 mmol, 1M solution in THF). Stir the resulting solution overnight while wanning to room temperature. Slowly add the reaction mixture to a mixture of 5N aqueous HC1 (100 mL) and THF (50 mL) at 0°C and stir for 2 h. Concentrate in vacua and take-up the residue in a minimum amount of methanol for filtration through a SCX-2 column (10 g) eluting with methanol followed by 3N ammonia in methanol to obtain the desired intermediate as an oil (5.85 g, 63%). MS (ES+) m/z: 207 (M+H)+. 3-Aminomethvl-6-(3.3-dimethvl-cvclohexyloxv)-pvridine Isomer 1 and 3-Aminomethvl-6-(3.3-dimethvl-cvclohexvloxv)-pvridine Isomer 2: Separate enantiomers of (±)-3-aminomethyl-6-(3,3-dimethyl-cyclohexyloxy)-pyridine by chiral Supercritical Fluid Chromatography (Instrument: Berger SFC Multigram; Column: 2xAD-H columns in series, 21.2x250 mm each; flow rate: 40 mL/min; mobile phase: 12% methanol with 0.2% dimethylethylamine/88% CO2). 3-Aminomethyl-6-(3,3-dimethyl-cyclohexyloxy)-pyridine Isomer 1 [MS (ES+) m/z: 235 (M+H)*, ee = 99%; 3-Aminomethyl-6-(3,3-dimethyl-cyclohexyloxy)-pyridine Isomer 2 [MS (ES+) m/z: 235 (M+H)"1", ee = 96%. Preparation 29 3-Aminomethyl-6-(wo-propoxy)methyl-pyridine -°r r°r t — n 6-(t'jo-Propoxv)metfavl-pvridine-3-carbonitrile: Add iso-propanol (2.2 g, 25 mmol) and tetraburylammonium sulfate (28 mg, 0.08 mmol) to.a solution of potassium hydroxide (7.1 g, 127 mmol) in water (7 mL) and stir at room temperature for 15 min. Add 6-bromomethyl-pyridine-3-carbonitrile (1 g, 5.08 mmol) and stir the mixture for 24 h at X room temperature. Add water (15 mL) and extract with DCM (15 mL). Filter through an 1ST® phase separator frit to separate the organic phase and concentrate in vacua. Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0 to 1:1 gradient) to obtain the desired intermediate as a crystalline solid (0.4 g, 45%). MS (ES+) m/z: 177 (M+H)4. 3-Aminomethvl-6-(fao-propoxv)methvl-Pvridine: Add a solution of borane-THF complex (4.5 mL, 4.54 mmol, 1M solution in THF) to neat 6-(wo-propoxy)methyl- pyridine-3-carbonitrile (0.4 g, 2.27 mmol) and stir the mixture for 16 h at reflux. Cool to room temperature and stir for 48 h. Add 2N aqueous HC1 (10 mL) until gas evolution stops and then concentrate in vacua. Dissolve the crude mixture in methanol and filter through a SCX-2 column eluting with methanol followed by 3N ammonia in methanol to obtain the title compound (190 mg, 46%). Preparations 30-32 The compounds of Preparations 30-32 may be prepared essentially as described in Preparation 29 using and 6-bromomethyl-pyridine-3-carbonitrile and the appropriate alcohol. Overall yields and MS (ES+) data are shown in the Table below. Prep. Structure Compound Yield MS(ES+) m/z 30 r'°v'T" II I1 T HjH 3-Aminomethyl-6-[(2,2-dunethylpropoxy)methyl] -pyridine 20 209 (M+Hf 31 §° 3-Aminomethyl-6-(cyclopentyloxy)methyl-pyridine 14 207 32 ll N tyT 3-Aminomethyl-6-(cyclohexyloxy)methyl-pyridine 12 221 (M+H)+ Preparation 33 2-Aminomethyl-5-cyclohexyloxy-pyridme Cl 6-Chloro-3-cvclohexyloxv-pvridine: Under a nitrogen atmosphere add 6-chloro-pyridin-3-ol (2.5 g, 19.3 mmol), cyclohexanol (1.93 g, 19.3 mmol), tri-n-butylphosphine (5.07 g, 25.1 mmol), and ADDP (6.32 g, 25.1 mmol) to benzene (100 mL) and THF (10 mL) at 0°C. Stir the mixture at 0°C for 1 h and at room temperature for 12 h. Dilute with EtOAc and water. Separate the layers and extract the aqueous layer with EtOAc. Wash the organic phase with water (30 mL) and brine (20 mL). Dry the organic phase over Na2SC>4, filter, and concentrate in vacuo. Purify the crude mixture by chromatography on silica gel (400 g) eluting with hexane/EtOAc (1:0 to 98:2 gradient) to obtain the desired intermediate as clear oil (1.8 g, 58%). MS (APCI+) m/z: 212 (M+H)+. 5-Cvclohexvloxv-pvridine-2-carbonitrile: Under a nitrogen atmosphere, add 6-chloro-3-cyclohexyloxy-pyridine (1.5 g, 7.1 mmol) and copper(I) cyanide (1.89 g, 21 mmol) to NMP(15mL). Heat the mixture at 180°C overnight. Cool the mixture to room temperature and add copper(I) cyanide (0.63 g, 7.1 mmol). Heat the mixture at 180°C for 6 h. Cool the mixture to room temperature, dilute with 5N aqueous NHLjOH and extract with DCM. Separate the layers and extract the aqueous phase With additional DCM. Wash the combined organic extracts with water and brine. Dry the organic phase over NajSOii, filter, and concentrate in vacuo. Purify the residue by chromatography on silica gel (500 g) eluting with hexane/EtOAc (20:1) to obtain the desired intermediate (820 mg, 57%). MS (ES+) m/z: 203 (M+H)+. 2-Aminomethvl-5-cvclQhexvloxv-pYridine: Under a nitrogen atmosphere, add borane-dimethylsulfide complex (20.3 mL, 40.6 mmol, 2M solution in THF) to a solution of 5-cyclohexyloxy-pyridine-2-carbonitrile (0.82 g, 4.06 mmol) in THF (800 mL) at 0°C. Warm the mixture to room temperature and stir overnight. Cool the mixture in an ice-bath, add methanol (15 mL) and concentrated HCI (2 mL). Stir for 2 h, and concentrate in vacuo. Dissolve the residue in saturated aqueous KjCOs. Extract with DCM and wash tt the organic phase with water and brine. Dry the organic phase over NaaSO^ filter, and concentrate in vacua to obtain the title compound (0.3 g, 36%). MS (ES+) m/z: 207 Preparation 34 2-Aminomethyl-5-cycloheptyloxy-pyridine Cl Cl Boc-HN- H2N' 6-Chloro-3-cycloheptyloxv-pvridine: Add 6-chloro-pyridin-3-ol (2 g, 15.4 mmol), cycloheptanol (1.93 g, 17 mmol), tri-n-butylphosphine (4.67 mL, 19.3 mmol), and ADDP (4.87 g, 19.3 mmol) to THF (60 mL) at 0°C under a nitrogen atmosphere. Stir the mixture at 0°C for 1 h and at room temperature for 12 h. Dilute with EtOAc (50 mL), add water (50 mL) and separate the layers. Extract the aqueous layer with EtOAc (4x30 mL). Wash the combined organic extracts with water (30 mL) and brine (20 mL). Dry the organic phase over NaiSO^ filter, and concentrate in vacua. Purify the crude mixture by chromatography on silica gel (120 g, pre-packed cartridge) eluting with hexane/EtOAc (1:0 to 1:1 gradient over 1.25 h, 80 mL/min) to obtain the desired intermediate as a colorless oil (2.36 g, 68%). MS (APCI+) m/z: 226 (M H)+. 5-Cvcloheptvloxy-pyridine-2-carbonitrile: Add 6-chloro-3-cycloheptyloxy-pyridine (2.35 g, 10.4 mmol) and copper(I) cyanide (1.16 g, 13.1 mmol) to NMP (25 mL). Heat the mixture to 190°C and stir overnight Cool the mixture to room temperature, add water (50 mL) and diethyl ether (30 mL). Extract the aqueous phase with diethyl ether (3x25 mL). Wash the combined organic extracts with brine (20 mL), dry over Na2SO4, filter, and concentrate in vacua. Purify the crude mixture by chromatography on silica gel (45 g, pre-packed cartridge) eluting with hexane/EtOAc (1:0 to 1:1 gradient over 60 min, 80 mL/min) to obtain the desired intermediate as a colorless oil (1.21 g, 54%). MS (APCI+) m/z: 217 (M+H)+. 2-(tert-Butoxvcarbonylamino-methvlVS-cvcloheptvloxv-pvridine: Add 5-cycloheptyloxy-pyridine-2-carbonitrile (1.6 g, 7.33 nrunol), di-fe/t-butyl-dicarbonate (3.17 g, 14.7 mmol) and 10% Pd/C (100 mg) to ethanol (25 mL). Bubble hydrogen (via balloon) through the vigorously stirred solution for 8 h and under static pressure overnight. Filter the mixture through cellulose powder (20 Dm) and rinse with ethanol. Concentrate in vacua and purify by chromatography on silica gel (45 g, pre-packed cartridge) eluting with hexane/EtOAc (1:0 to 4:1 over 30 min, 80 mL/min) to obtain the desired intermediate as a colorless oil (1.91 g, 81%). MS (APCI+) m/z: 321 (M+H)+. 2-Aminomethvl-5-cvcloheptyloxv-pyridine: Dissolve 2-{terr-butoxycarbonylamino-methyl)-5-cycloheptyloxy-pyridine (1.9 g, 5.95 mmol) in methanol (25 mL) and cool to 0°C. Bubble hydrogen chloride through the vigorously stirred solution for 30 min. Evaporate in vacua and partition the residue between 3N aqueous NaOH (10 mL) and DCM (20 mL). Separate the two layers and extract the aqueous layer with DCM (2x20 mL). Wash the combined organic extracts with brine (20 mL), dry over NajSO^ filter, and concentrate in vacua to obtain the title compound as a colorless oil (941 mg, 72%). MS (APCI+) m/z: 221 (M+H)+. Preparation 35 2-Aminomethyl-5-(3,3-dimethylcyclohexyloxy)-pvridine 3.3-Dunethvlcvclohexvl4-nietfavlbenzenesulfonate: Under a nitrogen atmosphere, add 3,3-dimethylcyclohexanol (1 g, 9.75 mmol), DMAP (238 mg, 1.95 mmol), triethylamine (2.70 mL, 19.5 mmol), andp-toluenesulfonyl chloride (2.045 g, 10.72 mmol) to DCM (25 mL) at 0°C. Stir the mixture for 1 h at 0°C and warm to room temperature overnight. Add saturated aqueous NaHCO3 (20 mL) and separate the layers. Extract the aqueous layer with DCM (3x20 mL). Wash the combined organic extracts with water and brine. Dry the organic phase over Na2SO4, filter, and concentrate in vacua. Purify the crude mixture by chromatography on silica gel (45 g, pre-packed cartridge) eluting with hexane/EtOAc (1:0 to 1:1 gradient over 60 min, 80 mL/rnin) to obtain the desired intermediate as a clear oil (1.93 g, 70%). MS (APCI+) m/z: 283 (M+H)*. 6-Chloro-3-(3.3-dimethylcvclohexvloxv)-pvridine: Under a nitrogen atmosphere, add 3,3-dimemylcyclohexyl 4-methylbenzenesulfonate (1.2 g, 4.25 mmol), 6-chloro-pyridin-3-ol (0.5 g, 3.86 mmol) and potassium hydroxide (238 mg, 4.25 mmol) to DMF (10 mL). Heat the mixture to 60°C and stir overnight. Add water (20 mL) and diethyl ether (20 mL) and separate the layers. Extract the aqueous layer with diethyl ether (3x20 mL). Wash the combined organic extracts with brine (20 mL), dry over Na2SC>4, filter, and concentrate in vacua. Purify by chromatography on silica gel (80 g, pre-packed cartridge) eluting with hexane/EtOAc (1:0 to 1:1 over 60 min, 80 mL/min) to obtain the desired intermediate as a white solid (728 mg, 79%). MS (APCI+) m/z: 240 (M+H)*. 5-(3.3-Dimethvlcvclohexvloxv)-pvridine-2-carbonitrile: Add 6-chloro-3-(3,3-dimethylcyclohexyloxy)-pyridine (1.1 g, 4.59 mmol) and copper(I) cyanide (1.23 g, 13.8 mmol) to NMP (20 mL). Heat the mixture to 190°C and stir overnight Cool the mixture to room temperature, add water (30 mL) and diethyl ether (30 mL). Extract the aqueous phase with diethyl ether (3x20 mL). Wash the combined organic extracts with brine (20 mL), dry over NajSO^ filter, and concentrate in vacua. Purify the crude mixture by chromatography on silica gel (80 g, pre-packed cartridge) eluting with hexane/EtOAc (1:0 to 1:1 gradient over 60 min, 80 mL/min) to obtain the desired intermediate as a colorless oil (412 mg, 39%). MS (APCI+) m/z: 231 (M+H)+. 2-Amuiomethvl-5-(3.3-dJmethvlcvclohexvloxv)-pvridine: Under a nitrogen atmosphere, add lithium aluminum hydride (264 mg, 6.95 mmol) to THF (15 mL) at 0°C. Add a solution of 5-(3,3-dirnethylcyclohexyloxy)-pyridme-2-carbonitrile (0.4 g, 1.74 mmol) in THF (5 mL), stir at 0°C for 1 h and warm to room temperature overnight. Cool the mixture at 0°C and carefully add water (0.3 mL). Add diethyl ether (25 mL), 3N aqueous NaOH (0.3 mL) and water (0.9 mL), and stir for 1 h at room temperature. Filter the solid residue and concentrate the filtrate in vacua to obtain the title compound as a colorless oil (360 mg, 88%). MS (APCI+) m/z: 235 (M+H)+. Preparation 36 (Z)-4-(2-Cyclohexylvinyl)-benzylamine HCI HjN'" Boc-HN^ Boc-HN^ Boc-HN H2N' jy-(ferf-Butoxvcarbonyl)-4-bromo-benzvlamine: Slurry 4-bromo-benzylamine hydrochloride (25 g, 112.6 mmol) in DCM (400 mL). Add triethylamine (31.4 mL. 225.2 mmol) and di-te/t-butyl-dicarbonate (24.55 g, 112.6 mmol) and stir the solution at room temperature for 16 h under a nitrogen atmosphere. Wash the mixture with water, dry the organic phase over NajSC^ and concentrate in vacua to obtain a solid. Wash the solid with hexane, filter and dry to obtain the desired intermediate as a white solid (31.735 g, 99%) suitable for use without further purification. MS (ES+) m/z: 230 [M-(f-Bu)+H]*. jY-(ferf-Butoxvcarbonvn-4-cyclohexvletfavnvl-beDzvlamine: Add cyclohexylacetylene (1.1 mL, 8.4 mmol) to a slurry of AHterf-butoxycarbonyl)-4-bromo-benzylarnine (2 g, 6.9 mmol), dichlorobis(triphenylphosphine)palladium (147 mg, 0.2 mmol), copper(I) iodide (67 mg, 0.4 mmol) and triethylamine (1.4 mL, 9.7 mmol) in DMF (7 mL). Stir the reaction in a sealed flask at 110 °C for 16 h. Cool to room temperature, dilute with water (10 mL) and hexane/EtOAc (1:1,100 mL). Filter the bi-phasic mixture through Celite®, collect the organic phase and wash with 5% aqueous NaCl (3x30 mL). Concentrate the organic phase in vacua and purify by chromatography on silica gel (120 g) eluting with hexane/EtOAc (20:1 to 3:2 gradient) to obtain the desired intermediate (0.75 g, 34%). MS (ES+) m/z: 258 [M-(r-Bu)+H]+. X (Z)-Af-(terr-Butoxvcarbonvl)-4-(2-cvclohexvlvinvn-benzvlamine: Dissolve N-(tert-butoxycarbonyl>4-cyclohexylemynyl-benzylamine (0.5 g, 1.6 mmol) in EtOAc (20 mL). Transfer the solution to a pressure vessel and hydrogenate at 30 psi for 3 h in the presence of 5% palladium on calcium carbonate (poisoned with 3.5% lead, 0.25 g). Filter the catalyst through Celite®, wash the filter cake with excess of EtOAc followed by excess of DCM and concentrate the filtrate in vacuo to an oil (HPLC shows starting material still present). Dissolve the oil in EtOAc (20 mL) again. Transfer the solution to a pressure vessel and hydrogenate contents at 30 psi for 2 h in the presence of 5% palladium on calcium carbonate (poisoned with 3.5% lead, 0.25 g). Filter the catalyst through Celite®, wash the filter cake with excess of EtOAc followed by excess of DCM and concentrate the filtrate in vacuo to an oil (HPLC shows all starting material consumed). Use this material in the next step without additional purification (0.49 g). MS (ES+) m/z: 260.2 (Z)-4-(2-Cyclohexylvinyl)-benzvlaroine: Add trifluoroacetic acid (1 mL) to a solution of (Z)-A^-(/cr/-butoxycarbonyl)-4-(2-cyclohexylvinyl)-benzylamine (0.49 g, 1.5 mmol) in DCM (10 mL). Stir the mixture at room temperature for 2 h, concentrate in vacuo and purify the residue by SCX chromatography to obtain the title compound (0.3 g, 87%, estimate 10% of alkane present). Use this material in the next step without additional purification. MS (ES+) m/z: 199.3 (M-^SfH3+H)+. Preparation 37 (£)-3-Aminomethyl-6-(2-cyclohexylvinyl)-pyridine H2N Boc-HN Boc-HN 3-(terr-Butoxvcarbonylarnino-methvl)-6-chloropvridine: Dissolve 3-aminomethyl-6-chloropyridine (1.65 g, 11.57 mmol) in DCM (58 mL) and add triethylamine (2.42 mL, 17.26 mmol) followed by di-terf-butyl-dicarbonate (3.03 g, 13.88 rnmol). Stir the resulting solution at room temperature overnight. Add DCM and saturated aqueous NaHCOs. Separate the aqueous phase and extract twice with DCM. Dry the combined organic extracts over MgSO4, filter and concentrate in vacua. Purify by chromatography on silica gel (120 g, pre-packed cartridge) eluting stepwise with hexane/EtOAc (1:0 over 5 min, 19:1 over 5 min, 9:1 over 5 min and 85:15 over 5 min; 50 mL/min) to obtain the desired intermediate (2.41 g, 86%). MS (APCI+) m/z: 187 [M-(/-Bu)+H]t. f£J)-3-(terr-Butoxvcarbonylammo-methvlV6-(2-cyclohexvlvmyl')-pvridine: Combine 3-(te/t-butoxycarbonylamino-methyl)-6-chloropyridine (1.42 g, 5.85 mmol), 2-cyclohexylvinyl boronic acid (1.35 g, 8.78 mmol), [l,l'-bis(diphenylphosphino)-ferrocene]dichloropalladium(II) complex with DCM (239 mg, 0.293 mmol), and 2M aqueous NazCO3 (9.65 mL, 19.2 mmol) in 1,4-dioxane (60 mL). Purge the resulting solution with nitrogen for 5 min and heat at 90°C overnight. Cool the reaction mixture to room temperature and partition the mixture between EtOAc and water. Separate the aqueous phase and extract twice with EtOAc. Dry the combined organic extracts over MgSC«4, filter and concentrate in vacua. Purify by chromatography on silica gel (120 g, pre-packed cartridge) eluting stepwise with hexane/EtOAc (1:0 over 5 min, 49:1 over 5 min, 19:1 over 5 min, 9:1 over 5 min and 85:15 over 5 min; 50 mL/min) to obtain the desired intermediate (1.3 g, 70%). MS (APCI+) m/z: 317 (M+H)*. (£V3-Aminomethvl-6-(2-cyclohexvlvinvl)-pvridine: Dissolve (£)-3-(terr-butoxycarbonylamino-methyl)-6-(2-cyclohexylvinyl)-pyridine (1.3 g, 4.11 mmol) in EtOAc (60 mL) and bubble hydrogen chloride through the solution for 20 min. Stir the mixture overnight at room temperature. Concentrate the mixture in vacua and dissolve the resulting solid hi water. Adjust the pH to 9-11 with 20% aqueous K^COs and extract with DCM. Dry the combined organic exracts over MgSCu, filter and concentrate in vacuo to obtain the title compound (0.78 g, 88%). MS (APCI+) m/z: 217 (M+H)"1". Preparation 38 (£)-2-Ammomethyl-5-(2"Cyclohexylvinyl)-pyridine N H2N' (£V5-f2-Cyclohexvlvinyl)-pvridine-2-carbonitrile: Combine a mixture of 5-bromo-2-cyano-pyridine (2 g, 10.93 mmol), 2-cyclohexylvinyl boronic acid (2.52 g, 16.39 mmol), [l,r-bis(diphenylphosphino)fenocene]dichloropalladium(II) complex withDCM (446 mg, 0.546 mmol) and 2M aqueous Na2CO3 (18.2 mL, 36.07 mmol) in 1,4-dioxane (110 mL). Purge with nitrogen and heat at 90°C overnight. Cool the reaction to room temperature and partition between EtOAc and water. Separate the aqueous phase and extract with EtOAc. Dry the combined organic extracts over MgSO4, filter and concentrate in vacuo. Purify by chromatography on silica gel (120 g, pre-packed cartridge) eluting stepwise with hexane/EtOAc (1:0 over 5 min, 49:1 over 5 min and 19:1 over 5 min; 50 mL/min) to obtain the desired intermediate (1.76 g, 76%). MS (APCI+) tn/z: 213 (M+H)+. (Jg)-2-Aminomethyl-5-f2-cvclohexvlvinvl)-pvridine: Cool a stirred solution of (£)-5-(2-cycIohexylvinyl)-pyridine-2-carbonitrile (1.76 g, 8.3 mmol) in THF (55 mL) to 0°C under nitrogen. Carefully add lithium aluminum hydride (1.26 g, 33.2 mmol) and warm to room temperature overnight Quench the reaction mixture with sequential addition of water (1.26 mL), 15% aqueous NaOH (1.26 mL) and water (3x1.26 mL), and stir for 3 h. Filter the mixture through Celite®, wash with EtOAc, and concentrate in vacuo. Purify the crude mixture by chromatography on silica gel (120 g, pre-packed cartridge) eluting stepwise with DCM/(chloroform:methanol:concentrated NH4OH 80:18:2) (1:0 over 5 min, 49:1 over 5 min, 19:1 over 5 min, 93:7 over 5 min and 9:1 over 5 min; 50 mL/min) to obtain the title compound (608 mg, 34%). MS (APCI+) m/z: 217 (M+H)+. Preparation 39 (Z)-3-Aminomethyl-6-(2-cyclohexylvinyl)-pyridine Boc-HN Boc-HN Boc-HN' 3-fterf-Butoxvcarbonvlamino-metfavl)-6-cvclohexvlethynyl-pvridine: Under a nitrogen atmosphere, add 3"(tert-butoxycarbonylamino-methyl)-6-chloropyridine (1 g, 4.12 mmol), cyclohexylacetylene (0.446 g, 4.12 mmol), dichlorobis(triphenylphosphine)-palladium (578 mg, 0.824 mmol), copper(I) iodide (157 rag, 0.824 mmol) and triethylamine (8.6 mL, 6.18 mmol) to THF (20 mL). Heat the mixture to reflux overnight. Cool the mixture to room temperature, and dilute with saturated aqueous NaHCOs (50 mL) and EtOAc (50 mL). Separate the layers and extract the aqueous layer with EtOAc (4x30 mL). Wash the combined organic extracts with brine (20 mL), dry over Na2SO4, filter and concentrate in vacua. Purify the crude mixture by chromatography on silica gel (120 g, pre-packed cartridge) eluting with hexane/EtOAc (1:0 to 6:1 gradient over 1.25 h, 80 mL/min) to obtain the desired intermediate as a colorless oil (0.71 g, 55%). MS (APCI+) m/z: 215 (M-Boc+H)+. (Z)-3-(terr-Butoxv<^fbonvlamino-methvl)-6-(2-cvclohexvlvinvl)-pvridine: Add3-(rm-butoxycaibonylamino-methyl)-6-cyclohexylethynyl-pyridine (0.7 g, 2.21 mmol) and Lindlar's Catalyst (0.1 g) to EtOAc (20 mL). Bubble hydrogen (via balloon) through the mixture for 2 h and stir under static atmosphere of hydrogen overnight. Filter the catalyst through Celite® and concentrate the filtrate in vacua. Purify the crude mixture by chromatography on silica gel (80 g, pre-packed cartridge) eluting with hexane/EtOAc (1:0 to 9:1 gradient over 1.25 h, 80 mL/min) to obtain the desired intermediate as a colorless oil (0.21 g, 30%) and starting material (0.42 g, 60%). Repeat the reaction on the recovered starting material to obtain the desired intermediate (242 mg, 57%; 452 mg total, 64% overall). MS (APCI+) m/z: 217 (M-Boc+H)+. (Z)-3-Aminomethvl-6-(2-cvclohexvlvinvn-pvridine: Add (Z)-butoxycarbonylamino-methyl)-6-(2-cyclohexylvinyl)-pyridine (0.42 g, 1.33 mmol) to methanol (20 raL) and cool to 0°C. Bubble hydrogen chloride into the solution until saturated, and allow the mixture to warm to room temperature. Concentrate the mixture in vacuo and partition the residue between 3N aqueous NaOH (30 mL) and DCM (30 mL). Separate the layers and extract the aqueous phase with DCM (3x30 mL). Wash the combined organic extracts with brine (30 mL), dry over NaaSCU, filter, and concentrate in vacuo to obtain the title compound as a colorless oil (0.89 g, 80%). MS (APCI+) m/z: 217 Preparation 40 (Z)-2-Aminomethyl-5-(2-cyclohexylvinyl)-pyridine 0 II CN 5-Cvclohexvlethvnvl-pvridine-2-carbom'trile: Under a nitrogen atmosphere, add 5-bromo-2-cyano-pyridine (1.5 g, 8.2 mmol), cyclohexylacetylene (0.887 g, 8.2 mmol), dichlorobis(triphenylphosphine)palladiuni (575 mg, 0.82 mmol), copper(I) iodide (234 mg, 1.23 mmol) and triethylamine (11.4 mL, 82 mmol) to THF (50 mL). Heat the mixture to reflux and stir for 4 h. Cool the mixture to room temperature and dilute with saturated aqueous NaHCO3 (50 mL) and EtOAc (50 mL). Separate the layers and extract the aqueous layer with EtOAc (4x30 mL). Wash the combined organic extracts with brine (20 mL), dry over Na2SO4, filter and concentrate in vacuo. Purify the crude mixture by chromatography on silica gel (120 g, pre-packed cartridge) eluting with hexane/EtOAc (1:0 to 9:1 gradient over 1.25 h, 80 mL/rain) to obtain the desired intermediate as a colorless oil (1.28 g, 74%). MS (APCI+) m/z: 211 (M H)+. (Z)-5-(2-Cvclohexvlvinyl)-pvridine-2-carbonitrile: Add 5-cyclohexylethynyl-pyridine-2-carbonitrile (1.4 g, 4.16 mmol) and Lindlar's Catalyst (0.5 g) to EtOAc (20 mL). Bubble hydrogen (via balloon) through the mixture for 2 h and stir under static atmosphere of hydrogen overnight. Filter the catalyst through Celite® and concentrate the filtrate in vacua. Purify by chromatography on silica gel (80 g, pre-packed cartridge) eluting with hexane/EtOAc (1:0 to 9:1 gradient over 1.25 h, 80 mL/min) to obtain the desired intermediate as a colorless oil (0.89 g, 80%). MS (APCI+) m/z: 213 (M+ H)+. (Z)-2-Aminomethvl-S-(2-cvclohexvlvinvlVpvridine: Under a nitrogen atmosphere, add lithium aluminum hydride (965 mg, 25.4 mmol) to THF (20 mL) at 0°C. Add a solution of (Z)-5-(2-cyclohexylvinyl)-pyridine-2-carbonitrile (1.8 g, 1.74 mmol) in THF (5 mL) and stir at 0°C for 1 h and to room temperature overnight. Cool the mixture to 0°C and carefully add water (0.95 mL). Add diethyl ether (125 mL), 3N aqueous NaOH (0.95 mL), and water (2.85 mL) and stir for 1 h at room temperature. Filter the solid residue and concentrate in vacua to obtain the title compound as a colorless oil (0.49 g, 30%). MS (APCI+) m/z: 217 (M+H)+. Preparation 41 4-(2-Cyclohexyl-2-oxo-ethyl)-benzylamine 4-f2-Cvclohexvl-2-oxo-ethvlV-benzonitrile: Add 4-iodobenzonitrile (1.0 g, 4.37 mmol) and 1-cyclohexyl-ethanone (717 mg, 5.68 mmol) to a suspension of tris(dibenzylideneacetone)dipalladium(0) (60 mg, 0.065 mmol), BINAP (98 mg, 0.157 mmol) and sodium terf-butoxide (546 mg, 5.68 mmol) in anhydrous THF (26 mL). Hea* the mixture at 70 °C under nitrogen atmosphere. After 6 h, add tris(dibenzylideneacetone)dipalladium(0) (60 mg, 0.065 mmol), BINAP (98 mg, 0.157 mmol), sodium tert-butoxide (294 mg, 3.06 mmol) and 1-cyclohexyl-ethanone (386 mg, 3.06 mmol) and allow to stir the mixture at 70 °C under nitrogen overnight. Add water X and extract twice with EtOAc. Dry the combined organic extracts over MgSCXt, filter and concentrate in vacua. Purify by chromatography on silica gel eluting with hexane/EtOAc (92:8) to obtain the desired intermediate as a yellow oil (902 mg, 91%). 4-(2-Cvclohexvl-2-oxo-emvlVbenzylamine: Bubble nitrogen for 10 min into a solution of 4-(2-cyclohexyl-2-oxo-ethyl)-benzonitrile (478 mg, 2.10 mmol) in methanol (80 mL) with concentrated HC1 (5 drops). Add 10% Pd/C (Degussa type E101,96 mg) and submit the mixture to hydrogenation at atmospheric pressure overnight. Filter the catalyst through Celite® and concentrate in vacua to obtain the hydrochloride salt of the title compound. Wash with diethyl ether/hexane (1:1) and filter the white solid. Add saturated aqueous NaHCOs and extract twice with EtOAc. Dry the combined organic extracts over MgSCU, filter and concentrate in vacua to obtain the title compound as a yellow oil (145 mg, 30%). MS (ES+) m/z: 232 (M+H)+. Preparation 42 4-(Morphobn-4-ylmethyl)-benzylamine H2N 4-(Morpholin-4-vlmethyl)-benzonitrile: Dissolve 4-cyanobenzaldehyde (5 g, 38.1 mmol), morpholine (4.15 g, 47.7 mmol) and acetic acid (2.2 mL, 38.1 mmol) in DCE (100 mL). Add sodium cyanoborohydride (3.59 g, 57.2 mmol), and stir the mixture overnight. Add water (100 mL), separate the layers and extract the aqueous layer with DCM (3x50 mL). Wash the combined organic extracts with brine, dry over Na2SO4, filter and concentrate in vacua. Purify by chromatography on silica gel (80 g, pre-packed cartridge) eluting with hexane/EtOAc (1:0 to 1:2 over 1.25 h, 80 mL/min) to obtain the desired intermediate as a colorless oil (6.1 g, 79%). MS (APCI+) m/z: 203 (M+ H)+. 4-(Morpholin-4-vlmethyl')-benzvlamine: Under a nitrogen atmosphere, add lithium aluminum hydride (1.13 g, 29.7 mmol) to THF (50 mL) at 0°C followed by a solution of 4-(morpholin-4-ylmethyl)-benzonitrile (2 g, 9.89 mmol) in THF (10 mL). Stir at 0°C for 1 h and at room temperature overnight. Cool (he mixture to 0°C, and carefully add water (1.15 mL). Add diethyl ether (125 mL), 3N aqueous NaOH (1.15 mL), water (3.45 mL), and stir for 1 h at room temperature. Filter the solid residue and concentrate the filtrate in vacua to obtain the title compound as a colorless oil (1.87 g, 94%). MS (APCI+) m/z\ 207 Preparation 43 4-(Pyrrolidin- l-ylmethyl)-benzylamine CN CN 4-fPvrrolidin-1 -vlmethvlVbenzonitrile: Add pyrrolidine (0.89 mL, 10.74.mmol) to a stirred solution of 4-bromomethyl-benzonitrile (1 g, 5.1 mmol) and triethylamine (1.5 mL, 10.74 mmol) in anhydrous THF (26 mL). Stir reaction overnight at room temperature. Partition the reaction mixture between EtOAc and water. Extract the aqueous phase twice with EtOAc. Dry the combined organic extracts overMgSCU, filter, and concentrate in vacua to obtain the desired intermediate (918 mg, 97%) suitable for use without further purification. MS (APCI+) m/z: 187 (M+H)+. 4-(PytTolidin-l-vlmetfavl)-benzvlamme: Dissolve 4-(pyrrolidin-l-yhTiethyl)-benzonitrile (918 mg, 4.93 mmol) in methanol (32 mL). Add cobalt(II) chloride hexahydrate (2.7 g, 9.87 mmol) and stir for 20 min. Cool the mixture to 0°C, and carefully add sodium borohydride (1.86 g, 49.3 mmol) in small batches. Stk the mixture for 1.5 h at room temperature. Quench the mixture with water and partition between water and chloroform. Extract the aqueous phase three times with chloroform/wo-propanol (3:1). Dry the combined organic extracts overMgSCU, filter, and concentrate in vacua. Purify by chromatography on silica gel (80 g) eluting with a gradient of DCM/(chlorofonn:methanol:concentrated NH4OH 80:18:2) (1:0 over 5 min, 19:1 over 5 min, 9:1 over 5 min, 85:15; 50 mL/min) to give the title compound (421 mg, 45%). MS (ES+)m/z:191(M+H)+ Preparation 44 4-(Piperidin-l-ylmethyl)-benzylamine 4-(Piperidin- l-vknetfayl)-benzonitrile: Under a nitrogen atmosphere, add sodium cyanoborohydride (5.77 g, 91.6 mmol) to a solution of 4-cyanobenzaldehyde (3 g, 22.9 mmol), piperidine (5.84 g, 68.7 mmol) and acetic acid (2.75 g, 45.8 mmol) in methanol (30 mL) at 0°C with stirring. Warm the mixture to room temperature and stir overnight. Add water (100 mL), saturated aqueous K2CO3 (50 mL), and extract with DCM. Wash the combined organic extracts with water and brine. Dry the organic phase over Na2SO4, filter, and concentrate in vacua. Purify by chromatography on silica gel (400 g) eluting with hexane/EtOAc (1:0 to 4:1 gradient) to obtain the desired intermediate as a clear oil (2.48 g, 54%). MS (APCI+) m/z 201 (M+H)+. 4-(Piperidin-l-vhnethviybenzylamine! Add 4-(piperidm-l-ylmethyl)-beozonitrile (890 mg, 4.45 mmol), 2M hydrogen chloride in ether (8.9 mL, 17.8 mmol) and 10% Pd/C (90 mg) to methanol (100 mL) in a pressure vessel. Flush the vessel three times with hydrogen and charge to 50 psi with hydrogen. Stir at room temperature for 2 h. Filter the catalyst through Celite® and concentrate the filtrate in vacua. Purify by chromatography on silica gel (100 g) eluting with a gradient of DCM to 4:1 DCM/(cMoroform:methanol:concentrated NHUOH 80:18:2) to obtain the tide compound as a colorless oil (0.82 g, 90%). MS (ES+) m/z: 205 (M+H)*. Preparation 45 The compound of Preparation 45 may be prepared essentially as described in Preparation 44 by using 4-cyanobenzaldehyde and (±)-l-methyl-2,2,2-trifluoro-ethylamine. MS (ES+) data is shown in the Table below. Prep. Structure Compound MS{ES+) m/z 45 JyCF, (±H-[(l-Methyl-2,2,2-trifluoro- 233 (M+H)+ J? ethylamino)-methyl]-benzylamine Preparation 46 (/?)- l-Methyl-2,2,2-trifluoro-ethylamine Hydrochloride 0 HCI H2N CF, f5)-(l-Phenvlethvn-(2'.2'.2'-trucluoro-l-methvlethvlideneVamine: Use a 22 liter 3-neck round-bottom flask equipped with a dry ice condenser and inlet tube in one side neck, mechanical stirrer in center neck and a Dean-Stark trap with dry ice condenser at top in other side neck. Chill a solution of cold 1,1,1-trifluoroacetone (2100 g, 18.74 mol) and cold toluene (1000 mL) in a wet ice-acetone bath at all times. To a cold mixture of ($)-(-)-Ormethylbenzylamine (550 g, 4.54 mol) and/j-toluenesulfonic acid monohydrate (8.63 g, 0.0454 mol) in toluene (1000 mL) at 0°C add a cooled solution of 1,1,1-trifluoroacetone (753 g, 6.72 mol) in cold toluene via teflon tubing under positive pressure of nitrogen (with the Teflon tubing below the surface of the reaction mixture and stopcock to prevent back-up). Remove the dry ice condenser in side neck and replace it with inlet with tubing. However, keep the Dean-Stark trap and dry ice condenser on the other side neck. Heat the reaction mixture slowly to 111°C. Remove water distillate and turn off heat Slowly add the organic distillate to the reaction mixture at a rate to keep trifluoroacetone distillation under control. Heat the reaction slowly to 111°C. Turn off heat and remove water and organic distillate. Add a cooled solution of 1,1,1- trifluoroacetone (789 g, 7.04 mol) in toluene to the hot reaction mixture at a rate to keep trifluoroacetone distillation under control. Heat the reaction mixture slowly to 1 1 1°C. Turn off heat and remove the distillate. Cool the reaction mixture and concentrate in vacua at 60°C. Add hexane (4 L) in portions to aid in removal of toluene to obtain the desired intermediate as a pale yellow oil of the crude product (1410 g). (/gVa'-PhenvlemvlideneVfZ^^-trifluoro-l-methvlethvn-amine: To crude phenylemyl)^2\2\2^trifluoro4-methylethylidene)-amine (1410 g, 4.54 mol theory) and washings with 20 g of toluene at room teemperature, add DBU (1050 g, 6.897 mol) in portions to keep temperature below 60°C. Heat the reaction at 60°C overnight (14 h) under nitrogen until the starting material rearranges to the desired intermediate (2460 g of solution). MS (ES+) m/z: 216.2 (M+H)+. (/?)- l-Methvl-2.2.2-trifluoro-ethvlamine Hydrochloride: Dilute the first half (1230 g) of the above reaction mixture with heptane (1500 mL) and DCM (1500 mL). Add 5N aqueous HCI (1250 mL) to the solution mixture and stir for 30 min until only acetophenone is present in the organic phase. Wash the bottom aqueous phase with 1:1 heptane/DCM (2x500 mL) and then cool the aqueous phase in an ice bath. Add ice-cold DCM (1500 mL) and then cold 5N aqueous NaOH (1250 mL) dropwise to the biphasic mixture and stir for 15 min. Separate the bottom organic phase. Extract the aqueous phase with DCM (2x500 mL) and distill the combined organic phase carefully (40-60°C pot temperature) while cooling the receiving flask in a dry ice/acetone bath. Collect the distillate. Add cold 5N aqueous HCI (500 mL) dropwise and stir for 30 min. Concentrate the mixture in vacua, using toluene for azeotropic removal of water, to afford the title compound as a white solid. Repeat the procedure with the second half of the previous reaction mixture to obtain the title compound as a white solid (451 g total, 66%). MS (ES+) m/z: 1 14.1 (M+H)+. [a]D = -1.4° (c=0.5, MeOH). Preparation 47 (/f)^[(l-Memyl-2,2,2-trifluoro-emylammo)-memyl]-benzylarnine H2N (/?)-4-f (1 -Methvl-2.2.2-trifluoro-ethvlamino)-methyn-benzonitrile: Add sodium cyanoborohydride (3.36 g, 53.5 mmol) to a solution of 4-cyanobenzaldehyde (1.75 g, 13.35 mmol) and (J?)-l-methyl-2,2,2-trrfluoro-ethylamine hydrochloride (2 g, 13.37 mmol) in methanol (17 mL) containing acetic acid (1.53 mL, 26.75 mmol). Stir the mixture at room temperature overnight. Partition the mixture between IN aqueous NaOH/DCM (1:1, 500 mL) and extract the aqueous layer twice with DCM. Dry the combined organic extracts over MgSO4, concentrate in vacua and purify by chromatography on silica gel (120 g) eluting with hexane/EtOAc (19:1, 9:1, 85:15 and 4:1) to obtain the desired intermediate (0.83 g, 27%). MS (ES+) m/z: 229 (M+H)+. f/?)-4-fn-Memvl-2.2.2-trifluoro-ethvIaminoVmethvl1-benzvIamine: Addcobalt(H) chloride hexahydrate (1.45 g, 6.09 mmol) to a solution of (/?)-4-[(l-methyl-2,2,2-trifluoro-ethylamino)-methyl]-benzonitrile (695 mg, 3.045 mmoi) in methanol (20 mL). Add sodium borohydride (1.15 g, 30.45 mmol) in small batches and stir at room temperature for 3 h. Quench with water, add chloroform and filter the mixture through Celite®. Separate layers and extract the aqueous phase twice with chloroform. Dry the combined organic extracts over MgSO4, filter and concentrate in vacua. Purify by chromatography on silica gel (40 g) eluting with a gradient of DCM to 19:1 and 9:1 DCM/(chlorofonn:methanol:concentrated NILtOH 80:18:2) to obtain the title compound as an oil (0.4 g, 57%). MS (ES+) m/z: 233 (M+H)+. Preparation 48 The compound of Preparation 48 may be prepared essentially as described in Preparation 47 by using 4-cyanobenzaldehyde and homopiperidine. Overall yield and MS (ES+) data are shown in the Table below. Prep. Structure Compound Yield (%) MS (ES+) m/z 48 o Hji 4-(Azepan-l -ylmethyl)-benzylamine 18 219 (M+H)+ Preparation 49 4-[(2,2,2-Trifluoroethylamino)-methyl]-benzylamine CN 4-f(2.2.2-Trifluoroethylamino)-methyll-ben2oriitrile: Add sodium cyanoborohydride (957 mg, 15.24 mmol) to a stirred solution of 4-cyanobenzaldehyde (500 mg, 3.81 mmol), 2,2,2-trifluoroethylamine (0.3 mL, 3.81 mmol) and acetic acid (0.44 mL, 7.62 mmol) in methanol (5 mL). Stir the mixture overnight at room temperature. Partition the mixture between IN aqueous NaOH and DCM. Extract the aqueous phase twice with DCM. Dry the combined organic extracts over MgSCU, filter and concentrate in vacua to obtain the desired intermediate (749 mg, 92%) suitable for use without further purification. MS (ES+)m/z:215(M+H)+ 4-f(2.2.2-TrifluoroemvlaminoX-memvn-bergyiamine: Dissolve 4-[(2,2,2-trifluoroemylanimo)-methyl]-benzorritrile (633 mg, 2.955 mmol) in methanol (22 mL). Add cobalt(II) chloride hexahydrate (1.41 g, 5.91 mmol) and stir for 20 min. Carefully add sodium borohydride (1.12 g, 29.55 mmol) in small batches and stir the mixture overnight Quench the mixture with water and filter through celite, washing filtercake with chloroform:methanol:concentrated NH/jOH (80:18:2). Concentrate the filtrate in vacua, and partition the residue between water and chloroform. Extract the aqueous phase three times with ddoroform/«0-propanol (3:1). Dry the combined organic extracts over MgSO*, filter and concentrate in vacuo. Purify by chromatography on silica gel (40 g, pre-packed cartridge) eluting with DCM/(chloroform:methanol:concentrated NHjOH 80:18:2) (1:0 over 5 min, 19:1 over 5 min, 9:1 over 5 min, 85:15 over 5 min, 4:1; 50 mL/min) to obtain the title compound (316 mg, 49%). MS (ES+) m/z: 219 (M+H)+. Preparation 50 4-[A^-(tert-ButoxyMrbonyl)-JV-(cyclohexyl)-aminomethyl]-benzylamine 4-(Cvclohexvlamino-methyl)-benzonitrile: Under a nitrogen atmosphere, add sodium cyanoborohydride (9.6 g, 152 mmol) to a solution of 4-cyanobenzaldehyde (5 g, 38 mmol), cyclohexylamine (3.8 g, 38 mmol) and acetic acid (0.46 g, 7.6 mmol) in methanol (100 mL) at 0°C. Warm the mixture to room temperature and stir overnight. Add water (100 mL) and adjust the pH to 10 with 3N aqueous NaOH. Extract with DCM and wash the organic phase with water and brine. Dry the organic phase over NaaSCv, filter and concentrate in vacua. Purify by chromatography on silica gel (500 g) eluting with hexane/EtOAc (1:0 to 1:1 gradient) to obtain the desired intermediate (6.9 g, 86%). MS (APCI+) m/z: 215 (M+H)+. 4-W-(fgyt-ButoxycarbonvlVJV-fcvclohexvi)-aininomethyll-benzonitrile: Add4-(cyclohexylamino-methyl)-benzonitrile (3.5 g, 16.3 mmol), triethylamine (2.26 mL, 16.3 mmol), and di-tert-butyl-dicarbonate (3.55 g, 16.3 mmol) to DCM (20 mL). Stir the mixture at room temperature overnight and concentrate in vacua. Purify by chromatography on silica gel (150 g) eluting with hexane/EtOAc (1:0 to 9:1 gradient) to obtain the desired intermediate (3.7 g, 72%). MS (APCI+) m/z: 215 (M-Boc+H)*. 4-W-(te/t-ButoxycarbonvlV^-fcvclohexvn-aininometfavl1-benzvlamine: Under a nitrogen atmosphere, add borane-dunethylsulfide complex (29.3 mL, 58.7 mmol, 2M solution in THF) to 4-[A'-(tert-butoxycarbonyl)-Ar-(cyclohexyl)-aminomethyl]-benzonitrile (3.7 g, 11.7 mmol) in THF (100 mL) at 0°C. Warm to room temperature and stir overnight. Heat the mixture under reflux for 30 min. Cool the mixture in an ice-bath, and add methanol (20 mL). Warm to room temperature, and add KHSO4 (20 g in 100 mL of water). Stir the mixture for 2 h and adjust the pH to 10 with 3N aqueous NaOH. Extract the mixture with DCM. Dry the organic phase over NaaSO/i, filter, and concentrate in vacua. Purify by chromatography on silica gel (150 g) eluting with a gradient of DCM to 1:1 DCM/(chloroform:methanol:concentrated NHjOH 80:18:2) to obtain the title compound as an oil (2.43 g, 65%). MS (ES+) m/z: 319 (M+H)*. Preparation 51 '4-(t'jo-Butylamino-methYl)-benzonitrile: Under a nitrogen atmosphere add sodium cyanoborohydride (5.77 g, 91.6 mmol) to 4-cyanobenzaldehyde (3 g, 22.9 mmol), wo-butylanune (3.34 g, 45.8 mmol) and acetic acid (1.37 g, 22.9 mmol) in methanol (30 mL) at 0°C. Warm the mixture to room temperature and stir overnight. Add water (40 mL), saturated aqueous K^COj (30 mL) and extract with DCM. Wash the combined organic extracts with water and brine. Dry the organic phase over NajSO^ filter and concentrate in vacua. Purify the residue by chromatography on silica gel (500 g) eluting with 9: 1 DCM/(chlorofonn:methanol:concentrated NRiOH 80:18:2) to obtain the desired intermediate (3.63 g, 84%). MS (APCI+) m/z: 189 (M+H)+. 4-W-(ferf-ButoxvcarfaonvlV^-0'jo-buM)-aminomethvl1-benzonitrile: Add 4 butylamuio-methyO-benzonitrile (2 g, 10.6 mmol), triethylamine (3 mL, 21.2 mmol), and di-/ert-butyl-dicarbonate (2.44 g, 11.2 mmol) to DCM (30 mL). Stir the mixture at room temperature for 1 h and concentrate in vacua. Purify by chromatography on silica gel (80 g) eluting with hexane/EtOAc (1:0 to 9:1 gradient) to obtain the desired intermediate as a clear oil (3.01 g, 98%). MS (ES+) m/z: 189 (M-Boc+H)*. ^^•(/c/t-Butoxvcarbonvn-JV-ftJQ-butvn-aminomethvn-benzvlamine: Under a nitrogen atmosphere, add borane-dimethylsulfide complex (13 mL, 26 mmol, 2M solution in THF) to 4-[A^-(re^butoxycarbonyl)-//-(wo-butyl)-aminomethyl]-benzonitrile (1.5 g, 5.2 mmol) in THF (20 mL) at 0°C. Heat the mixture under reflux overnight. Cool the mixture in an ice-bath and add raethanol (20 mL). Warm to room temperature and add KHSCU (7 g in 50 mL of water). Stir for 2 h at room temperature and basify with 3N aqueous NaOH. Extract with DCM, dry the organic phase over NajSC^, and concentrate in vacuo. Purify by chromatography on silica gel (150 g) eluting with a gradient of DCM to 4:1 DCM/(chloroform:methanol:concentrated NtUOH 80:18:2) to obtain the title compound as an oil (0.72 g, 47%). MS (APCI+) m/z: 293 (M+H)+. Preparation 52 4-[A^-(r€^Butoxycarbonyl)-^-(iso-propyl)-aminomethyl]-benzylamine Y H H2N 4-0'iyo-Propvlamino-methyn-benzonitrile: Under a nitrogen atmosphere, add sodium cyanoborohydride (5.77 g, 91.6 mmol) to a solution of 4-cyanobenzaldehyde (3 g, 22.9 mmol), iso-propylamine (2.03 g, 34.4 mmol) and acetic acid (1.37 g, 22.9 mmol) in methanol (30 mL) at 0°C with stirring. Warm the mixture to room temperature and stir overnight. Add water (100 mL), saturated aqueous KjCOa (50 mL), and extract with DCM. Wash the combined organic extracts with water and brine. Dry the organic phase over Na2SC<4, filter and concentrate in vacuo. Purify by chromatography on silica gel (300 g) eluting with 9:1 DCM/(chloroform:methanol:concentrated NHtOH 80:18:2) to obtain the desired intermediate (1.53 g, 38%). MS (APCI+) m/z: 175 (M+H)+. 4-f^-(te/t-Butoxycarbc^vlVA^-(t'gc^propvlVarfu^omethyl1-benzonitrile: Add4-(wo-propylamino-methyO-benzonitrile (1.53 g, 8.9 mmol), triethylamine (2.48 mL, 17.8 mmol) and di-terf-butyl-dicarbonate (2.01 g, 9.23 mmol) to DCM (30 mL). Stir the mixture at room temperature for 2 h and concentrate in vacuo. Purify by chromatography lot on silica gel (100 g) eluting with hexane/EtOAc (1:0 to 9:1 gradient) to obtain the desired intermediate as a clear oil (2.3 g, 95%). MS (ES+) w/z: 175 (M-Boc+H)+, 4-rAr-(fgrf-Butoxvcarbonvl)-N-(Mo-propyl)-aminomethvn-benzvlamine: Under a nitrogen atmosphere add borane-dimethylsulfide complex (13.7 mL, 27.4 mmol, 2M solution in THF) to 4-[N-(te/t-butoxycarbonyl)-A'-(wo-propyl)-aminomethyl]-benzonitrile (1.5 g, 5.5 mmol) in THF (20 mL) at 0°C. Warm to room temperature and stir overnight. Heat the mixture under reflux for 2 h. Cool the mixture in an ice-bath and add methanol (20 mL). Warm to room temperature and add KHSCv (7 g in 50 mL of water). Stir for 2 h at room temperature and basify with 3N aqueous NaOH. Extract with DCM, dry the organic phase over Na2SO4 and concentrate in vacua. Purify by chromatography on silica gel (150 g) eluting with a gradient of DCM to 4:1 DCM/(chloroform:methanol:concentrated NIttOH 80:18:2) to obtain the title compound as an oil (1.3 g, 85%). MS (APCI-f) m/z: 279 (M+H)+. Preparation 53 4-[(N-methyl-«o-propylamino)-methyl]-benzylamine ,Br CN 4-fW-methvl-/go-propvlamino)-methvn-benzonitrile: Add 4-bromomethyl-benzonitrile (784 mg, 4 mmol) to a stirring mixture of #-isopropyl-methylamine (730 mg, 10 mmol), triethylamine (1.4 mL, 10 mmol) and THF (20 mL) at room temperature, and stir for 12 h. Dilute the mixture with water and EtOAc. Extract the aqueous layer with EtOAc and wash the organic phase with water and brine. Dry the organic solution over NazSCU, filter, and concentrate in vacua. Purify by chromatography on silica gel (12 g) eluting with a gradient of DCM to 9:1 DCM/(chlorofonn:methanol:concentrated NHjOH 80:18:2) to obtain the desired compound (660 mg, 88%). MS (APCI+) m/z: 189 (M+H)+. 4-fW-methvl-iJo-propylamino)-methvn-benz¥lamine: Under a nitrogen atmosphere, add borane-dimethyl sulfide complex (8.7 mL, 17.4 mmol, 2M solution in THF) to a solution of 4-[(A^-methyl-wo-propylamino)-methyl]-benzonitrile (660 mg, 3.51 mmol) in THF (20 mL) at room temperature then heat to reflux for 30 min. Cool the mixture in an ice-bath and carefully add methanol (10 mL). Warm the mixture to room temperature and add concentrated HCI (10 mL). Stir the mixture for 12 h, and concentrate in vacua. Purify by chromatography on silica gel (25 g) eluting with a gradient of DCM to 1:1 DCM/(chloroform:methanol:concentrated NJUOH 80:18:2) to obtain the title compound (550 mg, 82%). MS (ES+) m/z: 193 (M+H)+. Preparation 54 6-Ammomemyl-3-[A^(cyclohexyl)-A^-(2,2,2-uifluoroacetyl)-aniinornethyl]-pyridine H2N 6-Chloro-3-(cvclohexvlamino-methyl)-pvridine: Under a nitrogen atmosphere, add sodium cyanoborohydride (3.53 g, 56 mmol) to a solution of 3-aminomelhyl-6-chloro-pyridine (2 g, 14 mmol), cyclohexanone (1.38 g, 14 mmol) and acetic acid (168 mg, 0.2 mmol) in methanol (20 mL) at 0°C. Warm the mixture to room temperature and stir overnight. Add water (100 mL) and saturated aqueous KjCOs. Extract three times with DCM and wash the combined organic extracts with water and brine. Dry over Na2SO4, filter, and concentrate in vacua. Purify by chromatography on silica gel (150 g) eluting with 9:1 DCM/(chlorofonn:methanol:concenttated NRtOH 80:18:2) to obtain the desired intermediate (2.86 g, 91%). MS (APCI+) m/z: 225 (M+H)+. 6-Chloro-34JV-fcvclohexvl)-N-(2.2.2-trifluoroacetvlVaminomethvl1-pvridine: Add trifluoroacetic anhydride (4 g, 19.1 mmol) to 6-chloro-3-(cyclohexylamino-methyl)-pyridine (2.86 g, 12.7 mmol) and triethylamine (2.66 mL, 19.1 mmol) in DCM (20 mL) at 0°C. Warm to room temperature and stir for 12 h. Concentrate in vacua and dilute with water and EtOAc. Separate the layers and extract the aqueous layer with EtOAc. Wash the combined organic extracts with water and brine. Dry over NajSO^ filter and concentrate in vacua. Purify by chromatography on silica gel (400 g) eluting with hexane/EtOAc (1:0 to 4:1 gradient) to obtain the desired intermediate as a white solid (3.7 g, 91%). MS (APCI+) m/r. 321 (M+H)*. 6-Cvano-3-fA^-(cYclohexvl)-^-(2.2.2-trifluoroa(^yl)-aminomethvl1-pvridine: Under a nitrogen atmosphere add 6-chloro-3-[N-(cyclohexyl)-W-(2,2,2-uifluoroacetyl)-aminomethyl]-pyridine (3.7 g, 11.5 mmol), zinc cyanide (2.02 g, 17.3 mmol), tris(dibenzylideneacetone)dipalladium(0) (0.48 g, 0.57 mmol) and DPPF (0.63 g, 1.15 mmol) to DMF (40 mL). Heat the mixture at 95°C for 2 h. Cool the mixture to room temperature and dilute with water and EtOAc. Separate the layers and extract the aqueous layer with EtOAc. Wash the combined organic extracts with water and brine. Dry the organic phase over NaaSO4, filter and concentrate in vacua. Purify by chromatography on silica gel (400 g) eluting with hexane/EtOAc (1:0 to 3:2 gradient) to obtain the desired intermediate (3.33 g, 93%). MS (APCI+) m/z: 312 (M+H)+. 6-Armnomemvl-34^-(cYclohexylVA^(2.2.2-trifluoroacetvlVammomemvll-pvridme Add 6-cyano-3-[A^-(cyclohexyl)-A'-(2,2^-trifluoroacetyl)-aminomethyl]-pyridme (1.5 g, 4.8 mmol), 2M hydrogen chloride in ether (7.2 mL, 14.4 mmol) and 10% Pd/C (0.3 g) to methanol (30 mL) in a pressure vessel. Flush the vessel three times with hydrogen and charge to 50 psi with hydrogen. Stir at room temperature for 4 h. Filter the mixture through Whatman® GF/B glass microfiber filter paper, and concentrate in vacua. Purify the residue by chromatography on silica gel (100 g) eluting with a gradient of DCM to 4:1 DCM/(chloroform:methanol:concentrated NH|OH 80:18:2) to obtain the title compound as a clear oil (1.6 g, 99%). MS (ES+) m/z: 316 (M+H)+. Preparation 55 5-Aminomethyl-2-(piperidin-l-ylniethyl)-pyridine [tit Boc-HN Boc-HN Boc-HN BocHN BocHN 3-(teyt-Butoxvcarbonvlanuno-me&vlV6-cvano-pvridine: Under a nitrogen atmosphere, add 3-(te/t-butoxycarbonylamino-methyl)-6-chloropyridine (13.1 g, 54 mmol), zinc cyanide (9.5 g, 81 mmol), tris(dibenzylideneacetone)dipalladium(0) (494 mg, O.S4 mmol), and dppf (550 mg, 0.81 mmol) to DMF (130 mL). Heat the mixture at 70°C overnight. Cool the mixture to room temperature and dilute with water and EtOAc. Separate the layers, and extract the aqueous layer with EtOAc. Wash the combined organic extracts with water and brine. Dry the organic solution over NazSOij, filter, and concentrate in vacuo. Purify by chromatography on silica gel (500 g) eluting with hexane/EtOAc (1 :0 to 7:3 gradient) to provide the desired intermediate as a white solid (1 1 .3 g, 90%). MS (ES+)/n/z:234(M+H)+. 3-(terf-Butoxvcarbonvlamino-methvl')-6-hvdroxvmethvl-pvriduie: Add butoxycarbonylamino-methyl)-6-cyano-pyridine (10.81 g, 46.4 mmol), KHSO4 (18.9 g, 16.2 mmol), 5% Pd/C (Degussa type E101, 4 g) to a mixture of methanol (250 mL) and water (20 mL) in a pressure vessel. Flush the vessel three times with hydrogen and charge with hydrogen to 50 psi. Stir at room temperature, recharging to 50 psi hydrogen as necessary, until no change hi pressure is observed. Add an aqueous NaOH solution (6.1 1 g of NaOH in 20 mL of water) to the mixture and stir for 15 min. Filter the mixture through glass microfiber filter paper. Dilute the filtrate with water and DCM. Separate the layers, and extract the aqueous layer with DCM. Wash the combined organic extracts with water and brine. Dry the organic solution over NaiSO^ filter and concentrate in vacuo. Purify by chromatography on silica gel (600 g) eluting with DCM/(chloroform:methanol:concentrated NEjOH 80:18:2) (1:0 to 7:3 gradient) to obtain 6-ammomemyl-3-(ter/-butoxycarbonylamino-methyl)-pyriduie as a clear oil [3.4 g, 31%, MS (ES+) m/z: 238 (M+H)*] and the desired intermediate 3-(tert-butoxycarbonylamino- methyl)-6-hydroxymethyl-pyridine as colorless oil (5.6 g, 52%). MS (ES+) m/z: 239 3-(fgr/-Butoxvcarbonvlamino-methylV6-chlorQmethyl-pvridine: butoxycarbonylamino-methyl)-6-hydroxymethyl-pyridine (2.3 g, 9.65 mmol) and triethylamine (2.05 mL, 14.5 mmol) to DCM (30 mL). Cool the mixture to 0°C and add methanesulfonyl chloride (0.83 mL, 10.6 mmol) to the mixture. Allow the mixture to warm to room temperature and stir overnight. Dilute the mixture with water (10 mL) and saturated aqueous NaHCO3 (10 mL). Separate the layers, and extract the aqueous layer with DCM (3x20 mL). Dry the combined organic extracts over Na2SC>4, filter and concentrate in vacuo. Purify by chromatography on silica gel (80 g) eluting with hexane/EtOAc (1:0 to 1:1 gradient over 60 min, 80 mL/min) to obtain the desired intermediate as a colorless oil (1.14 g, 46%). MS (APCI+) m/z: 257 (M+H)"1". 3-(fgrt-Butoxvcarbonvlamino-methyl)-6-(piperidin-l-vhnethyl)-pvridine: butoxycarbcmylamino-methyl)-6-chloromethyI-pvridine (500 mg, 1 .95 mmol) to a solution of piperidine (0.58 mL, 5.84 mmol) and saturated aqueous NaHCOa (2.5 mL) in acetonitrile (15 mL). Stir the mixture at room temperature overnight. Dilute the mixture with water (20 mL) and DCM (25 mL), separate the layers and extract the aqueous layer with DCM (3x20 mL). Dry the combined organic extracts over Na2SO4, filter and concentrate in vacuo. Purify by chromatography on silica gel (80 g pre-packed cartridge) eluting with hexane/EtOAc (1:0 to 1:1 gradient over 60 min, 80 mL/min) to obtain the desired intermediate as a colorless oil (547 mg, 92%). MS (APCI+) m/z: 306 (M+H)+. 5- Ammomethvl-2-f piperidin- 1 - vlmethvD-pvridine: Dissolve 3-(te/t-butoxycarbonylamino-methyl)-6-(piperidin-l-ylmethyl)-pyridine (540 mg, 1.76 mmol) in methanol (10 mL) and cool to 0°C. Bubble hydrogen chloride through the vigorously stirred solution for 30 min. Concentrate in vacuo. Partition the residue between 3N aqueous NaOH (10 mL) and DCM (20 mL). Separate the two layers and extract the aqueous layer with DCM (2x20 mL). Wash the combined organic extracts with brine (20 mL). Dry over Na2SO4, filter and concentrate in vacuo to obtain the desired intermediate as a colorless oil (351 mg, 95%). MS (APCI+) m/z: 206 (M+H)*. 106 Preparation 56 4-(2,2-Dimethyl-propionylamino)-benzylamine Boc-HN H2N 4-(2.2-Dimethvl-propionvlamino)-benzonitrile: Add dropwise trimethylacetyl chloride (3.3 mL, 27 mmol) to a mixture of 4-aminobenzonitrile (2.92 g, 24.7 mmol) and triethylamine (3.8 mL, 27 mmol) in anhydrous DCM (25 mL) at 0°C. Stir the mixture to room temperature overnight. Partition the reaction mixture between DCM (500 mL) and water (250 mL) and extract the aqueous phase with DCM (250 mL). Wash the combined organic extracts with water (3x250 mL), dry over NazSC^, filter and concentrate in vacua to obtain the desired intermediate (5 g, 100%). MS (ES+) m/z: 203.2 (M+H)*. Ar-(ferr-ButoxycarbonvlM-(2.2-dimethvl-propionYlamino)-benzyleniine Add a solution of 4-(2,2-dimethyl-propionylamino)-benzonitrile (5 g, 24.7 mmol) in THF/wo-propanol (1:2,60 mL) to 10% Pd/C (Degussa type E101,3 g, 1.41 mmol) via cannula under nitrogen. Add a solution of di-te/f-butyl-dicarbonate (6.74 g, 30.9 mmol) in THF (19 mL) to the reaction mixture via cannula under nitrogen. Purge the reaction mixture with nitrogen and then submit to hydrogenation at 50 psi overnight Filter the catalyst through Celite® and wash thoroughly with iso-propanol (500 mL) and THF (500 mL). Concentrate in vacua to obtain a solid. Recrystallize from EtOAc, cool to 0°C, filter and wash with cold EtOAc to obtain the desired intermediate as a white solid (5.748 g, 76%). MS (ES+) m/z: 307.3 (M+H)+. 4-(2t2-pimethyl-propionvlammo)-benzYlaniirie: Add 4M hydrogen chloride in dioxane (20 mL) to a solution of JV-(terr-butoxycarbonyl)-4-(2,2-dimethyl-propionylamino)-benzylamine (2 g, 6.53 mmol) in anhydrous 1,4-dioxane (50 mL) at room temperature. Stir overnight and partition me reaction mixture between saturated aqueous NaHCCb (200 mL) and DCM (500 mL). Extract the aqueous phase with DCM/wo-propanol (85:15, 2x100 mL) and then with DCM/wo-propanol (3:1,2x100 mL). Dry the combined organic extracts over NaaSCv, filter and concentrate in vacua. Purify by SCX chromatography eluting with DCM and DCM/2M ammonia in methanol (1:1) to obtain the title compound as a waxy colorless oil (1.13 g, 84%). MS (ES-) m/z: 205.1 (M-H)Preparations 57-58 The compounds of Preparations 57-58 may be prepared essentially as described in Preparation 56 using 4-aminobenzonitrile and the appropriate acid chloride. Overall yields and MS (ES+) data are shown in the Table below. Step 1 of Preparation 58 was purified by chromatography on silica gel eluting with hexane/EtOAc (1:0 to 67:33 gradient over 71 min and 67:33 to 0:1 gradient over 71 min; 50 mL/min). Prep. Structure Compound Yield MS(ES+) m/z 57 "V \7 4-(Cyclopropanecarbonyl-amino)-benzylamine 39 191 58 A H.N 4-[(l-Methyl-cyclopropanecarbonyl)-amino]-benzylamine 34 205 Preparation 59 4-[(2,2,3,3-Tetramethyl-cyclopropanecarbonyl)-amino]-benzylamine Boc-HN 4-r(2.2.3.3-Tetramethyl-cyclopropanecarbonvlVaminol-benzonitrile: Add a solution of 2,2,3 ,3-tetramethyl-cyclopropane-carbonyl chloride (5 g, 31.1 mmol) in anhydrous DCM to a mixture of 4-aminobenzonitrile (3.34 g, 28.3 mmol) and triethylamine (4.3 mL, 31 lot mmol) in anhydrous DCM (20 mL) at 0°C. After stirring at 0CC for 20 min, warm the mixture to room temperature and stir overnight. Partition the reaction mixture between DCM (500 mL) and water (250 mL) and extract the aqueous phase with DCM (250 mL). Wash combined organic extracts with water (3x250 mL), dry over NaaSCU, filter and concentrate in vacua. Purify the crude mixture by chromatography on silica gel eluting with hexane/EtOAc (1:0 over 36 min; 1:0 to 3:1 gradient over 36 min; 3:1 to 1:1 gradient over 71 min; 50 mL/min) to obtain the desired intermediate as a solid (2.31 g, 34%). MS (ES+) m/z: 243.2 (M+H)+. ^-(fgrf-ButoxvcarbonylM-f^^.SJ-tetramethvl-cyclopropanecarbonvD-aminol-benzvlamine: Add a solution of di-tert-butyl-dicarbonate (1.8 g, 82.6 mmol) in methanol (7 mL) and nickel(II) chloride hexahydrate (0.098 g, 0.41 mmol) to a cooled solution of 4-[(2,2,3,3-tetramethyl-cyclopropanecarbonyl)-amino]-benzonitrile (1 g, 41.3 mmol) in methanol (30 mL) at 0°C. Add sodium borohydride (0.89 g, 23.5 mmol) in portions over 25 min under a nitrogen atmosphere at a rate to keep gas evolution under control. Stir the reaction mixture at 0°C for 6 h and then slowly warm the reaction mixture in cooling bath until the reaction is complete. Concentrate in vacua and partition the residue between EtOAc (250 mL) and saturated aqueous NaHCO3 (100 mL). Extract the aqueous phase with EtOAc (3x50 mL). Dry the combined organic extracts over NaaSC^, filter and concentrate in vacua. Slurry the residue in enough DCM and filter undissolved solid product (0.58 g). Concentrate in vacua and purify by chromatography on silica gel eluting with hexane/EtOAc (1:0 to 3:1 gradient over 30 min; 3:1 over 3 min; 3:1 to 1:1 gradient over 30 min and 1:1 over 3 min; 35 mL/min) to obtain crude product. Dissolve the undissolved solid filtered above (0.58 g) in EtOAc (5.8 mL). Add hexane (11.6 mL) to precipitate out solid. Heat the slurry to reflux until homogeneous and then cool to room temparature and 0°C. Filter and wash solid with cold hexane (10 mL) and dry to obtain 0.173 g (12%) of the desired intermediate as a white solid. Combine the filtrate with the crude product isolated from the chromatography and concentrate in vacua to obtain 1.766 g. Dissolve this material in EtOAc (12.6 mL) and add hexane (25.2 mL) to precipitate out solid. Heat the slurry to reflux until homogeneous and then cool to room temperature and store in freezer overnight Filter and wash solid with cold hexane (10 mL) and dry to 104 obtain the desired intermediate as a white solid (0.548 g, 50% overall). MS (ES+) m/z: 347.3 (M+H)+. 4-ff2.2.3.3-Tetramethvl-cvclopropanecarbonyl)-amino1-benzylaniineAdd 4M hydrogen chloride in dioxane (6.1 mL) to a solution of/V-(tert-butoxycarbonyl)-4-[(2,2,3,3-tetramethyl-cyclopropanecarbonyt)-amino]-benzylamine (0.678 g, 1.958 mmol) in anhydrous 1,4-dioxane (12.2 mL) at room temperature. After stirring at room temperature for 3 h, the reaction is a solid mass. Add more 1,4-dioxane (12.2 mL), DCM (24.4 mL) and more 4M hydrogen chloride in dioxane (6.1 mL), and stir overnight Concentrate in vacua and partition the residue between saturated aqueous NaHCOs (200 mL) and DCM (500 mL). Dry the organic phase over Na2SO4, filter and concentrate in vacua. The aqueous phase was extracted with DCM/wo-propanol (3:1,4x200 mL). Dry the combined organic extracts over NajSC^, filter, combine with the organic fraction isolated above and concentrate in vacua. Purify by SCX chromatography eluting with DCM and DCM/2M ammonia in methanol (1:1) to obtain the title compound (0.519 g, 100%). MS (ES+) m/z: 247.2 (M+H)+. Preparation 60 (±)-/ro^^[(2-Memyl-cyclopropanecarbonyl)--amino]-benzylamine Cl Boc-HN H2N' (±)-cfo- and (±)-tra/iJ-2-Metfavl-cyclopropanecarbonyl chloride: Add thionyl chloride (39.3 mL, 539 mmol) at room temperature to a mixture of (±)-cis- and (±)-trans-2-methyl-cyclopropanecarboxylic acid (5 g, 49.9 mmol). Heat the reaction mixture at reflux overnight. Cool reaction mixture to room temperature and remove thionyl chloride by short-path distillation to afford a mixture of (±)-cw- and (±)-f/ww-2-methyl-cyclopropanecarbonyl chloride (5.53 g, 93%) as an amber oil. Translcis ratio is 16.7/1.0 by'HNMR. (±Vfra>M-4-r(2-Methvl-cyclopropanecarbonvIV-amino1-benzonitrile: To a mixture of 4-aminobenzonitrile (4.53 g, 38.4 ramol) and triethylamine (5.9 mL, 42 mmol) in anhydrous DCM (38.4 mL), add dropwise at 0°C a solution of (±)-cis- and (±)-mz/w-2-methyl-cyclopropanecarbonyl chloride (5 g, 42.2 mmol) in anhydrous DCM (9 mL). Stir at 0°C for 20 min, warm the mixture to room temperature and stir overnight. Partition the reaction mixture between DCM (500 mL) and water (250 mL) and extract the aqueous layer with DCM (250 mL). Wash the combined organic extracts with water (3x250 mL), dry over NaaSCXj, filter and concentrate in vacuo. Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0 to 3:1 over 71 min; 3:1 to 1:1 over 71 min; 50 mL/min) to afford (±)-/raiM-4-[(2-methyl-cyclopropanecarbonyl)-amino]-benzonitrile as a solid (2.31 g, 30 %) and a fraction containing a mixture of both isomers. (±)-fro^-A^-(/e>t-Butoxvcarbonyl)^-r(2-methvI-cyclopropanecarbonyl)-aniino1-benzylamine: Add a solution of (±)-tran5-4-[(2-methyl-cyclopropanecarbonyl)-anuno]-benzonitrile (2.316 g, 11.6 mmol) in THF/iso-propanol (1.0:1.8,28 mL) to 10% Pd/C (Degussa type E101,1.41 g, 0.66 mmol) via cannula under nitrogen. Add a solution of di-ferr-butyl dicarbonate (3.16 g, 14.5 mmol) in THF (8 mL) via cannula under Na. Purge the reaction mixture with nitrogen and then with hydrogen. Stir under 50 psi of hydrogen overnight Filter the mixture over Celite®, wash with wo-propanol (100 mL) and THF (100 mL), and concentrate in vacuo to give a solid. Recrystallize the crude mixture hi EtOAc (89 mL) and cool to 0°C. Filter and wash the solid with cold hexane (2x10 mL) to afford the desired intermediate as a white solid (1.893 g, 54%). More material can be obtained by recrystallizing again the compound remaining in filtrate. (±Vfr-benzylamine (0.6 g, 2.54 mmol) in DCM (12 mL). Stir the mixture for 1 h at room temperature. Partition the mixture between DCM and water. Extract the aqueous phase twice with DCM. Dry the combined organic extracts over MgSCU, filter and concentrate in vacuo. Purify by chromatography on silica gel (120 g) eluting with DCM/(chloroform:methanol:concentrated NHUOH 80:18:2) (1:0 over 5 min, 19:1 over 5 min, 9:1 over 5 min, 85:15; 50 mL/min) to obtain the desired intermediate (529 mg, 68%). MS(APCI+)m/fc249[M-(r-Bu)+Hr 4-ffCvclopropanecarbonyl-amino)-methvn-benzvlamine: Dissolve ^-(tert-butoxyc»rbonylM-[(cyclopropanecaAonyl-amino)-methyl]-benzylamine (529 mg, 1.74 mmol) in EtOAc (20 mL) and MeOH (15 mL). Bubble hydrogen chloride through the solution for 15 min, and stir the mixture overnight at room temperature. Concentrate the mixture in vacuo and dissolve the resulting solid in water. Adjust the pH to 9-11 with 20% aqueous K^COa (w/w %) and extract three times with chloroform/iso-propanol (3:1). Dry the combined organic extracts over MgSO.4, filter and concentrate in vacuo. Purify the crude mixture by chromatography on silica gel (40 g, pre-packed cartridge) eluting with DCM/(cMoroform:methanol:concentrated NfyOH 80:18:2) (1:0 over 5 min, 19:1 over 5 min, 9::1 over 5 min, 4:1 over 5 min, 1:1 over 10 min, 1:3; 50 mL/min) to obtain the desired intermediate (275 mg, 77%). MS (APCI-f) m/z: 188 (M-NH3+H)+. Preparation 65 4-[2-(2,2-Dimethyl-propionylamino)-ethyl]-benzylamine H2N 4-[2-(2.2-Dimethvl-propionvlamino')-ethyri-benzonitrile: Dissolve 4-(2-amino-ethyl)-benzonitrile hydrochloride (300 mg, 1.65 inmol) into saturated aqueous NaHCO3 and extract twice with EtOAc. Dry the combined organic extracts over NaaSCU and concentrate in vacua to obtain 4-(2-amino-ethyl)-benzonitrile (205 mg, 85%). Dissolve 4-(2-amino-ethyl)-benzonitrile (200 mg, 1.37 mmol) in DCM (2 mL), add triethylamine (54 \jL, 0,38 mmol) and cool the mixture at 0 °C. Add 2,2-dimethyl-propionyl chloride (169 uL, 1.37 mmol) dropwise and allow to stir the mixture at 0 °C for 15 min and at room temperature for 2 h. Add water, separate the organic phase and extract the aqueous phase twice with. DCM. Dry the combined organic extracts over NajSO^ filter and concentrate in vacua to obtain the desired intermediate (182 mg, 58%). 4-f2-(2.2-Drniemvl-propionvlarnino)-ethvri-benzvlamine: Bubble nitrogen for 15 min into a solution of 4-[2-(2^-dunethyl-propionylamino)-ethyl]-benzonitrile (175 mg, 0.76 mmol) in methanol (31 mL) with concentrated HC1 (3 drops). Add 10% Pd/C (Degussa type E101,18 mg) and submit the mixture to hydrogenation at atmospheric pressure for 64 h. Filter the catalyst through Celite® and concentrate in vacua to obtain the hydrochloride salt of the title compound. Add saturated aqueous NaHCOa and extract twice with EtOAc. Dry the combined organic extracts over MgSC>4, filter and concentrate in vacua to obtain the title compound as a yellow oil (110 mg, 62%). MS (ES+) m/z: 235 Preparation 66 4-(wo-Propylcarbamoyl-methyl)-benzylamine HCIHjN' Boo-HN Boc-HlT H2N' r4-ffeit-ButoxvcarbonvlaminomethvlVphenvl1l-aceticacid: Add NaOH (0.992 g, 24.8 mmol) and di-rert-butyl-dicarbonate (5.4 g, 24.8 mmol) to a solution of (4-aminomethyl-phenyl)-acetic acid hydrochloride (5.0 g, 24.8 mmol) in dioxane/water (1:1, 40 mL) and stk for 24 h. Remove dioxane in vacuo and and acidify the aqueous phase with 10% aqueous citric acid. Extract twice with EtOAc, dry the combined organic extracts over NazSC^, filter and concentrate in vacuo to obtain a solid. Wash the solid with hexane, filter and dry to obtain the desired intermediate (3.3 g, 50%). ^-(fert-Butoxy(^bonvl)-^fa<>-propvlcarbaniovl-methvl)-benzvlarnine: Combine [4-(/ert-butoxycarbonylaminomethyl)-phenyl]-acetic acid (400 nig, 1.5 mmol), isopropylamine (0.14 mL, 1.65 mmol), EDC (345 mg, 1.8 mmol), HOBt (243 mg, 1.8 mmol), triethylamine (0.63 mL, 4.5 mmol) and DMAP (18.3 mg, 0.15 mmol) in anhydrous DCM (15 mL). Stir at room temperature for 1 day under nitrogen. Concentrate in vacua and purify the crude mixture by chromatography on silica gel eluting with hexane/EtOAc (1:1) to obtain the desired intermediate as a white solid (426 mg, 92%). MS (ES+) m/z: 324 4-(&o-Propylcarbamoyl-mernylVbenzvlamine: Dissolve JV-(te7f-butoxycarbonyl)-4-(itt>-propylcarbamoyl-methyl)-benzylamhie (426 mg, 1.4 mmol) in DCM (5 mL). Add 4M hydrogen chloride in dioxane (3.5 mL, 14 mmol) and stir at room temperature for 1 h. Concentrate in vacuo and elute the compound through a SCX column to obtain the title compound as a white solid (281 mg, 98%). MS (ES+) m/z: 207 (M+H)*. Preparation 67 The compound of Preparation 67 may be prepared essentially as described in Preparation 66 by using [4-(terr-butoxycarbonylaminomethyl)-phenyl]-acetic acid and 2,2-dimethyl-propylamine. Overall yield and MS (ES) data are shown hi the Table below. Prep. Structure Compound Yield (%) MS(ES) m/z 67 rW H/T 4-[(2,2-Dimethyl-propylcarbamoyl)-methyl]-benzylamine 83 235 (M+H)+ Preparation 68 4-(2-Oxo-2-pyrrolidin-l-yl-ethyl)-benzylamine Boo-HN H,N' N-(te7t-Butoxvcarbonvl>-4-(2-oxo-2-pyn:olidin- 1 -vl-ethyl)-ben7.ylamine! Combine 4-(2-oxo-2-pyrrolidin-l-yl-ethyl)-benzonitrile (200 mg, 0.93 mmol), di-tert-butyl-dicarbonate (244 mg, 1.1 mmol) and 10% Pd/C (Degussa type E101, 100 mg) in methanol (18 mL). Submit the mixture to hydrogenation at atmospheric pressure for 40 h. Filter the catalyst through Celite® and concentrate the fdtrate in vacua. Purify by chromatography on silica gel eluting with hexane/EtOAc (1:1) to obtain the desired intermediate as a white solid (267 mg, 90%). 4-f2-Oxo-2-pyrrolidin-l-yl-etfavn-benzylamine: Dissolve W-(terf-butoxycarbonyl)-4-(2-oxo-2-pyrrolidin-l-yl-ethyl)-benzylamine (267 mg, 0.8 mmol) in DCM (4 mL). Add 4M hydrogen chloride in dioxane (2 mL, 8 mmol) and stir at room temperature for 1 h. Concentrate in vacua and elute the compound through a SCX column to obtain the tide compound (179 mg, 98%). MS(ES+)m/z:219(M+H)+. Preparation 69 (/?)-4-[(l-Memyl-2^^-trifluoto^uiylcarbamoyl)-methyl]-benzylamine X Boc-HN Boc-HN H2N (/?)-A^(terf-Butoxycatfaonvl)4-ffl-memyl-2.2.2-trifluoro-emvlcarbamovl)-methvl1-benzvlamine: Dissolve [4-(tert-butoxycarbonylamino-methyl)-phenyl]-acetic acid (190 mg, 0.63 mmol) in DCM (12.4 mL) and add triethylamine (354 pL, 2.5 mmol), DMAP (8 mg, 0.063 mmol), EDC (145 mg, 0.756 mmol), HOBt (102 mg, 0.756 mmol) and (/?)-!-methyl-2,2,2-trifluoro-ethylamine hydrochloride (71 mg, 0.63 mmol) under nitrogen atmosphere. Stir the reaction overnight at room temperature. Concentrate in vacua and purify by chromatography on silica gel eluting with hexane/EtOAc (1:1 and 0:1) to obtain the desired intermediate (155 mg, 68%). (J?">-4-f(l-Methvl-2.2.2-trifluoro-ethvlcarbamovlVmethyn-b^nzYlamine-- Dissolve (terr-butoxycarbonyl)^-[(l-memyl-2,2,2-trifluoro^mylcarbamoyl)-methyl]-benzylamine (155 mg, 0.43 mmol) in DCM (8 mL). Add 4M hydrogen chloride in dioxane (0.85 mL) and stir at room temperature overnight. Concentrate in vacua and partition the hydrochloride salt between saturated aqueous NaHCOs and EtOAc. Extract the aqueous phase twice with EtOAc. Dry the combined organic extracts over Na2SC>4, filter and concentrate in vacua to obtain the title compound (105 mg, 91%). MS (ES+) m/i: 261 Preparation 70 (±)^-[H2,2-Dimemylpropyl-carbamoyl)-ethyl]-benzylamine (±)-4-ri-(2.2-Dimethvlpropvl-carbamovlVethvn-benzonitrile Add AIMe3 (1.72 mL, 3.44 mmol, 2M solution in hexane) to a solution of 2,2-dimethyl-propylamine (402 pL, 3.44 mmol) in DCM (0.5 mL) under nitrogen atmosphere. Stir the mixture for 15 min at room temperature and add ethyl 2-(4-cyanophenyl)propanoate. Heat the mixture at 40°C overnight. Quench the reaction with ION aqueous HC1 and extract twice with DCM. Dry the combined organics extracts over NaiSC^, filter and concentrate in vacua. Purify by chromatography on silica gel eluting with hexane/EtOAc (7:3) to obtain the desired intermediate (170 mg, 41%). (±)-4-fl-(2.2-Dimethvlpropvl-carbaniovl)-ethvn-benzvlamine: Bubble nitrogen into a solution of (±)-4-[l-(2,2-dimethylpropyl:carbamoyl>-ethyl]-benzonitrile (80 mg, 0.33 mmol) in memanol (9 mL) with 2 drops of concentrated HC1 for 10 min. Add 10% Pd/C (Degussa type E101, 8 mg) and submit the mixture to hydrogenation at atmospheric pressure overnight. Filter the catalyst over Celite® and concentrate the filtrate in vacua. Partition the solid between saturated aqueous NaHCO3 and EtOAc, and extract again with EtOAc. Dry the combined organics extracts over MgSO4, filter and concentrate in vacua to afford the title compound as a yellow oil (69 mg, 85%). MS (ES+) m/z: 249 (M+H)+. Preparation 71 The compound of Preparation 71 may be prepared essentially as described in Preparation 70 using methyl (4-cyanophenyl)acetate and cyclohexylmethyl amine. Overall yield and MS (ES+) data are shown in the Table below. Prep. Structure Compound Yield MS(ES) m/z 71 9 4-[(Cyclohexylmethyl-carbamoyl)- 48 261 C HIJ r*i 9 H/T methylj-benzylamine Preparation 72 4-[(3,3-Dimethylbutyl-carbamoyI)-methyl]-benzylamine 4-rf3.3-Dimethvlbutvl-carbamovl)-methvn-benzonitrile: Dissolve 3,3- dimethylbutylamine (0.8 mL, 6.4 rnmol) in anhydrous THF (2 mL) under nitrogen. Cool the solution at 0°C and add DIBAL-H (6.2 ml,, 6.2 rnmol, 1M solution in toluene). Allow the mixture to warm up to room temperature and stir for 2 h. Add this complex to a solution of methyl (4-cyanophenyl)acetate (192 mg, 1.1 mmol) in THF (4 mL) and stir at room temperature overnight. Dilute with EtOAc and quench with 5% KHSCU. Dry the organic phase over MgSCU, filter and concentrate in vacua. Purify by chromatography on silica gel eluting with hexane/EtOAc (7:3) to obtain the desired intermediate (160 mg, 60%). MS (ES+) m/z: 245 (M+H)+. 4-ff3.3-Dimemvlbutvl-(arbamoyl)-metfavl1-bcnzylanune: Bubble nitrogen into a solution of 4-[(3,3-dimethylbutyl-carbamoyl)-memyl]-benzonitrile (240 mg, 0.9 mmol) in methanol (20 ml.) with 3 drops of concentrated HC1 for 10 min. Add 10% Pd/C (Degussa type E101, 48 mg) and submit the mixture to hydrogenation at atmospheric pressure overnight. Filter the catalyst over Celite® and concentrate the filtrate m vacua. Elute the compound through a SCX column to obtain the title compound (240 mg, 98%). MS (ES+) m/z: 249 (M+H)+. Preparation 73 4-[2-(tert-Butylcarbamoyl)-ethyl]-benzylamine 4-r2-fteyt-Butvlcarbamovn-ethvl1-benzonitrile: Dissolve 3-(4-cyanophenyl)-propionic acid (0.4 g, 2.48 mmol) and thionyl chloride (1.1 mL, 14.9 mmol) in toluene (2 mL) and reflux the mixture for 2 h. Concentrate in vacua, dissolve the residue in DCM (1.5 mL) and add the solution to a cold solution (0 °C) of te/f-butylamine (300 fiL, 2.85 mmol) in DCM (1.5 mL) and triethylamine (97 pL, 0.69 mmol). Allow the mixture to stir at 0 °C for 15 rain and at room temperature for 16 h. Add water, separate the organic phase and extract the aqueous phase twice with DCM. Dry the combined organic extracts over NajSCv, filter and concentrate in vacua. Purify by chromatography on silica gel eluting with hexane/EtOAc (65:35) to obtain the desired intermediate (306 mg, 54%). 4-r2-(fgrt-Butylcarbamovl)-ethvn-benzylamine: Add 10% Pd/C (Degussa type E101,62 mg) to a solution of ethanol/water/acetic acid (10:5.6:0.6 mL). Add a solution of 4-[2-(te;t-burylcarbamoyl)-ernyl]-benzonitrile (306 mg, 1.33 mmol) in ethanol (3.5 mL) and submit the mixture to hydrogenation at 60 psi overnight. Filter the catalyst through Celite® and concentrate in vacua to obtain the acetate salt of the title compound. Wash with diethyl ether and filter the solid in vacua. Add saturated aqueous NaHCOs and extract twice with EtOAc. Dry the combined organic extracts over MgSC<4, filter and concentrate in vacua to obtain the title compound as a yellow oil (70 mg, 26%). MS (ES+)/n/z:235(M+H)+. Preparation 74 4-[2-(2,2-Dunemylpropyl-<»rbamoyl)^myl]-benzylamme NHZ 4-f2-(2.2-Dimethvlpropvl-carbamoyl)-etfavl1-benzonitrile: Combine 3-(4-cyanophenyl)-propionic acid (870 mg, 4.9 mmol), 2,2-dimethylpropylamine (0.6 mL, 5.4 mmol), EDCI (1.0 g, 5.4 mmol), HOBT (804 mg, 5.9 mmol), triethylamine (2 mL, 14.8 mmol) and DMAP (60.5 mg, 0.5 mmol) in anhydrous DCM (50 mL). Stir at room temperature for 1 day under nitrogen. Concentrate the mixture in vacua and purify by chromatography on silica gel eluting with hexane/EtOAc (1:1) to obtain the desired intermediate as a white soUd (740 mg, 61%). MS (ES+) m/z: 245 (M+H)+. 4-r2-(2.2-Dimethvlpropvl-carbamovn-ethvn-benzvlamine: Bubble nitrogen into a solution of 4-[2-(2,2-dimethylpropyl-carbamoyl)-ethyl]-benzonitrile (740 mg, 3.0 mmol) in methanol (60 mL) with 3 drops of concentrated HC1 for 10 min. Add 10% Pd/C (Degussa type E101,148 mg) and submit the mixture to hydrogenation at atmospheric pressure overnight. Filter the catalyst over Celite® and concentrate the filtrate m vacua. Elute the compound through a SCX column to obtain the title compound (717 mg, 95%). MS (ES+) m/z: 249 (M+H)+. Preparation 75 4-Cyclohexanesulfonyl-benzylamine CN 4-Cvclohexvlthio-ben2X)nitrile: Dissolve sodium metal (343 mg, 14.9 mmoles) in anhydrous ethanol (20 mL) at room temperature under nitrogen atmosphere. Then add cydohexyl mercaptan (2 mL, 16.37 mmoles) and stir at room temperature for 30 min. Add then neat 4-fluoro-benzonitrile (1.8 g, 14.9 mmol) and heat the resulting solution at 80°C overnight. Cool the reaction to room temperature and quench the reaction by adding IN aqueous HC1 (100 mL). Concentrate the mixture in vacua and take up the residue with EtOAc (100 mL). Wash the organic layer with saturated aqueous NaHCO3 (100 mL) and brine (100 mL). Dry the organic phase over MgSO4 and concentrate in vacua. Purify die crude mixture by chromatography on silica gel (120 g, pre-packed cartridge) eluting with cyclohexane/EtOAc (98:2 to 80:20 gradient) to afford the desired intermediate (2.2 g,68%). GC-MS m/z: 217 (M*). 129 4-Cvclohexanesulfonvl-benzonitrile: Disolve 4-cyclohexylthio-benzonitrile (1.17 g, 5.4 mmol) in acetone (10 mL) and add water until the sulfide starts to come out of solution. Then add a drop of acetone to rehomogenize the solution. Cool the mixture to 0°C and then add oxone (4.2 g, 6.73 mmol) in one portion while stirring vigourously at 0°C for 5 h. Concentrate in vacua, take up the residue in DCM and filter the suspension through a frit. Concentrate in vacua to obtain the desired intermediate (1.27 g, 94%) as a white solid. 4-Cyclohexanesulfonvl-benzylamine: Disolve 4-cyclohexanesulfonyl-benzonitrile (1.27 g, 5.1 mmol) in anhydrous THF (15 mL) at 0°C under nitrogen and then add a solution of borane-THF complex (15.3 ml-, 15.3 mL, 1M solution in THF). Stir overnight while wanning to room temperature. Add the reaction to a mixture of 5N aqueous HC1 (50 mL), THF (50 mL) and ice and stir for 1 hour. Concentrate the mixture, in vacua and take up the resulting white residue through a SCX 2 column eluting with methanol followed by 3N ammonia in methanol to obtain the title compound as a white solid (625 mg, 50%). MS (ES+) m/z: 254.1 (M+H)+ Preparation 76 3-ArMttomethyl-6-[(2-mcthyl-2-propane)sulfonyhriethyl]-pvridine H2N l-HvQ^oxv^f(2-memyl-2-propane)sdfonvlmemvll-pvridine-3-carbonitrile: To a solution of 6-(tert-butylthio)methyl-pyridine-3-carbonitrile (2.5g, 12.13 mmol) in TFA (17 mL) at 0°C add dropwise a solution of hydrogen peroxide in water (16.8 mL, 30% sol.) and warm the reaction to room temperature overnight Concentrate in vacua and take-up the resulting crude into saturated aqueous NaHCO3 (50 mL). Extract the aqueous layer several times with EtOAc (100 mL each). Dry the combined organic extracts over MgSCU, filter and concentrate in vacua to obtain the desired intermediate as a white solid (2.8 g, 100%). MS (ES+) m/z: 255 (M+H)+, 277 (M+Na)+. \IL> 3-Aminomethvl-6-r(2-methvl-2-propane)sulfonvlmethvn-pvridine: Add a solution of 1-hydroxy-6-[(2-methyl-2-propane)sulfonylmetl:iyl]-pyridine-3-carbonitrile (150 mg, 0.59 mmol) in ethanol (12 raL) to an aqueous slurry of Raney Ni (50%, Ig). Submit the suspension to hydrogenation at 60 psi for 10 h and then filtrate the mixture through Celite® to provide an inseparable mixture of the title compound and the corresponding N-oxide. Take this mixture up in DCM (5 mL), add di-tert-butyl-dicarbonate (196 mg, 0.9 mmol) and stir overnight at room temperature. Concentrate in vacua and purify by chromatography on silica gel eluting with DCM/EtOAc (7:3 to 0:1 gradient) to obtain 3-(rerf-butoxycarbonylarnmo-methyl)-6^[(2-methyl-2-propane)siu^onylmemyl)-pyridineasa white solid (93 mg). Dilute this material in DCM (5 mL), add trifluoroacetic acid at room temperature and stir for 30 min. Concentrate in vacua, take the residue up in methanol and filter through a SCX-2 column eluting with methanol followed by 3N ammonia in methanol to obtain the title compound as a colourless oil (66 mg, 46%). MS (ES+) m/z: 243 (M+H)+. Preparation 77 3-Aminomethyl-6-[(2,2-dimethylpropane)sulfonyhnethyl]-pyridine J< BocHN^ BocHN 2.2-Dimethvl-propane-l-thiol: Add sulfur (3.05 g, 95 mmol) and ether (60 mL) to 2,2-dimethylpropylmagnesium chloride (95 mL, 95 mmol, 1M solution in diethyl ether) under nitrogen at 0°C. Warm the mixture to room temperature and stir for 2 h. Cool to 0°C and add IN aqueous HC1 (120 mL). Extract into diethyl ether (-100 mL) by continuous extraction. Distill diethyl ether through a 22 cm long Vigreux column by heating with an oil bath (50-120°C) under nitrogen. Cool and remove the Vigreux column and install a short path distillation head. Distill the product (60-100°C) with the oil bath at -140°C to obtain the desired intermediate (8.5 g, 86%). 3-(terr-Butoxycarbonvlamino-rnethvlV6-f(2.2-dimethvlpropyl)thiomethvl1-pyridine: Under a nitrogen atmosphere, add sodium methoxide (630 mg, 3.51 mmol, 30% w/w in methanol) to a stirring mixture of 2,2-dimethyl-propane-l-thiol (365 mg, 3.51 mmol) and methanol (10 mL) at room temperature and stir for 30 min. Add 3-(tert-butoxycarbonylainino-methyl)-6-chloromethyl~pyridine (450 mg, 1.76 mmol) in methanol (5 mL) and stir the mixture for 2 h. Dilute the mixture with water and ethyl acetate. Separate the layers and extract the aqueous layer with ethyl acetate. Wash the combined organic extracts with water and brine. Dry the organic phase over Na2SO4, filter, and concentrate in vacua to obtain the desired intermediate suitable for use without additional purification. MS (APCI+) m/z: 325 (M+H)4. 3-(rgrr-Butoxvcari3onvlamino-methyl)-6-f(2.2-dimethvl-propane)-sulfonvuiiethvIl-pvridine: Add m-CPB A (977 mg, 4.36 mmol, 70-77% pure) to a solution of 3-(tert-butoxycarbonylanmo-memyl)^[(2,2Hiimethylpropyl)thiomethyl3-pyridine (700 mg, 2.16 mmol) in DCM (20 mL) at 0°C. Warm the mixture to room temperature and stir overnight. Dilute the mixture with 10% aqueous K^COs (30 mL) and DCM. Separate the layers and extract the aqueous phase with DCM. Wash the combined organic extracts with water and brine. Dry the organic phase over NaiSO^ filter and concentrate in vacua. Purify the residue by chromatography on silica gel (45 g, pre-packed cartridge) eluting with hexane/EtOAc (1:0 to 1:1 gradient) to obtain the desired intermediate (480 mg, 62%). MS (APCI-f) m/z: 357 (M+H)+. 3-Arninomemyl-6-r(2.2-dimemvl-propane)sulfonybiiethvll-pyridme: Bubble hydrogen chloride into a mixture of 3^tert-butoxycarbonylamino-methyl)-6-[(2,2-dimethyl-propane)sulfonylmethyl]-pyridine (480 mg, 1.35 mmol), methanol (10 mL) and EtOAc (10 mL) at room temperature until saturated. After stirring for 1 h, concentrate the mixture in vacuo. Purify by chromatography on silica gel (25 g, pre-packed cartridge) eluting withDCM/(chloroform;methanol:concentratedNH4OH 80:18:2) (1:0 to 1:1 gradient) to obtain the title compound (325 mg, 94%). MS (APCI+) m/z: 257 (M+H)+. Preparation 78 The compound of Preparation 78 may be prepared essentially as described in Preparation 77 by using 3-(tert-butoxyc»rbonylaniino-rnethyl)-6-chlorornethyl-pyridine and cyclohexanethiol. Overall yield and MS (ES) data are shown in the Table below. Prep. Structure Compound Yield (%) MS(ES) m/z 78 o,.o <>V' 6° v H,N 3-Aminomethyl-6-(cyclohexanesulfonyl)methyl-pyridine 43 269 (M+H)* Preparation 79 4-(2,2-Dimethylpropane-sulfonylmethyl)-benzylamine CN 4-(2.2-Dimethvlpropane-thiomethyl)-benzonitriie: Add sodium hydride (3 17 mg, 7.92 mmol, 60% dispersion in mineral oil) to a solution of 2,2-dimethyl-propane-l-thiol (635 mg, 6.09 mmol) in anhydrous DMF (50 mL) under nitrogen at 0°C. Stir the mixture for 15 min, add 4-(bromomethyl)-benzonitrile (597 mg, 3.04 mmol) and stir the resulting mixture overnight at room temperature. Add water and extract the aqueous phase twice with EtOAc. Wash the combined organic extracts twice with water, dry over MgzSCU, filter, and concentrate in vacuo to obtain the desired compound (867 mg, 100%) suitable for use without further purification. MS (ES+) m/z: 220 (M+H)* 4-(2.2-Punethylpropane-sutfonylmethvlVbenzonitrile: Dissolve 4-(2,2-dimethylpropane-thiomethyl)-benzonitrile (867 mg, 3.95 mmol) in DCM (20 mL). Cool the mixture to 0°C, and add m-CPBA (1.95 g, 8.69 mmol, 70-77% pure) slowly. Allow the mixture to warm to room temperature and stir overnight. Dilute the mixture with DCM and wash with saturated aqueous NazSOs followed by saturated aqueous NaHCOa (2x). Dry over MgSC>4, filter, and concentrate m vacua to obtain the desired compound (966 mg, 97%) suitable for use without further purification. MS (APCI+) m/z: 252 (M+H)+ 4-(2T2-Dimethvlpropane-sulfonvlmethvlVbenzylarnine: Add cobalt(II) chloride hexahydrate (1.83 mg, 7.7 mmol) to a solution of 4-(2,2-dimethylpropane-sulfonylmethyl)-benzonitrile (966 mg, 3.85 mmol) in methanol (25 mL). Cool the mixture to 0°C and stir for 15 min. Carefully add sodium borohydride (1.46 g, 38.49 mmol) in small batches, allow the mixture to warm to room temperature and stir for 2 h. Dilute the mixture with water arid partition between water and chloroform. Extract the aqueous phase three times with chloroform/uo-propanol (3:1). Dry the combined organic extracts over MgSO4, filter and concentrate in vacua. Purify by chromatography on silica gel (80 g) eluting with DCM/(chloroform:methanol:concentrated NRjOH 80:18:2) (1:0 over 5 min, 19:1 over 5 min, 9:1 over 35 min, 85:15; 50 mL/min) to give the title compound (181 mg, 49%). MS (APCI+) m/t. 256 (M+Hf. Preparation 80 3Kter^Butoxycarbonyl)-7ibamovlVvinvl1-benzylarnine: Add 1M lithium aluminum hydride in THF (3.0 mL, 3.0 mmol) to a solution of 4-[5-(cyclopropylmethyl-amino)-isothiazol-3-yl]-benzonitrile (210 mg, 0.82 mmol) in THF (8 mL) at room temperature under a nitrogen atmosphere. Stir the mixture at ambient temperature for 45 min, then quench the reaction sequentially with water (0.3 mL) and 5N aqueous NaOH (0.3 mL). Filter the slurry through Celite®, dry the filtrate over Na2SC>4, filter and concentrate in vacua. Purify the residue by chromatography on silica gel (8 g) eluting with DCM/2M ammonia in methanol (20:1) to obtain the desired intermediate (110 mg, 51%). MS (ES+) m/r. 245.1 (M-NH3+Hf. 4-f5-(Cvclopropyunemyl-aminoVisoflu'azol-3-vU-benzvlariune: Add 30% hydrogen peroxide solution (0.13 mL, 1.1 mmol) to a solution of 4-[l-anuno-2-(cyclopropylmethyl-thiocarbamoyl)-vinyl]-benzylamine (150 mg, 0.57 mmol) in methanol (5 mL). Stir the solution for 16 h at room temperature. Quench the reaction with aqueous saturated sodium hydrogensulfite (1 mL). Extract the mixture with EtOAc (2x30 mL), collect the organic layer and concentrate in vacua. Purify the residue by chromatography on silica gel (4 g) eluting with DCM/ammonia in methanol (97:3) to obtain the title compound as a yellow solid (68 mg, 46%). MS (ES+) m/z: 243.1 (M-NH3+H)+. Preparation 84 4-[2<3-Memyl-butylamino)-thiazol-4-yl]-benzylamine 123 4-(2-Amino-thiazol-4-yl)-benzonitrile: Slurry 4-cyanophenacyl bromide (40 g, 179 mmol), thiourea (13.6 g, 181 mmol) and sodium bicarbonate (15.3 g, 181 mmol) in absolute ethanol (560 mL). Stir the mixture at reflux for 20 h under a nitrogen atmosphere. Cool the slurry to room temperature, filter, wash the solids with ethanol (100 mL), water (3x75 mL) and hexane (3x75 mL). Collect the yellow solid, add water (200 mL) and stir the slurry for 30 rain at room temperatue. Filter and wash the solid with hexane (excess). Slurry the solid in EtOAc (50 mL) and concentrate in vacua twice to remove residual water. Collect the desired intermediate as a light yellow solid (36 g, 99%). MS (ES+) m/z: 202.1 (M+H)4. 4-f2-(3-Methvl-butvlaminoVthiazol-4-vn-benzonitrile: Slurry 4-(2-amino-thiazol-4-yl)-benzonitrile (2.0 g, 9.9 mmol), sodium triacetoxyborohydride (6.3 g, 29.7 mmol), isovaleraldehyde (1.7 g, 19.8 mmol) and acetic acid (3.6 mL) in 1,2-dichloroethane (100 mL) at room temperature under a nitrogen atmosphere. Stir the mixture for 16 h at room temperature. Quench the reaction with saturated aqueous NaHCOs (75 mL, pH to 7.0-7.5). Extract the mixture twice with DCM (100 mL) and concentrate in vacua. Purify the crude mixture by chromatography on silica gel (40 g) eluting with hexane/EtOAc (20:1 to 3:2 gradient) to obtain the desired intermediate (1.8 g, 61%). MS (ES+) m/z: 272 4-r2-(3-Methyl-butvIamino)-thiazol-4-vn-benzylamine: Add lithium aluminum hydride (210 mg, 5.5 mmol) portionwise over 3 min to a solution of 4-[2-(3-methyl-butylamino)-thiazol-4-yl]-benzonitrile (500 mg, 1.8 mmol) in THF (20 mL) at room temperature under a nitrogen atmosphere. Stir the mixture for 1 h at 60 °C. Cool the mixture, quench slowly with water (0.2 mL) and IN NaOH (0.2 mL). Add sodium sulfate to absorb residual water, filter the mixture through Celite®, wash with DCM (50 mL) and concentrate in vacuo. Purify the residue by SCX chromatography to obtain the desired intermediate (493 mg, 97%). MS (ES+) m/z: 276 (M+H)+. Preparations 85-88 The compounds of Preparations 85-88 may be prepared essentially as described in Preparation 84 using 4-(2-amino-thiazol-4-yl)-benzonitrile and the appropriate aldehyde. Overall yields and MS (ES+) data are shown in the Table below. Prep. Structure 85 Compound 4-[2-(2,2-Dimethyl-propylamino)-thiazol-4-yl]-benzylamine Yield MS (ES+) (%) m/z 26 276 86 4-(2-Cyclopentyhnethylamino-thiazol-4-yl)-benzylamine 18 288 87 88 38 4-(2-Cyclohexylmethylamino-thiazol-4-yl)-benzylamine 4-[2-(3,3,3-Trifluoropropylamino)- 14 thiazol-4-yl]-benzylamine 302.3 302 Preparation 89 The compound of Preparation 89 may be prepared essentially as described in Preparation 4 by using 4-cyanophenacyl bromide and benzyltbiourea. Overall yield and MS (ES+) data are shown in the Table below. Prep. Structure Compound Yield MS(ES+) m/z 89 r"i 4-(2-Benzylamino-uuazol-4-yl)- 25 296 1 benzylamine (M+H)+ Preparation 90 4-(2-Cyclopropylmethylamino-5-methyl-thiazol-4-yl)-benzylamine -a. Br Br A^ l-Bromo-4-(2-cvclopropylmethvlamino-5-metfavl-thiazol"4-vl)-benzene: Slurry 2,4'-dibromopropiophenone (2.92 g, 10 mraol), cyclopropopylmethji-thiourea (1.3 g, 10 mmol) and sodium bicarbonate (840 mg, 10 mmol) in absolute ethanol (SO mL). Stir the mixture at reflux overnight under a nitrogen atmosphere. Cool to room temperature and pour into water (400 mL) and filter the resulting off-white solid. Wash the solid with hexane (10 mL) and dry in vacua to obtain the desired intermediate as a white solid (2.4 g, 74%). MS (ES-) m/z: 321 (M-H)'. 4-(2-Cvclopropvlmethvlamino-5-methvl-thiazol-4-yl)-benzonitrile: Slurry l-bromo-4-(2-cyclopropylmethylamino-5-methyl-thiazol-4-yl)-benzene (1.0 g, 3.09 mmol), l.l'-bis-(diphenylphosphino)fenocene (275 mg, 0.494 mmol), zinc cyanide (325 mg, 2.75 mmol) and tris(dibenzylideneacetone)dipalladium(0) (254 mg, 0.28 mmol) in DMF (6 mL) and heat in a sealed tube at 110 °C overnight Cool the mixture to room temperature, dilute with dichloromethane (100 mL) and filter over Celite®. Concentrate in vacua and purify the crude mixture by chromatography on silica gel (40 g) eluting with hexane/EtOAc (19:1 to 7:3 gradient over 30 min; 40 mL/min) to obtain the desired intermediate (416 mg, 52%) as a yellow solid. MS (ES+) m/z: 270 (M+H)*. 4-(2-Cvclopropvlmethvlammo-5-methvl-thiazol-4-viVbenzylamine: Add a solution of 1M lithium aluminum hydride in THF (4.6 ml-, 4.6 mmol) over 5 min to a solution of 4-(2-cyclopropylmethylamino-5-methyl-thiazol-4-yl)-benzonitrile (410 mg, 1.52 mmol) in anhydrous THF (10 mL). Heat to reflux for 30 min, cool to room temperature and quench by dropwise addition of water (5 mL), ether (50 mL), 3N NaOH (5 mL) and additional water (15 mL). Stir vigorously for 30 min and filter over a bed of Celite®. Wash the filtrate with water (2x100 mL) and brine (100 mL). Dry the organic phase over MgSO4, filter and concentrate in vacua to obtain the title compound as a yellow oil (340 mg, 82%) that was used without further purification. MS (ES+) m/z: 274 (M+H)*. Preparation 91 4-[2-(2,2,2-Trifluoroethylamino)-thiazol-4-yl]-benzylamine OS s H.N CF, Ph N N' CF, *" H.N^^N^^CF. z * H H 3 * H 3 l-Benzovl-3-(2.2.2-trtfluoroethvl)-thiourea: Dissolve trifluoroethylamine (2.2 g, 22 mmol) in chloroform (20 mL) and add the solution to a mixture of benzoyl isothiocyanate (3.5 g, 22 mmol) in chloroform (20 mL) at room temperature. Stir the mixture in a sealed flask for 16 h at room temperature. Concentrate the mixture in vacua to obtain the desired intermediate as a solid (5.5 g, 95%). MS (ES+) m/z: 263 (M+H)+. 2.2.2-Trifluoroethvl'tfaiourea: Slurry l-benzoyl-3-(2,2)2-trifluoroethyl)-thiourea (5.5 g, 21.2 mmol) and potassium carbonate (11.7 g, 84.7 mmol) in methanol (180 mL) and water (40 mL). Stir the mixture at room temperature for 16 h. Concentrate the solution in vacua to a paste. Triturate with hot water (20 mL, 60 °C), filter off the solids, wash with water (20 mL, 25 °C) and hexane (excess). Collect the solids, slurry in EtOAc and concentrate in vacua twice to remove residual water. Dry the material in a vacuum oven at 45 °C for 16 h to obtain the desired intermediate as an off-white solid (2.2 g, 66%). MS (ES+)/n/z:159.1(M+H)+. 4-f2-f2.2.2-Trifluoroethylamino)-thiazol-4-vn-benzonitrile: Slurry 4-cyanophenacyl bromide (1.4 g, 6.3 mmol), 2,2,2-trifluoroethyl-thiourea (1.0 g, 6.3'mmol) and sodium bicarbonate (529 mg, 6.3 mmol) in absolute ethanol (30 mL). Stir the mixture at reflux for 1 h under a nitrogen atmosphere. Cool to room temperature and concentrate in vacua. Partition the residue between DCM (100 mL) and water (20 mL). Dry the organic layer over Na2SO4 and concentrate in vacua to obtain the desired intermediate (1.7 g, 95%). MS (ES+) m/r. 284 (M+H)+. 4-f2-(2.2.2-Trifluoroethylamino)-thiazol-4-yll-benzvlamine: Add lithium aluminum hydride (402 mg, 10.6 mmol) portionwise over 3 min to a solution of 4-[2-(2,2,2-trifluoroethylamino)-thiazol-4-yl]-benzonitrile (1.0 g, 3.5 mmol) in THF (40 mL) at room temperature under a nitrogen atmosphere. Stir the mixture for 1 h at 55 °C. Cool the mixture to room temperature, quench slowly with water (0.4 mL) and IN NaOH (0.4 mL). Add sodium sulfate to absorb residual water, filter through Celite®, wash with DCM (50 mL) and concentrate in vacua. Purify the residue by SCX chromatography to obtain the desired intermediate (902 mg, 90%). MS (ES+) m/z: 288 (M+H)+. Preparation 92 (/?H-[2-(l-Memyl-2,2,2-trifluoroetliylammo)-tm'azol^yl]-benzylamine NH2.HCI X f/?Vl-BeDzovl-3-(l-methvl-2.2.2-trifluoroethvlV-thiourea: Dissolve (/?H-methyl-2,2,2-trifluoroethylamine hydrochloride (3.73 g, 25 mmol) in chloroform (50 mL) containing triethylamine (3.5 mL, 25 mmol). Cool to 0 °C in an ice bath and dropwise add benzoyl isothiocyanate (3.35 mL, 25 mmol) over 10 min. Warm the mixture to room temperature and stir overnight Concentrate in vacua and purify by chromatography on silica gel (200 g) eluting with hexane/EtOAc (19:1 to 4:1 over 40 min; 50 mL/min) to afford the desired intermediate as a light yellow oil (6.2 g, 90%). f/g)-a-Methvl-2.2.2-trifluoroethvn-thiourea: Dissolve (/0-l-benzoyl-3-(l-methyl-2,2,2-trifluoroethyl)-thiourea (6.2 g, 22.5 mmol) in methanol and add a solution of potassium carbonate (13.8 g, 100 mmol) in water (30 mL). Stir vigorously at room temperature overnight. Evaporate to dryness, dissolve residue in hot water (ca. 100 mL) and filter the resulting white crystals. Cool filtrate to 0 °C, seed with crystals from hot water filtration, filter and collect resulting white crystals to obtain the desired intermediate (2.9 g, 74%). MS (ES-f) m/z: 173 (M+H)+. (^^r2-(l-Memvl-2.2.2-trifluoroemvlaminoVthiazol-4-vn-benzonitrile: Dissolve 4-cyanophenacyl bromide (1.82 g, 8.14 mmol), (/?J-(l-methyl-2,2,2-trifluoroethyl)-thiourea (1.4 g, 8.14 mmol) and sodium bicarbonate (0.68 g, 8.14 mmpl) in absolute cthanol. Heat at reflux 2 h, cool to room temperature and let stand over 2 days. Filter and collect the resulting crude product as a tan solid. Purify by chromatography on silica gel (34 g) eluting with hexane/EtOAc (19:1 to 4:1 over 30 min, 4:1 over 10 min; 40 mL/min) to obtain the desired intermediate as a white solid (1.23 g, 52%). MS (ES-f) m/z: 298 f/?)^r2-(l-Memvl-2.2.2-ttifluoroetfavlamino')-miazQl-4-vl1-benzvlamine: Add a solution of 1M lithium aluminum hydride in THF (12 mL, 12 mmol) dropwise to an ice-cooled solution of (/?)^[2-(l-memyl-2,2,2-trifluoroemylaniino)-thiazol-4-yl]-benzonitrile in anhydrous THF (10 mL). Heat to reflux for 1 h, cool to room temperature, quench by slow addition of water (12 mL), ether (50 mL), IN NaOH (12 mL) and additional water (36 mL). Add EtOAc (50 raL), stir vigorously for 20 min and filter over a bed of Celite®. Dry the organic phase over MgSC>4, filter and concentrate in vacua to obtain the title compound (765 rag, 64%). MS (ES+) m/z: 302 (M+H)*. Preparation 93 The compound of Preparation 93 may be prepared essentially as described in Preparation 92 by using (5)-l-methyl-2,2,2-trifluoroethylamine hydrochloride. Overall yield and MS (ES-f) data are shown in the Table below. Structure Compound Yield MS(ES+) m/z 93 F)Cv_ (5)-4-[2-(l-Methyl-2,2,2- 51 302 if x>_w' trifluoroemylamino)-thiazol- (M+H)+ H,^OTN 4-yl]-benzylamine Preparation 94 Cyclopropylmethyl-thiourea S 1 l-Benzovl-3-cvclopropvlmethvl-thiourea: Add benzoyl isothiocyanate (500 g, 3.06 mol) to chloroform (5 L) and cool to <5 °C. Add a solution of cyclopropylmethylamine (230 g, 3.22 mol) in chloroform (500 mL) with vigorous stirring maintaining a temperature below 20 °C. Remove the ice-water bath, and stir the mixture at room temperature overnight. Concentrate the mixture in vacua to obtain the desired intermediate as a white solid (720 g, 100%). MS (APCI) m/z: 235 (M+H)+. Cvclopropylmethvl-thiourea: Add l-benzoyl-3-cyclopropyknethyl-thiourea (718 g, 3.06 mol) to methanol (6 L) and heat gently to dissolve. Add a solution of potassium carbonate (1.70 kg, 12.3 mol) in water (2 L) and stir overnight at room temperature. Filter any solids that form and concentrate the filtrate in vacua until 10% of the volume. Dilute the residue with water (2 L) and EtOAc (-3.5 L) and extract the aqueous phase with EtOAc (4x2.5 L). Wash the combined organic extracts with aqueous IN NaOH (2x1 L) and brine (2 L). Dry the organic layer over Na2S04, filter, and concentrate in vacua. Redissolve the residue in warm EtOAc (4 L), concentrate in vacua until -20% of the volume and filter the precipitate, rinsing with cold (~5°C) EtOAc (-500 mL). Dry the solid under high vacuum to obtain the title compound as an off-white solid (220 g, 55%). Concentrate the filtrate in vacua until ~10% of the volume and filter the precipitate, rinsing with cold EtOAc. Dry the solid under high vacuum to provide a second crop of cyclopropylmethyl-miourea as an off-white solid (103 g, 26%). Total yield (323 g, 81%). MS (APCI) m/z: 131 (M+H)+. Preparation 95 2-Aminomemyl-5-(2-cyclopropylmemylamino-thiazol-4-yl)-pyridine Br *J> ,J> yj> H H 2-Bromo-5-(2-bromo-acetvlVpYridine: Add pyridinium tribromide (7.0 g, 22 mmol) to a solution of 5-acetyl-2-bromo-pyridine (4.0 g, 20 mmol) in THF (100 mL) at room temperature. Stir the mixture for 16 h at room temperature under a nitrogen atmosphere. Quench the mixture with saturated aqueous NaHCOs (50 mL, pH to 7.8). Extract the mixture with EtOAc (150 mL). Wash the organic layer with brine (50 mL) and concentrate in vacua to obtain the desired intermediate as a dark brown oil (11.5 g) that was used without further purification. MS (ES+) m/z: 280 (M+H)+. 6-Bromo-3-f2-cvclopropvlmethvlaniinn-thiazol-4-yl)-pvridine: Slurry crude 2-bromo-5-(2-bromo*acetyl)-pyridine (11.5 g, ca. 48%), cyclopropylmethyl-thiourea (2.2 g, 16.9 mmol) and sodium bicarbonate (1.7 g, 20 mmol) in ethanol (100 mL) at room temperature. Stir the mixture at reflux for 1 h under a nitrogen atmosphere. Turn off heat and stir the mixture for 16 h at room temperature. Filter the slurry, then wash the solids with ethanol (50 mL), water (2x50 mL) and hexane (excess). Dry the solid in a vacuum oven for 20 h at 50 °C to obtain the desired intermediate as a tan solid (3.2 g, 61% over 2 steps). MS (ES+) m/z: 312 (M+2)+. 5-(2-CvcLopropvlmethvlamino-thiazol-4-vtVpvridme-2-carbonitrile: Slurry 6-bromo-3-(2-cyclopropyknethylamino-thiazol-4-yl)-pyridine(l.l g, 3.6 mmol), l,l'-bis-(diphenylphosphino)ferrocene (320 mg, 0.6 mmol), zinc cyanide (337 mg, 2.9 mmol) and tris(dibenzylideneacetone)dipalladium(0) (231 mg, 0.25 mmol) in wet DMF (6 mL). Stir the mixture in a sealed tube at 115 °C for 6 h. Cool the mixture to room temperature, dilute with EtOAc (50 mL) and wash with 5% aqueous sodium chloride (3x30 mL). Collect the organic layer and concentrate in vacua. Purify the residue by chromatography on silica gel (40 g) eluting with hexane/(THF with 1% methanol) (4:1) to obtain the desired intermediate (350 mg, 38%). MS (ES+) m/z: 257.3 (M+H)+. 2-AminomemYl-S-(2-nicotinonitrile (14.5 g, ca. 80%) in THF (120 mL) and 2.5 N hydrochloric acid (40 mL). Stir the solution for 16 h at room temperature. Quench the reaction with saturated aqueous NaHCOs (pH to 7.5). Extract the mixture with EtOAc (200 mL). Dry the organic layer over Na2SC>4, filter and concentrate in vacua. Purify the crude mixture by chromatography on silica gel (120 g) eluting with hexane/EtOAc (9:1 to 3:1 gradient) to obtain the desired intermediate (4.2 g, 65%). 6-(2-Bromo-acetvl>-nicoUnonitrile: Add pyridinium tribromide (9.2 g, 28.7 mmol) to a solution of 6-acetyl-nicotinonitrile (4.2 g, 28.7 mmol) in THF (200 mL) at room temperature. Filter off the solids and wash with minimal THF. Recrystalize the solid from EtOAc/hexane to obtain the desired intennediate as a light orange solid (5.2 g, 80%) that was used without further purification. MS (ES-) m/z: 223 (M-H)~. 6-r2-(Cvclopropvlmethvlamino)-tfuazol-4-vn-nicotinonitrile: Slurry crude 6-(2-bromo-acetyl)-mcotinonitrile (5.2 g), cyclopropylmethyl-tbiourea (2.7 g, 20.8 mmol) and sodium bicarbonate (1.95 g, 23.1 mmol) in ethanol (135 mL) at room temperature. Stir the mixture at reflux for 1 h under a nitrogen atmosphere. Cool the mixture to room temperature and concentrate in vacua to a solid. Recrystallize from ethanol (20 mL) and water (100 mL) at 5 °C to obtain the desired intennediate as a tan solid (4.8 g, 81%). MS (ES+)m/z:257(M+H)+. 3-Aminomethvl-6-f2-cvclopropvlmethylamino-thiazol-4-vlVpvridine: Add6-[2-(cyclopropylmetfiylamino)-thiazol-4-yl]-nicotinonitrile (2.0 g, 7.8 mmol), Raney Nickel (2.0 mL), and 2M ammonia in rnethanol (200 mL) to a pressure vessel under a nitrogen atmosphere. Pressurize the vessel to 60 psi with hydrogen, and stir the mixture for 6 h at 40 °C. Filter the mixture through Celite® and concentrate in vacua to an oil. Dissolve the oil in BtOAc (300 mL) and saturated ammonium hydroxide (50 mL). Stir the solution for 20 h in a sealed flask at room temperature. Collect the organic layer and concentrate in vacua. Purify the crude mixture by SCX chroraatography followed by chromatography on silica gel (150 g) eluting with DCM / 2M ammonia in methanol (99:1 to 85:15 gradient) to obtain the title compound (1.05 g, 51%). MS (ES+) m/z: 261 (M+H)*. Preparation 97 4-[(2-Cyclopropanecarbonyl-araino)-thiazol-4-yl}-benzylamine jl-4-vl)-A^-(terr-butoxvcarbonvl)-benzylamine: To a mechanically-stirred slurry of lithium aluminum hydride (2.64 g, 69.7 mmol) in anhydrous dioxane (150 mL) at room temperature, add a warmed slurry of 4-(2-amino-thiazol-4-yl)-benzonitrile (4 g, 19.9 mmol) in dioxane (200 mL) in portions. Heat the reaction mixture at 75 °C for 4 h and then cool the mixture to 0 °C. Quench the reaction with water (2.6 mL) drop wise. Add 15% aqueous NaOH (2.6 mL) and water (8 mL). Stir the mixture for 2 h at room temperature and filter the slurry over Celite®. Wash the Celite® filter pad with dioxane (500 mL) and concentrate the filtrate. Dissolve the residue in dioxane (300 mL) and then add a solution of di-terr-butyl dicarbonate (5.2 g, 23.8 mmol) in dioxane (100 mL). Stir at room temperature for 24 h and concentrate the reaction mixture in vacua. Dissolve the residue in EtOAc (500 mL) and wash the solution with saturated aqueous NaHCO3 (250 mL). Dry the organic phase over Na2SO4, filter and concentrate in vacua. Dissolve the residue in dichloromethane, add silica gel (12 g) and concentrate the mixture to a powder. Load the powder on to a dry column attached to an Analogix® column (330 g) and elute by preparative liquid chromatography (0:1 to 2:3 EtOAc/hexane over 33 min, 2:3 EtOAc/hexane over 33 min, 2:3 to 1:0 EtOAc/hexane over 33 min, 1:1 EtOAc/DCM over 99 min; 35 mL/min) to afford the desired intermediate (2.98 g, 49%) as a yellow solid. MS (ES+) m/z: 306.2 (M+H)+. 4-rf2-Cvclopropane(^bonyl-ammoVtm'azoM-vl]-N-(ter?-butoxycarbonyn-benzvlarrune: To a mixture of 4-(2-ammothiazol-^yl)-Jv'-(terr-butoxycarbonyl)-benzylamine (2.98 g, 9.76 mmol) in DCM/dioxane (2:1,150 mL) at room temperature, add triethylamine (2.0 mL, 15 mmol) and cyclopropanecarbonyl chloride (1.1 mL, 12 mmol). Stir at room temperature overnight and partition the reaction mixture between EtOAc (500 mL) and saturated aqueous NaHCOs (250 mL). Dry the organic extract over NaaSO^ filter and concentrate in vacua. Combine the residue with DCM and silica gel (12 g) and concentrate to a powder. Load powder on to a dry column attached to an Analogix® column (330 g) and purify by preparative liquid chromatography (0:1 to 1:4 EtOAc/hexane over 33 min, 1:4 EtOAc/hexane over 33 min, 1:4 to 1:1 EtOAc/hexane over 33 min, 1:1 EtOAc/hexane over 66 min; 35 mL/min) to afford the desired intermediate (2.381 g, 65%) as a yellow solid. MS (ES+) m/z: 374.2 (M+H)*. 4-f(2-Cvclopropanecarbgnyl-amnio)-tm'azol-4-vlVbenzvlamuie: To a solution of 4-[(2-<^clopropanecai^onyl-arm^o)-miazoM-yl]-A'^tert-butoxy(aubonyl)-benzylaniine (2.381 g, 6.376 mmol) in anhydrous DCM (53 mL), add trifluoroacetic acid (45 mL) at room temperature and stir overnight. Concentrate the reaction mixture in vacua and elute the residue through a SCX column (20 g). Dissolve the residue in DCM, add silica gel (14 g) and concentrate to a podwer. Load the powder on to a dry column attached to an Analogix® column (150 g) and purify by preparative liquid chromatography (0:1 to 1:4 2M ammonia in methanol/DCM over 33 min, 1:4 2M ammonia in methanol/DCM over 33 min; 35 mL/min) to afford the title compound (1.668 g, 96%) as an off-white solid. MS (ES+) m/z: 274.1 (M+H)+. Preparation 98 4-[3-(Cyclopropyhriemyl-aniino)-pvrazol-l-yl]-benzylaniine IL^ NHj /Tft HCI N---^ HaN' 4-(3-Amino-pvrazol-l-vI)-benzonitrile: Suspend 4-cyanophenyl hydrazine hydrochloride (5 g, 29.58 mmol) in tert-butanol (60 mL). Add methoxyacrylonitrile (2.458 g, 29.58 mmol) and potassium tert-butoxide (3.975 g, 35.49 mmol) and heat the mixture at 90 °C overnight Concentrate in vacua and partition the residuee between EtOAc/water. Extract the organic phase with 10% hydrochloric acid. Neutralize the aqueous phase with saturated aqueous NaHCOs and extract twice with EtOAc. Dry the combined organic extracts over MgSO4, filter and concentrate in vacua to obtain a solid that was washed with ether/hexane. Filter and dry the solid in vacua to obtain the desired intermediate. 4-f3 -fCvclopropvlroetfayl-aminoVpyrazol-1 -vll-benzonitrile: Dissolve 4-(3-amino-pyrazol-l-yl)-benzonitrile (200 mg) in 1,2-dichloroethane (12 mL). Add acetic acid (0.36 mL) and cyclopropanecarboxaldehyde (0.08 mL, 1.06 mmol) and stir the mixture at room temperature under a nitrogen atmosphere for 40 min. Add sodium tnacetoxyborohydride (674 mg, 3.18 mmol) and stir for 3 h at room temperature. Quench the reaction with water. Extract the mixture three tuned with EtOAc. Dry the combined organic extracts over Na2S04, filter and concentrate in vacua to obtain the desired intermediate (136 mg, 54%) that was used without further purification. 4-f 3-(Cyclopropvlmethvl-amino)-pyrazol-1 -yll-benzylamine: Add a solution of 1M lithium aluminum hydride in THF (1.4 mL, 1.4 mmol) to a solution of 4-[3-(cyclopropyhnethyl-amino)-pyrazol-l-yl]-benzonitrile (136 mg, 0.57 mmol) in THF (10 mL) at room temperature under a nitrogen atmosphere. Stir the mixture for 1 h at 60 °C. Cool the mixture to room temperature and quench slowly with water, IN NaOH and additional water. Dilute with EtOAc, stir vigorously for 20 min and filter through Celite®. Dry the organic phase over NaaSCU, filter and concentrate in vacua. Purify the residue by SCX chromatography to obtain the desired intermediate that was used without further purification (130 mg, 94%). MS (ES+) m/z: 243 (M+H)+. Preparation 99 4-(l-Cyclopropyhriemyl-lH-pyrazol-3-yl)-benzylamine -f) >N H2N 4-(l-Cvclopropvlmethyl-l//-pyra2ol-3-yl)-benzonitrile: Add sodium hydride (64 mg, 2.65 mmol) to a solution of 4-(l//-pyrazol-3-yl)-benzonitrile (300 mg, 1.77 mmol) in DMF (5 mL) under nitrogen atmosphere. Stir the mixture for 15 min at 0 °C and add (bromomethyl)cyclopropane (206 Dl, 2.12 mmol). Stir the mixture for 5 min at 0 °C and then at room temperature overnight. Quenck the reaction mixture with water and extract twice with EtOAc. Dry the combined organics extracts over NajSO^ filter and concentrate in vacuo. Purify the crude mixture by chromatography on silica gel eluting with hexane/EtOAc (75:25) to obtain the desired intermediate (256 mg, 65%). 4-(l-Cvclopropvhiiethyl-lff-pvrazol-3-vlVbenzvlamine: Bubble nitrogen into a solution of 4-(l-cyclopropylmethyHff-pyrazol-3-yl)-benzonitrile (256 mg, 1.15 mmol) in methanol (48 roL) with 5 drops of concentrated hydrochloric acid for 10 min. Add 10% Pd/C (Degussa type, 48 mg) and submit the mixture to hydrogenation at atmospheric pressure overnight Filter the mixture over Celite® and concentrate in vacuo. Add saturated aqueous NaHCOs and extract twice with AcOEt Dry the combined organic extracts over MgSO4, filter and concentrate in vacuo to give the title compound as a yellow oil (207 mg, 80%). MS (ES+) m/z: 228 (M+H)+. Preparation 100 4-[6-(Cyclopropymiethyl-ammo)-pyrhiiidin-4-yl]-benzylarnine N^N 6-Chlorc^-rcyclopropyhTteihYliarnino>-pyrirnidine: In a microwave reaction vessel, slurry 4,6-dichloropyrimidine (540 mg, 3.6 mmol), cyclopropyknethylamine (280 OL, 3.24 mmol), and diisopropylethylamine (1.25 mL, 7.2 mmol) in iso-propanol (3 mL). Irradiate in microwave (300 watts) at 140 °C for 40 min. Cool to room temperature and concentrate in vacuo. Purify by chromatography on silica gel (40 g) eluting with hexane/EtOAc (9:1 to 3:1 over 30 min; 40 mL/rnin) to obtain the desired intermediate (567 mg, 86%) as an off-white solid. MS (ES+) m/z: 184 (M+H)+. 4-[6-(CyclopropylmethyI-animo)-pvriim'drn^yH In a microwave reaction vessel, slurry 6-chloro-4-(cyclopropylmethyl-amino)-pvrimidine (560 mg, 3 mmol), [4-(JV-tert-butoxycarbonyl-aminomethyl)phenyl]boronic acid (1.1 g, 4 mmol), and tetrakis(triphenylphosphine)palladium(0) (190 mg, 0.15 mmol) in toluene (4 mL). Add ethanol (1 mL) followed by potassium carbonate (0.9 g, 6 mmol) dissolved in water (300 DL). Irradiate in microwave (300 watts) at 120 °C for 60 tnjn. Cool to room temperature, pour reaction mixture into IN NaOH (250 mL) and extract with DCM (3x100 mL). Wash the combined organic extracts with brine, dry over MgSO4, filter and concentrate in vacuo. Purify by chromatography on silica gel (40 g) eluting with hexane/EtOAc (4:1 to 2:3 over 45 min; 40 mL/min) to obtain the desired intermediate (450 mg, 38%) as a yellow solid. MS (ES+) m/z: 355 (M+H)*. 4-r6^(Cyclor^opvlmemvl-ammoVpyrimidin-4-yn-benzylamine: Dissolve 4-[6- (cyclopropylmernyl-amtoo)-pyriinidm^yl]-Mpyrimidm^yl]-ben2ylamine NHBoc 4-Chloro-2-(cyclopropvhnethvl-amino)-pyrimidine: In a microwave reaction vessel, slurry2,4-dichloropyrimidine (1.0 g, 6.7 mmol), cyclopropylmethylamine (550 (jJU 6.0 mmol), and diisopropylethylamine (2.35 ml,, 13.4 mmol) in toluene (3 mL). Irradiate in microwave (300 watts) at 120 °C for 30 min. Cool to room temperature and concentrate in vacua. Purify by chromatography on silica gel (40 g) eluting with hexane/EtOAc (4:1 to 3:7 over 30 min; 40 mL/min) to obtain the desired intermediate (157.5 mg, 15%) as a colorless oil. Slurry 4-chloro-2^cydopropylmemyl-ammo)-pyrimidine (155 mg, 0.62 mmol), tert-butoxycarbonyl-aminomethyl)phenyl]boronic acid (160 mg, 0.86 mmol), and tetrakis(triphenylphosphine)palladium(0) (36 mg, 0.031 mmol) in toluene (3 mL). Add ethanol (0.5 mL) followed by potassium carbonate (175 mg, 1.24 mmol) dissolved in water (300 uX). Irradiate in microwave (300 watts) at 120 °C for 60 min. Cool to room temperature, pour reaction mixture into water (100 mL) containing IN NaOH (25 mL) and extract with DCM (3x50 mL). Wash the combined organic extracts with brine, dry over MgSO4, filter and concentrate in vacua. Purify by chromatography on silica gel (12 g) eluting with hexane/EtOAc (4: 1 to 3:7 over 30 min; 30 mL/min) to obtain the desired intermediate (200 mg, 90%) as a light yellow solid. MS (ES+) m/z: 355 (M+H)+. 4-f2-(Cvclopropvlmethvl-ainino)-pyrimidin-4-vl1-benzyIamine: Dissolve 4-[2-(cyclopropylmethyl-anu^o)-pyrimioUn^-yl]-A/^-(te7t-butoxycarbonyl)-benzylamine(195 mg, 0.55 mmol) in DCM (3 mL) and add trifluoroacetic acid (1.5 mL). Stir at room temperature for 3 h. Concentrate in vacua and purify the crude mixture by SCX chromatography (5 g) to obtain the title compound (140 mg, 93%) suitable for use without additional purification. MS (ES+) m/z: 255 (M+H)+. Preparation 103 4-[5-(3,3-Dimethylbutyryl)tiophen-2-yl]-benzylamine ar-Q 2-Bromo-5-(3.3-dimethylbutvrvl)-tfaiophene: Stir overnight at room temperature a mixture of 5-bromothiophene (1 g, 6.1 mmol), 3,3-dimethylbutyryl chloride (1.3 mL, 9.1 mmol) and ytterbium(ni) trifluoromethanesulfonate (378 mg, 0.6 mmol) in nitromethane (15 mL). Wash the mixture sequentially with water, saturated aqueous NaHCOs and water. Extract with chloroform, dry over MgSO4, filter and concentrate in vacua. Purify the crude mixture by chromatography on silica gel eluting with hexane to obtain the desired intermediate (1.3 g, 80%). A^^tert-ButoxvcarbonvlM45-(3.3-dimemylbutvrvl)tiophen^-vl1-benzylamine: To a solution of 2-bromo-5-(3,3-dunethylbutyryl)-thiophene (187 mg, 0.7 mmol) in dioxane (7 mL) add a solution of aqueous 2M Na2CO3 (0.9 mL), ^(Af-tert-butoxycarbonyl-aminomethyl)phenyl]boronic acid (216 mg, 0.8 mmol) and tetrakis(triphenylphosphinc)-palladium(0) (41 mg, 0.03 mmol). Heat the mixture at 90 °C overnight Cool at room temperature, add water and extract with EtOAc. Dry the organic phase over MgSC-4, filtei and concentrate in vacua. Purify the crude mixture by chromatography on silica gel eluting with hexane/EtOAc (4:1) to obtain the desired intermediate (174 mg, 63%). 4-[S-(3.3-DimethvlbutvrvntioDhen-2-vn-benzvlamine: To a solution of N-( butoxycarbonyl)-4-[5-(33-dimethylbutyryl)tiophen-2-yl]-benzylamine (174 mg, 0.4 rnmol) in anhydrous dichloromethane (0.3 mL) add a solution of 4M hydrogen chloride in dioxane (1.7 mL, 6.7 mmol) and stir for 2 h at room temperature. Concentrate in vacua and purify the crude mixture by SCX chromatography to obtain the title compound (128 mg, 99%). MS (ES+) m/z: 288 (M+H)+. Preparation 104 3»Animomemyl^[(2^-dimethylpropane)sulfonyl]-pyridine (Formula Removed) N-(te/t-ButoxvcarbonvlV3-ammomethvl-6-f(2.2-dimethvlpropane)thiol-pvridine:Add sodium hydride (590 mg, 15.5 mmol, 60% in mineral oil) to DMF (50 mL) and cool to 0 °C. Add 2,2-dimethyl-propane-l-thiol (966 mg, 9.27 mmol) and stir the mixture for 1 h at 0 °C. Add 3-(ferr-butx>xycarbonylamino-niethyl)-6-chloropyridine (1.5 g, 6.18 mmol) to the mixture and heat to 70 °C overnight. Cool the mixture to room temperature and carefully dilute with water (50 mL). Extract the mixture with EtOAc (5x25 mL). Wash the combined organic extracts with water (3x20 mL) and brine (50 mL). Dry the organic layer over Na2SC>4, filter, and concentrate w vacua. Puriry the residue by chromatography on silica gel (120 g) eluting with hexane:EtOAc (1:0 to 1:1 over 1 h, 80 mL/min) to provide the desired intermediate as a light yellow oil (915 mg, 48%). MS (APCI) m/z: 211 Add 3-chloroperbenzoic acid (1.83 g, -70%, 7.44 mmol) to DCM (25 mL) and cool to 0 °C. Slowly add a solution of N-(tert- butoxycarbonyl)-3-anunomethyl-6-[(2,2-dimethylpropane)thio]-pyridine (924 mg, 2.98 mmol) in DCM (10 mL) maintaining the temperature below 10 °C. Allow the mixture to warm to room temperature and stir for 3 h. Wash the mixture with aqueous 3N NaOH (3x25 mL), water (25 mL), and brine (25 mL). Dry tie organic layer over NajSCU, filter, and concentrate in vacua. Puriry the crude mixture by chromatography on silica gel (120 g), eluting with DCM/ (chloroform:metitianol:concentrated NHtOH) (1:1 over 1.5 h, 80 raL/min) to provide the desired intermediate as a light yellow oil (961 mg, 94%). MS (APCI) m/z: 243 (M- 3-Aminomethvl-6«r(2.2-dimetfavlprooane'>sulfonvn-Pvridine: butoxycarbonyl>3-aniinomemyl-6-[(2,2-dimemylpropane)sulfonyl]-pyridine (1.13 g, 3.21 mmol) to methanol (25 mL) and cool to 0 °C. Bubble anhydrous hydrogen chloride gas into the mixture until saturated and stir for 1 h. Concentrate the mixture in vacua. Purify the residue by cfaromatography on silica gel (45 g), eluting with DCM/ (chloroform:methanol:concentrated NH4OH) (1:3 over 30 min; 80 mL/min) to provide the desired intermediate as a light yellow oil (344 mg, 42%). MS (APCI) m/z: 243 (M+H)+. Preparation 105 4-[2<2;2,2-TrifiuorcKAyluuo>l,l-(emylenedioxy)ethyl]-beraylamine (Formula Removed) 4-(2.2.2-TrifluiJroemyluiiomethvl(^rbonvl)-benzonitrile: To a solution of 2,2,2-trifluoroethanethiol (1.5 mL, 17.2 mmol) in anhydrous THF (28 mL) at 0 "C under nitrogen, add sodium hydride (629 mg, 15.7 mmol) and stir for 15 min. Then, add 4-cyanophenacyl bromide (3.2 g, 14.3 mmol) and stir at ambient temperature overnight. Quench with water and extract with EtOAc. Dry the combined organics extracts over MgSO4, filter and concentrate in vacua. Purify the crude mixture by chromatography on silica gel eluting with hexane/EtOAc (7:3) to obtain the desired intermediate (3.1 mg, 84%). 4-[2-(2.2.2-Trifluoroemvlthio)4J-femvlened^oxv)emyl1-benzonitrUe^ To a solution of 4-(2,2,2-trifluoroemylthiomethylcarbonyl)-benzonitrile (770 mg, 2.9 mmol) in anhydrous toluene (15 mL), add ethyleneglycol (0.33 mL, 5.9 mmol) andp-toluenesulfonic acid (564 mg, 2.9 mmol) and reflux with a Dean-Stark apparatus overnight Cool to room temperature, wash with saturated aqueous NaHCOj and brine. Dry the combined organic extracts over MgSO-t, filter and concentrate in vacua. Purify the crude mixture by chromatography on silica gel eluting with hexane/EtOAc (4:1), to obtain the desired intermediate (459 mg, 51%). 4-r242.2.2-Trifluoroethvltfaio)-l.l-(ethvlenedioxv^emvl1-benzvlarnine: To a solution of 4-[2-(2,2,2-trifluoroethylthio>l,l-(etliylenedioxy)ethyl]-benzonitrile (248 mg, 0.8 mmol) in anhydrous THF (8 mL) under nitrogen, add borane-tetrahydofurane complex (9.8 mL, 9.8 mmol) and heat at 60 °C for 3 h. Cool to room temperature and quench with methanol dropwise. Concentrate in vacua and purify by SCX chromatography to obtain the title compound (250 mg, 99%). MS (ES+) m/z: 308 (M+H)+. Example 1 7-Chlon>^-[4-(l-memoxymTino^myl)-beraylamino]-2,3,4,5-tetrahydro-lH- benzo[d]azepine Succinate (Formula Removed) Add O-methylhydroxylamine hydrochloride (10 mg, 0.12 mmol) and pyridine (0.02 mL, 0.24 mmol) to a solution of 6-(4-acetyl-benzylamino)-7-chloro-3-(2,2,2-trifluoroacetyl>2,3,4,5-tetrahydro-lH-benzo[d]azepuie (50 mg, 0.12 mmol) in ethanol (10 mL). Heat the mixture to reflux for 1.5 h. Remove the solvent in vacuo and partition the residue between DCM and 0.1N aqueous HC1. Dry die organic phase over NajSC^, filter and concentrate in vacuo. Purify by chromatography on silica gel eluting with hexane/EtOAc (95:5 to 1:1 gradient over 30 min). Concentrate in vacuo to obtain 7-chloro-6-[4-( 1 Hinethoxymiino-ethyl)-benzylanuno]-3-(2,2^-trifluoroacetyl)-2,3,4,5- tetrahydi»4H-benzo[d]az,epine as a colorless oil (45 mg, 83%). MS (ES+) tn/z: 454 (M+H)*. Use a method similar to the General Procedure 2-1, using 7-chloro-6-[4-(l-methoxyiiruno^thyl)-beraylarruno]-3^ benzo[d]azepine (45 mg, 0.099 mmol), to obtain 7-chloro-6-[4-(l-methoxyiminoethyl)-benzylamino]-2,3,4,5-tetrahydro-lH-benzo[4]azepine as a colorless oil (30 mg, 85%) suitable for use without additional purification. Use a method similar to the General Procedure 3-1, using 7-chloro-6-[4-(l- methoxvimmoemyl)-benzylainino]-2,3A5-tet^ mg, 0.084 mmol) to obtain lie title compound, a mixture of E- and Z- isomers, as a white solid (35.7 mg, 89%). MS (ES+) mfc 358 (M+H)+. Examples 2-3 Examples 2-3 may be prepared essentially as described in Example 1 by using 6-(4-acetyl-berizylamino)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-lH-benzo[benzyla 2,3,4,5-tetrahydro-lH-benzo[rfjazepine as an off-white solid (19.1 mg, 44%). MS (ES+) m/z: 482 (M+H)+. Use a method similar to the General Procedure 2-1, using 7-chloro-6-[4-(l-hydroxyinmc>-3-methyl-butyl>beiizylanun^ lH-benzo[if]azepine (45 mg, 0.099 mmol), to obtain 7-chloro-6-[4-(l-hydroxyimino-3-methyl-butyl)-benzylamino]-2,3,4,5-tetrahydro-lflr-benzo[^]azepine as a colorless oil (14.5 mg, 42%). Use a method similar to the General Procedure 3-1, using 7-chloro-6-[4-(l-hydroxyrauno-3-metliyl-butyl)-benzylamino]-2,3,4,5-tetrahydro- lH-benzo[benzylarnmo]-3-(2,2,2-trinuoroacetyl)-2f3,4,5-tetrahydrcH benzo[d]azepine and 0-methylhydroxylamme hydrochloride. Example 5 was obtained as a mixture of E- and Z- isomers. (Formula Removed) Example 6 7-CWoro-6-[4-(2-memylarmo-thiazol-4-yl)-benzylarnino]-2,3,4,5-tetrahydro-lH- benzo[d]azepine Succinate (Formula Removed) Use a method similar to the General Procedure 1-3, using 7-chloro-3-(2,2,2-trifluoimcetyl)-6-trifluoromernanesulfonyto^ (0.48 g, 1.14 mmol) and 4K2-rnemylamino-thiazol-4-yl)-benzylamine (0.4 g, 1.8 mmol), to obtain 7<;Uoro^[4-(2-memylammo-tluazol-4-yl)-benzylaminol-3-(212,2-trifluoroacetyl)-2,3,4,5-tetrahydro-lH-benzo[d]azepine as an off-white solid (0.12 g, 21%). MS (ES+) m/z: 495 (M+H)*. Use a method similar to the General Procedure 2-1 to deprotect 7-chloro-6-[4-(2-methylammcHmiazol-4-yl)-benzylarmBo]-3-(2,2,2-trifluoroac«tyl)-2,3J4,5-tet^ benzo[d]azepine (112 mg, 0.227 mmol) to obtain 7-chloro-6-I4-(2-mefiiylanuno-miazol-4-yl)-benzylamino]-2,3,4^-tetrahydro-lH-benzo[d]azepine as an off-white foam (70 mg, 78%). Use a method similar to the General Procedure 3-1, using 7-chloro-6-[4-(2-me%larm^<)-thiazol-4-yl)-benzylanuno3-2,3,4,5-tetrahydro-lflr-benzo[d]azepine (69 mg, 3.17 mmol) to obtain the title compound as an off-white foam (76.6 mg, 85%). MS (ES+) >n/z: 399 Examples 7-12 Examples 7-12 may be prepared essentially as described in Example 6 using 7-cUoro-3-(2,2,2-trifluoroacetyl>-6-trifluorom benzo[benzylammo]-3-(2,2;2-trffluoro^^ benzo[d]azepine. Purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (1:0 to 30:1 gradient) to obtain 7-chloro-6-[4-(2-methylammo-oxazol-4-yl)-benzylamino]-2,3,4,5-tetrahydro-lH-benzo[d]azepine. Dissolve 7-chloro-6-[4-(2-memylamino<>xazoM-yl)-benzylammo]-23A,5-tetrahydro-lH-beriZo[d]azepine (27 mg, 0.07 mmol) and (L)-tartaric acid (11 mg) in methanol. Concentrate in vacua to an oil. Triturate oil with diethyl ether and remove solvent in vacua to obtain the title compound as a solid (30 mg, 24%). MS (ES+) m/z: 383.1 (M+H)+. Example 14 7-Chloro-6-[4-(cyclopentylthiomethyl)-benzylamino]-2,3,4,5-tetrahydro-lflr-benzo[d]azepine (L)-Tartiate (Formula Removed) Use a method similar to the General Procedure 1-2 to couple 7-chloro-3-(2,2,2-trifluoroac«tyl)-6-truluoromewanesiufonyloxy (0.4 g, 0.94 mmol) with 4-(cyclopentylthiomethyl>benzylamine (229 mg, 1.03 mmol) in toluene (10 mL). Purify the crude mixture by chromatography on silica gel eluting with isohexane/EtOAc (1:0 to 4:1 gradient) to obtain 7-chloro-6-[4-(cyclopentylthiomethyl)-benzylammo]-3-<2^,2-truluoroa(»tyl>2,3A54etiahydnj-lH-benzo[d]azepine (190 mg, 41%). MS (ES+) m/z: 498 (M+H)+. Use a method similar to the General Procedure 2-1 to deprotect 7-chloro-6-[4-(cyclor)entylttoomernylHenzylammo]-3-(2^^ benzo[d]azepine (190 mg, 0.38 mmol). Purify by SCX chromatography eluting with methanol and 3N ammonia in methanol to obtain 7-chloro-6-[4-(cyclopentylthio-methyl)-berjzylamino]-2,,3,4,5-tetrahydro-lH-benzo[d]azepine (142 mg). Use a method similar to the General Procedure 3-2 to obtain the title compound (195.4 mg, 93% over two steps). MS (ES+) m/z: Example 15 Example 15 may be prepared essentially as described in Example 14 using 7-cMor(>3<2,2>trifluoroacetyl)-6-trifluoromemanesulfonyloxy-2,3,4,5-tetrahydro-l/:/-benzo[d]azepine and 4-(cyclohexylthiomethyl)-benzylamine. Overall yield and MS (ES+) data are shown in the Table below. (Table Removed) Example 16 7-Chloro-6-[(5-cyclor«ntylttoomemyl-pyridm benzo[6-trifluoromernanesutfonylox^ (245 mg, 0.58 namol) wim 2-aminome1hyl-5-cyclopentylthiornethyl-pyridine (230 mg, 1 mmol) in toluene (5 mL). Purity the crude mixture by chromatography on silica gel eliiting wiuihexane/THF (49:1 to 7:3 gradient) to obtain 7-chloro-6-[(5-cyclopentyluiiomethyl-pyridin-2-ylmethyl>ajmno]-3-(2I2>trmuoroacetyl)-2,3,4,5-tetrahydro-lH-l)enzo[d]azepine (170 mg, 59%). MS (ES+) m/z: 498.1 (M+H)+. Use a method similar to the General Procedure 2-3 to deprotect 7-chloro-6-[(5-cyclopentylthiomethyl-pyrid1n-2-ymiemyl)-ammo]-3-(2,2,2-trifluoroac^ tetrahydro-lH-benzo[rf]azepine. Purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (99:1 to 9:1 gradient) to obtain 7-chloro-6-[(5- cyclopentylthiomemyl-pyridin-2-ylmethyl)-amino]-2)3,4,5-tetrahydro-lH-benzo[d]azepine. Dissolve 7-chloro-6-[(5-cyclopentylthiomethyl-pyridin-2-ylmethyl)-amino]-2,3,4,5-tetrahydro-l/f-benzo[d]azepine (68 mg, 0.14 mmol) and (L)-tartaric acid (21 mg, 0.14 mmol) in methanol. Concentrate in vacuo to an oil. Triturate oil with diethyl ether and remove solvent in vacuo to obtain the title compound as a solid (85 mg, 48%). MS (ES+) m/z: 402.1 (M+H)*. Examples 17-19 Examples 17-19 may be prepared essentially as described in Example 16 by using 7pyridm-3-ylmemyl]-ammo}-3-(2,2,2-trifluoroacetyl)-2,3,4,5-urtrahydro-lH-benzo[d]azepine (0.2 g, 0. 4 mmol). Purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (99:1 to 90:10) to obtain 7-chloro- lflr-benzo[rf]azepine. Use a method similar to the General Procedure 3-2 to obtain the title compound (103 mg, 62%). MS (ES+) m/z: 405 (M+H)*. Examples 21-23 Examples 21-23 may be prepared essentially as described hi Example 20 by using 7-cMoro-3-(2,2,2-tiffluoroaoetyl)-6-trffluoromern^ benzo[d}azepine and the appropriately substituted arnine. Overall yields and MS (ES+) data are shown in the Table below. (Table Removed) Example 24 6-[(6-tert-Butyl.thiome%l-pyridin-3-ylmethyl>ammo]-7-(Woix)-2,3,4,5-tetrahyQ^o^ benzo[d]azepine (L)-Tartrate (Formula Removed) Use a method similar to the General Procedure 1-3. Add 3-aminomethyl-6-(ter?-butylthio)memyl-pyridine (2.99 g, 14.2mmol), 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethancsulfonyloxy-2,3,4,5-tetrahyaxo-lH-beMo[pyridm-3-ylme^ 2,3,4,5-tetrahydro-l/f-benzo[ lH-benzo[rf]azepine. Purify by SCX chromatography eluting with methanol and 3N ammonia in methanol and then by reverse phase HPLC (Princeton SPHER-Cjg 100 A column 5 Qm, 100x20 mm; 20-95% of solvent B in 11 min then 95% of solvent B in 4 min; solvent A: water, 0.1% acetic acid; solvent B: acetonitrile, 0.1% acetic acid; 20 mL/min). Use a method similar to the General Procedure 3-2 to obtain the title compound (76 mg, 22%). MS (ES+) m/Z: 361 (M+H)+. Examples 34-36 Examples 34-36 may be prepared essentially as described in Example 33 using 7-chloro-3-(212,2-tiifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-lH-benzo[d]azepine and the appropriately substituted 3-aminomethy-pyriduie. Overall yields and MS (ES+) data are shown in the Table below. (Table Removed) Example 37 7-Qiloro-6-[(5-cyclohexyloxy-pyridui-2-ylmethyl>anuno]-2,3,4,5-tetrahydro- \H- benzo[^ lH-benzo[pyrid^ lH-benzo[d]azepine Succinate (Formula Removed) Use a method similar to the General Procedure 1-2 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine (579 mg, 1.361 mmol) and (E)-3-aminomethyl-6-(2-cyclohexylvinyl)-pyridine (368 mg, 1.701 mmol). Purity by chromatography on silica gel (80 g, pre-packed cartridge) eluting sequentially with. hexane/EtOAc (1:0,49:1,19:1, 93:7, 9:1 and 85:15) to obtain (E)7-chloro-6-{6-[(2-cyclohexyl-vinyl)-pyridin-3-ylmethyl]-amino}-3-(2,2,2-trifluroacetyl)-2,3,4,5-tetrahydro-lH-benzo[d]lazepine (445 mg, 66%). MS (APCH-) m/z\ 492 (M+H)+. Use a method similar to the General Procedure 2-3 to deprotect (E)-7-chloro-6-{6-[(2-cyclohexyl-vinyl)-pyridin-3-ylmethyl]-amino} -3-(2,2,2-trifluroacetyl)-2,3,4,5-tetrahydrc~lH-benzo[d]azepine (607 mg, 1.234 mmol) using lithium hydroxide monohydrate (525 mg, 12.52 mmol) in methanol (15 mL) for 2 h. Purity by chromatography on silica gel (120 g, pre-packed cartridge) eluting sequentially with DCM/(chloroform:methanol:concentrated NH4OH 80:18:2) (49:1,19:1,9:1 and 17:3) to obtain (E)-7-diloro-6-{6-[(2-cyclohexyl-vinyl)-pyridm-3-ylmethyl]-amino}-2,3,4,5-tetrahydro-lH-benzo[d]azepine (481 mg, 98%). MS (APCI+) m/z: 396 (M+H)+. Use a method similar to the General Procedure 3-1, using (E)-7-chloro-6-{6-[(2-cyclohexyl-vinyl)-pyridin-3-ylmethyl]-amino}-2,3,4,5-tetrahydro-lH-berizo[d]azepine (481 mg, 1.215 mmol) to obtain the title compound (605 mg, 97%). MS (APCI+) m/z: 396 (M+H)+. Examples 41-44 Examples 41-44 may be prepared essentially as described in Example 40 by using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesuhconyloxy-2,3,4,5-tetrahydro- \H-benzo[d]azepine and the appropriately substituted amine. For Example 44, (L)-Tartrate salt was prepared essentially as described in General Procedure 3-2. Overall yields and MS (ES+) data are shown in the Table below. (Table Removed) Example 45 7-C^oro-6-[4-(2-cyclohexyl-2-oxo-ethyl)-benzylamino]-2,3I4,5-tetrahydro-lH- benzo[d]azepine (L)-Tarttate (Formula Removed) Use a method similar to the General Procedure 1-2 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromernanesdfonyloxy-,-2,3,4,5-tetrahydro-1H-benzo[d]azepine (137 mg, 0.325 mraol) and 4-(2-cyclohexyl-2-oxo-ethyl)-benzylamine (150 mg, 0.65 mmol). Purify by chromatography on silica gel eluting with hexane/EtOAc (95:5) to obtain 7-chloro-6-[4-(2-cyclohexyl-2-oxo-ethyl)-benzylammo]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-lH-benzo[benzylamino]-2,3,4,54etrahydro-lH-benzo[d]azepine (230 mg, 0.596 mmol) to obtain the title compound as an off-white solid (295 mg, 98%). MS (APCI+) m/z: 386 (M+H)+. Examples 47-48 Examples 47-48 may be prepared essentially as described in Example 46 by using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-lH-benzo[d]azepine and the appropriately substituted benzylamine. Enantiomeric excess of Example 47 was 92.7% [Analytical chiral conditions: Chiralpak® AD column; 250x4.6 mm, eluting with hexane/iso-propanol (95:5 with 0.1% diethylamine)]. Overall yields and MS (ES+) data are shown in the Table below. (Table Removed) Example 49 7-Chloro-6-[4-(piperidm-l-yuiiemyl)-benzylamino]-2,3,4,5-tetrahydro-lH-benzo[d]azepine Succinate (Formula Removed) Use a method similar to the General Procedurel-2 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethansutfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine (300 mg, 0.69 mmol) and 4-(piperidin-l-ylmethyl)-benzylamine (174 mg, 0.84 mmol). Purify by chromatography on silica gel (150 g) eluting with a gradient of DCM to 4:1 DCM/(chlorofonn:methanol:concentrated NHjOH 80:18:2) to obtain 7-chloro-6-(4-(piperidin-l-ylmethyl)-benzylammo]O-(2,2,2-trffluoroacetyl)-2,3,4,5-tetrahydro-lH-benzo[d]azepine as an oil (240 mg, 71%). MS (ES+) m/z: 480 (M+H)+ Use a method similar to the General Procedure 2-2, using 7-chloro-6-[4-(piperidin-l-yhiiemyl)-benzylamino]-3-(2,2,2-trifluoroacetyl)-2,314,5-tetrahydro-lH-benzo[methyl]-benzylamine (270 mg, 1.41 mmol) in toluene (10 mL). Purify by chromatography on silica gel (75 g) eluting with a gradient of 100% DCM to 9:1 DCM/(chloroform:methanol:concentrated NH4OH 80:18:2) to obtain 7-chloro-6-{4-((N-memyl-iso-propylamino)-methyl]-benzylamino}-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-lH-benzo[rflazepine (350 mg, 64%). MS (APCI) m/z: 468 (M+H)+. Dissolve 7-chloro-6-{4-[(N-methyl-wo-propylamino)-methyl]-benzylamino}-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-lH-benzo[d]azepine (350 mg, 0.75 mmol) in concentrated N1H4OH (10 mL) and MeOH (10 mL). Stir the reaction mixture overnight. Concentrate the mixture in vacua. Purify by chromatography on silica gel (45 g) eluting with a gradient of 100% DCM to 1:1 DCM/(chloroform:methanol:concentrated NH4OH 80:18:2) to obtain 7-choro-6-{4-[(N-methyl-iso-propylamino)-methyl]-benzylamino}-2,3,4,5-tetrahydro-lH-benzo[«flazepine (260 mg, 93%). MS (APCI+) m/z: 372 (M+H)+. Dissolve 7-chloro-6-{4-[(N-memyl-iso-propylammo)-methyl]-benzylamino}-2,3,4,5-tetrahydlro-lH-benzo[d]azepine (250 mg, 0.67 mmol) in methanol and add succinic acid (75 mg, 0.63 mmol). Stir the mixture until homogeneous. Concentrate the mixture in vacua, dissolve in water, and freeze dry the solution to obtain the title compound (325 mg, 95%). MS (APCI+) m/z: 372 (M+H)+. Example 57 7-Chloro-6- {5-[(N-cyclohexyl-aminomethyl)-pyridin-2-yl-methyl]-arnino} -2,3,4,5-tetrahydro-lH-benzo[d]azepine Succinate (Formula Removed) Use a method similar to the General Procedure 1-2 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-lH-berao[d]azepine (400 rag, 0.94 mmol) and 6-aminomethyl-3-[N-(cyclohexyl)-N-(2,2,2-trifluoroacetyl)-aminomethyl]-pyridine (440 mg, 1.41 mmol). Purify the crude mixture by chromatography on silica gel (150 g) eluting with hexane/EtOAc (1:0 to 7:3 gradient) to obtain 7-chloro-6- {5-[(N-cyclohexyl-N-(2,2,2-trifluoroacetyl)-aminoniethyl)-pyridm-2-yl-metiiyl]-amino}-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-lH-berizo[d]azepine as an oil (350 mg, 63%). MS (APCI+) m/z: 591 (M+H)+. Dissolve 7-chl oro-6- {5-[(Ar-cyclohexyl-N-(2,2,2-trifluoroacetyl)-aminomethyl)-pyridin-2-yl-methyll-amino} -3-(2l2,2-trifluoroacetyl)-2,3,4,5-tetrahydro- IH-benzo[d]azepine (350 mg, 0.59 mmol) in K2CO3 (400 mg, 2.9 mmol), methanol (10 mL), and water (10 mL), and stir for 12 h at 60 °C. Extract with DCM and purify the crude mixture by SCX chromatography (4 g) eluting with methanol and 3N ammonia in methanol to obtain 7-chloro-6-{5-[(N-cyclohexyl-ammomethyl)-pyridm-2-yl-methyl]-ammo}-2I3,4,5-tetrahydro-lH-benzo[d]azepine as an oil (210 mg, 89%). MS (APCI+) m/z: 399 (M+H)+. Use a method similar to the General Procedure 3-1, using 7-chloro-6-{5-[(N-cyclohexyl-ammomemyl)-pyridin-2-yl-memyl]-ammo}-2,3,4,5-tetrahydro-lH-benzo[d]azepine (210 mg, 0.53 mmol) to obtain the title compound as a yellow solid (260 mg,96%). MS(APCH")m/z:399(M+H)+. Example 58 7-Chloro-6-{6-[(piperidm-l-ylmethyl)-pyridm-3-yl-memyl]-ammo}-2,3,4,5-tetrahydro- lH-benzo[d]azepine Succinate (Formula Removed) Use a method similar to the General Procedure 1-2 to couple 7-chloro-3-(2,2,2--trifluoroacetyl)-6-tnfluoromethanesulfonyloxy-2,3,4,5-tetrahydro- Iff-benzofrflazepine (340 mg, 0.799 nunol) and 5-aniinomethyl-2-(piperidin-l-ylniethyl)-pyridine (246 mg, 1.19 mmol). Purify by chromatography on silica gel (80 g) eluting with hexane/EtOAc (1:0 to 1:2 gradient over 1.25 h, 80 mL/min) to obtain 7-chloro-6-{6-[(piperidin-l-ylmethyl)-pyridin-3-yl-methyl]-aniino}-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-lH-benzo[d]azepine as a light yellow oil (305 mg, 79%). MS (APCI+) m/z: 481 (M+H)+. Add 7-chloro-6- {6-[(piperidin-l-ylmethyl)-pyridin-3-yl-methyl]-amino} -3-(2,2,2-trifluoroacetyl)-2,3)4,5-tetrahydro-lH-benzo[rf]azepine (300 mg, 0.623 mmol) in methanol (10 mL). Add lithium hydroxide hydrate (456 mg, 19.0 mmol) and stir at room temperature overnight. Concentrate in vacua and dissolve the residue in water (10 mL). Extract the aqueous layer with DCM (3x15 mL). Dry the combined organic extracts over Na2SO4, filter and concentrate in vacua to provide 7-chloro-6-{6-[(piperidin-l-yhiiethyl)-pyridin-3-yl-methyl]-amino}-2,3,4I5-tetrahydro-lH-benzo[d]azepine as an off-white foam (234 mg, 96%). MS (APCI+) m/z: 385 (M+H)+. Use a method similar to the General Procedure 3-1, using 7-chloro-6-{6-[(piperidm-l-ylniemyl)-pyridin-3-yl-methyl]-amino}-2,3,4,5-tetrahydro-1H-benzo[djazepine (230 mg, 0.597 mmol) to obtain the title compound as an off-white solid (303 mg, 100%). MS (APCI+) m/z: 385 (M+H)+. Example 59 7-Chloro-6-[4-(2,2-dimethl-propionylammo)-benzylammo]-2,3,4,5-tetrahydro-lH- benzo[d-azepine Succinate (Formula Removed) Use a method similar to the General Procedure 1-3 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-23,4,5-tetrahydro-lfl-ben2o[dlazepine (0.33 g, 0.78 mmol) with a solution of 4-(2,2-dimethyl-propionylamino)-benzylamirie (0.32 g, 1.6 mmol) in anhydrous toluene/dioxane (4:1,10 mL). Purity the crude mixture by chromatography on silica gel eluting with hexane/EtOAc (1:0 to 7:3 gradient over 30 min; 35 mL/rnin) and then«by SCX chromatography to obtain 7-chloro-6-[4-(2,2-dimethyl-propionylamino)-benzylarnuio]-3-(2,212-trifluoroacetyl)-2,3,4,5-tetrahydro-lH-benzo[d]-azepine as a yellow oil (0.266 g, 70%). MS (ES+) m/z: 482 (M+H)+. Use a method similar to the General Procedure 2-1 to deprotect 7-chloro-6-[4-(2,2-dimemyl-propionylarmno)-benzylarnmo]-3-(2,2,2-trifluoroacetyl)-2,3,45,-tetrahydro lH-benzo[d] -azepine (0.259 g, 0.538 mmol). Purify the crude mixture by chromatography on silica gel eluting with DCM/2M ammonia in methanol (1:0 to 9:1 gradient over 30 min; 9:1 over 3 min; 9:1 to 4:1 gradient over 30 min and 4:1 over 3 min; 35 mL/min) to obtain 7-chloro-6-[4-(2,2-dimethyl-propionylamino)-benzylamino]-2,3,4,5-tetrahydro-lH-benzo[rf]-azepine as a white foam (0.173 g, 84%). Use a method similar to me General Procedure 3-1, using 7-chloro-6-[4-(2,2-dimemyl-propionylammo)-benzylamino]-2,3,4,5-tetrahydro-lH-benzo[d]-azepine (0.171 g, 0.443 mmol) to obtain the title compound as a white solid (215.5 mg, 96%). MS (ES+) m/z: 386.2 (M+H)+. Examples 60-61 Examples 60-61 may be prepared essentially as described in Example 59 using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trffluoromemanesulfonyloxy-2,3,4,5-tetrahydro-lH-benzp[d]lazepine and the appropriately substituted benzylamine. Overall yields and MS (ES+) data are shown in the Table below. (Table Removed) Examples 63 and 64 (+)-7-Chloro-6- {4-[(2-methyl-cyclopropanecatbonyl)-amino]-benzylamino} -2,3,4,5-tetrahydro- 1H-benzo[d]-azepine Succinate and (-)-7-Chloro-6-{4-[(2-methyl-cyclopropanecarbonyl)-amino] -benzylamino} -2,3,4,5-tetrahydro- lH-benzo[d]-azepine Succinate (Formula Removed) Use a method similar to the General Procedure 1-3 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)- 6-trifluoromethanesulfonylox y-2,3,4,5-tetrahydro- l/H-benzo|d]azepine (0.94 g, 2.2 mmol) with a solution of (±)-trans-4-[(2-memyl-cyclopropanecarbonyl)-amino]-benzylanune (0.899 g, 4.403 mmol) in anhydrous toluene (22 mL) and anhydrous dioxane (5.8 mL). Purify by chromatography on silica gel to afford (±)-trans-7-chloro-6-{4-[(2-methyl-cyclopropanesautonyl)-amino]-benzylarnmo}-3-(2,2,2-rrifluoroacetyl)-2,3,4,5-teteahydro- lH-benzo[d]-azepine (0.834 g, 79%) as an orange oil. Separate both enantiomers from the racemic mixture (0.747 g) by chiral chromatography (Chiralpak AD-H, 4.6x150 mm column; elute with 2B-3 ethanol (100%); 0.6 mL/min) to afford Isomer 1 (330 mg, 62%) and Isomer 2 (265 mg, 50%). Use a method similar to the General Procedure 2-1 to deprotect each isomer independently and a method similar to the General Procedure 3-1 to prepare independently the title compounds. MS (ES+) data and optical rotation for each enantiomer are shown in the Table below. (Table Removed) Example 65 7-Chloro-6-[4-(N-methyl-2,2-diethyl-propionylarnmo)-benzylanimo]-2,3,4,5-tetrahydro- lH-benzo[4]-azepine Succinate (Formula Removed) Use a method similar to the General Procedure 1-2 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-lH-berizo[d]azepine (0.23 g, 0.53 mraol) with a solution of 4-(N-methyl-2,2-dimethyl-propionylamino)-benzylamine (0.23 g, 1.06 mmol) in anhydrous toluene/dioxane (4:1,7 mL). Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0 to 17:3 gradient over 30 min, 17:3 over 30 min, 17:3 to 7:3 gradient over 30 min and 7:3 over 30 min; 35 mL/min) to obtain 7-chloro-6-[4-(N-methyl-2,2-dimethyl-propionylamino)-benzylarnino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-lH-benzo[d]-azepine as a yellow oil (0.235 g, 90%). Use a method similar to the General Procedure 2-1 to deprotect 7-chloro-6-[4-(N-methyl-2,2-dimethyl-propionyiammo)-benzylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-lH-benzp[d]-azepine (0.217 g, 0.437 mmol). Purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (1:0 to 9:1 over 30 min, 9:1 over 3 min; 35 mL/mm) to obtain 7-chloro-6-[4-(N-methyl-2,2-dimethyl-propionylamino)-benzylamino]-2,3,4,5-tetrahydro-lH-benzo[d]-azepine as a colorless oil (0.127 g, 73%). Use a method similar to me General Procedure 3-1, using 7-chloro-6-[4-(N-memyl-2,2-dimethyl-propionylanimo)-benzylaniino]-23»4,5-tetrahydro-l/f-benzo[rf]-azepine (0.124 g, 0.309 mmol) to obtain the title compound as a white solid (154 mg, 96%). MS (ES+) m/r. 400.2 (M+H)4. Example 66 7-Chloro-6-[4-(cyclohexanecarbonyl-amino)-benzylamino]-2,3t4,5-tetrahydro-lH- benzo[d-azepine Succinate (Formula Removed) Add a solution of triethylamine (24 mg, 0.117 mmol) in DCM (3.6 mL) to a hetereogeneous mixture of 6-(4-amino-benzylamino)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-lH-benzo[d]-azepine hydrochloride (181 mg, 0.385 mmol) in anhydrous DCM (18.2 mL) at 0°C. Add a solution of cyclohexanecarbonyl chloride (56 mg, 0.39 mmol) in anhydrous DCM (3.6 mL). Stir at 0°C for 15 min and then at room temperature overnight. Partition the reaction mixture between DCM (100 mL) and water (50 mL). Extract the aqueous phase with DCM (50 mL). Wash the combined organic extracts with waiter (3x25 mL), dry over Na2SO4, filter and concentrate in vacua. Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0 to 3:1 over 30 min; 3:1 over 3 min; 3:1 to 1:1 over 30 min and 1:1 over 3 min; 35 mL/min) to obtain 7-chloro-6-[4-(cyclohexanecart)onyl-amino)-benzylamino]-3-(2,2,2-triluoroacetyl)-2,3,4,5-tetrahydro-17f-benzo[d]-azepine (0.161 g, 83%). MS (ES+) m/z: 508.3 (M+H)+. Use a method similar to the General Procedure 2-3, using 7-chloro-6-[4-(cyclohexanecaibonyl-aimao)-benzylamino]-3-(2,2,2-triluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]-azepine (0.120 g, 0.236 mmol) to obtain 7-chloro-6-[4-(cyclohexanecarbonyl-arorno)-beiizylarruno]-2,3,4,5-tetrahydro- l/f-benzo[d]-azepine (74 mg, 76%). MS (ES+) m/z: 412.3 (M-f-H)"*". Use a method similar to the General Procedure 3-1 to obtain the title compound as a white solid (95 mg, 100%). MS (ES+) m/z: 412.3 Examples 67-68 Examples 67-68 may be prepared essentially as described in Example 66 using 6-(4-arrmo-berizylarnino)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro- 1H-benzo[d]-azepine hydrochloride and the appropriate carbonyl chloride. Overall yields and MS (ES+) data are shown in the Table below. (Table Removed) Example 69 7-Chloro-6-{4-[(2,2-dimethyl-propionylamino)-methyl]-benzylamino}-2,3,4,5-tetrahydro- lH-benzo[d]azepine (L)-Tartrate (Formula Removed) Use a method similar to the General Procedure 1-2 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6~trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro- lH-beozo[d\ azepine (299 mg, 0.704 mmol) and 4-[(2,2-dimethyl-propionylarnino)-methyl]-benzylamine (310 mg, 1.41 mmol). Purify the crude mixture by chromatography on silica gel eluting with hexane/EtOAc (3:2) to obtam7-chloro-6-{4-[(2,2-dimethyl-propionylamino)-rnethyl]-benzylamino}-3-(2t2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-lH-benzo[d]azepine as a yellow oil (265 mg, 76%). MS (ES+) m/r. 496 (M+H)+. Use a meithod similar to the General Procedure 2-1 to deprotect 7-chloro-6-{4-t(2,2-dimethyl-propionylamino)-methyl]-benzylamuio} -3-(2t2,2-trifluoroacetyl)-2,3,4,5-tetrahydro- lH-benzo[d]azepine (265 mg, 0.53 mmol). Purify by reverse phase HPLC [Xterra MS C18 column, 100x19 mm, 5 M; flow rate: 25 mL/min, eluting with 3:7 to 6:4 acetonitrile/ammonium bicarbonate (20 mM at pH=8)] to obtain 7-chloro-6-{4-[(2,2-dmiemyl-propioiiylamino)-memyl]-benzylamuio}-2,3,4,5-tetrahydro-lH-benzo[d] azepine as a yellow oil (155 mg, 73%). MS (ES+) m/z: 400 (M+H)+. Use a method similar to the General Procedure 3-2, using 7-chloro-6-{4-[(2,2-dimethyl-propionylarmino)-memyl]-benzylamino}-2,3,4,5-tetrahydro-lH-benzo[d]aze (150 mg, 0.375 rnmol) to obtain the title compound as a white solid (206 mg, 99%). MS (ES+)m/z:400(M+H)*. Example 70 7-Chloro-6-{4-[(cyclopropanecart»onyl-amino)-methyl]-benzylamino}-2,3,4,5-tetrahydro- lH-benzo[d]azepine Succinate (Formula Removed) Use a method similar to the General Procedure 1-2 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-23,4,5-tetrahydro-lH-benz»[panecarbonyl-amino)-methyl]-benzylamino } -3 -(2,2,2-trifluoroac«tyl)-2,3A5-tetraydro-lH-benzo[JIazepine (335 mg, 0.698 mmol) in MeOH (10 mL). Add UOH-H2O (293 mg, 6.98 rnmol) and stir overnight. Partition the reaction mixture between chloroform and water. Separate the aqueous phase and extract three times with chloroform and once with chlorofonn/wo-propanol (3:1). Dry the combined organic extracts over MgS04, filter and concentrate in vacua. Purify the crude mixture by chromatography on silica gel (40 g, pre-packed cartridge) eluting with DCM/(chloroform:methanol:concentrated NH4OH 80:18:2) (1:0 over 5 min, 19:1 over 5 min, 9:1 over 5 min, 85:15; 50 mL/min) to obtain 7-chIoro-6-{4-[(cyclopropanecarbonyl-amino)-methyl]-benzylamino}-2,3,4,5-tetrahydro-lH-benzo[i/]azepine (244 mg, 91%). MS (APCI+) m/z: 384 (M+H)+. Use a method similar to the General Procedure 3-1, using 7-chloro-6-{4-[(cyclopropanecarbonyl-ammo)-methyl]-benzylamino}-2,3,4,5-tetrahydro-lH-benzo[d]azepine (240 mg, 0.625 mmol) to obtain the title compound (323 mg, 100%). MS (APCI+) m/z: 384 (M+H)+ Example 71 7-Chloro-6- {4-[2-(2,2-duriemyl-propionylamino)-ethyl]-benzylamino} -2,3,4,5-tetrahydro- lH-benzo[ethyl]-benzylarruno}-2,3,4,5-tetrahydro-1H-benzo[d]azepine (70 mg, 0.169 mmol) to obtain the title compound as a white solid (95 mg, 99%). MS (ES+) m/z: 414 (M+H)+. Example 72 7-Chloro-6-[4-(iso-propylcarbamoyl-memyl)-benzylamino]-2,3,4,5-tetrahydro-lH- benzo[d]azepine (L)-Tartrate (Formula Removed) Use a method similar to the General Procedure 1-2 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromeu\anesutfonyloxy-23,4,5-tetrahydro-1H-benzo[d]azepine (162 mg, 0.38 mmol) and 4-(wo-propylcarbamoyl-methyl)-benzylamine (157 mg, 0.76 mmol). Purify by chromatography on silica gel eluting with hexane/EtOAc (9:1, 4:1, 2:1 and 1:1) to obtain 7-chloro-6-[4-(iso-propylcarbamoyl-methyl)-benzylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-lH-benzo[d]azepine as an oil (117 mg, 64%). Use a method similar to the General Procedure 2-1, using 7-chloro-6-[4-(iso-propyicarbamoyl-methyl)-berizylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-lH-benzo[d]azepine (117 mg, 0.24 mmol) to obtain 7-chloro-6-[4-(iso-propylcaibamoyl-methyl)-benzyl;ammo]-2,3,4,5-tetrahydro-lff-benzo[d]azepine as an oil (83 mg, 89%) suitable for use without additional purification. Use a method similar to the General Procedure 3-2, using 7-chloro-6-[4-(iso-propylcari)amoyl-memyl)-benzylammo]-2,3,4,5-tetrahydro-lH-benzo[d]azepine (45 mg, 0.11 mmol) to obtain the title compound as a white solid (106 mg, 92%). MS (ES+) m/z: 386 (M+H)+. Examples 73-77 Examples 73-77 may be prepared essentially as described in Example 72 by using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromemanesulfonyloxy-2,3,4,5-tetrahydro-lH- benzo[d]azepine and the appropriately substituted benzylamine. Overall yields and MS (ES+) data are shown in the Table below. (Table Removed) Example 78 (R)-7-Chloro-6-{4-[(l-methyl-2,2,2-trifluoro-ethylcarbamoyl)-methyl]-benzylarnino}-2,3,4^-tetrahydro-lH-benzo[d]azepine(L)-Tartrate (Formula Removed) Use a method similar to the General Procedure 1-2 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-lxifluoromethanesulfonyloxy-2,3,4,5-tettahydro-l/f-benzo[rf]azepine (84 mg, 0.196 mmol) and (/?)-4-[(l-methyl-2,2,2-trifluoro-ethylcarbamoyl)-methyl]-benzylamine (102 mg, 0.39 mmol). Purify by chromatography on silica gel eluting with hexane/EtOAc (4:1) to obtain (J?)-7-chloro-6-{4-[(l-methyl-2,2,2-trifluoro-emylcarbamoyl)-raemyl]-benzylaim^o}-3-(2,2)2-trifluoroacetyl)-2,3,4,5-teurahydro-lH-benzo[d]azcpine as a yellow oil (47 mg, 45%). MS (ES+) m/z. 536 (M+H)+. Use a metliod similar to the General Procedure 2-1 to deprotect (/?)-7-chloro-6-{4-t(l-memyl-2,2,2-trifluoro-ethylcarbamoyl)-methyl]-benzylamino}-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-lH-benzo[d]azepine (45 mg, 0.08 mmol). Purify by reverse phase HPILC [Xterra MS C18 column, 100x19 mm, 5 µM; flow rate: 25 mL/min, eluting with 3:7 to 9:11 acetonitrile/ammonium bicarbonate (10 mM at pH=8)] to obtain (R)-7-chloro-6-{4-[(l-memyl-2,2,2-trifluoro-ethylcarbamoyl)-memyl]-benzylamino}-2,3,4,5-tetrahydro-lH-benzo[d]azephie as a yellow oil (15 mg, 42%). Use a method similar to the General Procedure 3-2, using (R)-7-chloro-6-{4-[(l-memyl-2,2,2-trifluoro-emylcarbamoyl)-memyl]-benzylammo}-2,3,4,5-telTahydro-lH-benzoUfljazepine (15 mg, 0.03 mmol) to obtain the title compound as a white solid (20 mg, 99%). MS (ES+) m/z: 440 (M+H)+. [α]o=-40 (c=0.225, MeOH). Example 79 6-{4-[2-(tert-Butylcarbamoyl)-emyl]-berizylammo}-7-chloro-2,3,4,5-tetTahydro-lH- benzo[d]azepine (L)-Tartrate (Formula Removed) Use a method similar to the General Procedure 1-2 to couple 7-chloro-3-(2,2,2-trffluoroacetyl)-6-trifluoromemanesuhconyloxy-2,3,4,5-tetrahydro-lH-benzo[d]azepuie (85 mg, 0.2 mmol) and 4-[2-(tert-butylcarbamoyl)-ethyl]-benzylamine (80 mg, 0.34 mmol). Purify the crude mixture by chromatograpby on silica gel eluting with hexane/EtOAc (95:5 to 1:1 gradient) to obtain 6-{4-[2-(tert-butylcarbamoyl)-ethyl]-berjzylaraino}-7-chloro-3(2,2,2-trifluoroacetyl)-2,3,4,5-teliahydro-lH-benzo[d]azepine. as a yellow oil (75 mg, 74%). MS (ES+) m/z: 510 (M+H)+. Use a method similar to the General Procedure 2-1, using 6-{4-[2-(rert-butylcarbamoyl)-ethyl]-benzylammo}-7-chloro-3-(2,22-trifluoroacetyl)-2,3,4,5-tetrahydro-lH-benzo[d]azepine (71 mg, 0.14 mmol) to obtain 6-{4-[2-(terf-butylcarbamoyl)-emyl]-benzylarmuo}-7-cMoro-2,3,4,5-tetrahydro-1H-benzo[d]azepine (57 mg, 99%) as a yellow oil suitable for use without additional purification. Use a method similar to the General Procedure 3-2, using 6-{4-[2-(tert-butylcarbamoyl)-emyl]-benzylainino}-7-chloro-2,3,4,5-tetrahydro-lflr-benzo[d]azepine (57 mg, 0.14 mmol) to obtain the title compound as a white solid (76 mg, 99%). MS (ES+) m/z: 414 (M+H)+. Example 80 Example 80 may be prepared essentially as described in Example 79 by using 7-chloro-3-(2,2/2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[J]azepine and 4-[2-(2,2-dimemylpropyl-carbamoyl)-ethyl]-benzylarnine. Overall yield and MS (ES+) data are shown in the Table below. (Table Removed) Example 81 7-Chloro-6-{6-[(2,2-dimemyl-propanesulfonymiemyl)-pyridm-3-ylmethyl]-amino}-2,3,4,5-tetrahydro-lH-benzo[d]azepineSuccinate (Formula Removed) Use a method similar to the General Procedure 1-2 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromernanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine (450 mg, 1.06 rrunol) with 3-aminomethyl-6-[(2^-dimethylpropane)sulfonylmethyl]-pyridine (325 mg, 1.27 mmol) using tm(dibenzylideneacetone)dipalladium(0) (95 mg, 0.1 mmol), BINAP (95 mg, 0.15 mmol) and cesium carbonate (520 mg, 1.5 mmol) in toluene (10 mL). Heat the mixture at 90°C for 12 h. Cool the mixture to room temperature and purify by chromatography on silica gel (75 g) eluting with hexane/EtOAc (1:0 to 1:1 gradient) to obtain 7-chloro-6-{6-[(2,2-dirnethyl-propanesulfouylmethyl)-pyridin-3-yhnethyl]-amino} -3-(2,2,2-trtfluoroacetyl)-2,3,4,5-tetrahydro-lH-benzo[dlazepine (470 mg, 83%). MS (APCI+) m/z: 532 (M+H)+. Dissolve 7-chloro-6-{ 6-[(2,2-dimethyl-propanesulfonylmethyl)-pyridin-3-ylmemyl]-ammo}-3-(2,2,2-triiluor6ac«tyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine mg, 0.88 mmol) in concentrated NR4OH/methanol (1:1,20 mL) and stir the mixture overnight at room temperature. Concentrate the mixture in vacua. Purify by chromatography on silica gel (45 g, pre-packed cartridge) eluting with a gradient of DCM to 4:1 DCM/(chloroform:methanol:concentrated NHUOH 80:18:2) to obtain 7-chloro-6-{6-[(2,2-dune(hyl-propanesulonylmemyl)-pyridm-3-yhiiemyl]-aniino} -2,3,4,5-tetrahydro-lH-benzo[dlazepine (380 mg, 99%). MS (APCI+) m/z: 436 (M-+-H)+ Dissolve 7-chloro-6-{6-[(2,2-dunemyl-propanesulfonyhnethyl)-pyridrn-3-ymiemyl]-arnino}-2,3,4,5-tetrahydro-lW-benzo[rflazepme (380 mg, 0.87 mmol) in methanol and add succinic acid (98 mg, 0.83 mmol). Stir the mixture until homogeneous. Concentrate die mixture in vacua, dissolve in water, and freeze dry the solution to obtain the title compound (470 mg, 98%) as a light yellow solid. MS (APCI+) /n/fc 436 (M+H)+ Example 82 Example 82 may be prepared essentially as described in Example 81 by using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-lH-benzo[d]azepine and 3-aminomethyl-6-(cycIohexanesuuconyl)methyl-pyridine. Overall yield and MS (ES+) data are shown in the Table below. (Table Removed) Example 83 7-Chloro-6-[4-(2,2-dimethyl-propanesulfonylmethyl)-benzylamino]-2,3,4,5-tetrahydro- lH-benzo[d]axepine Succinate (Formula Removed) Use a method similar to the General Procedure 1-2 to couple 7-chloro-3-(2,2,2-trifluoroaretyl)-6^trifluoromethanesiilfony (639 mg, 1.50 icnmol) with 4-(2,2-dnnethyl-propanesiu'fony[methyl)-benzylaniine (479 mg, 1.88 mmol), using tris(dibenzylideneacetone)dipalladium(0) (137 mg, 0.1S mmol), BINAP (187 mg, 0.3 mmol) and cesium carbonate (977 mg, 3 mmol) in toluene (20 mL). Heat the mixture at 90°C overnight Cool the mixture to room temperature and purify by chromatography on silica gel (80 g) eluting with hexane/EtOAc (1:0 to 4:1 gradient over 15 min; 50 mL/min) to give 7-chloro-6-[4-(2,2-dimethyl-propanesulfonyl-methyl)-benzylamino]-3-(2,2,2-tru^uoroaoetyl)-2,3,4,5-tetraydro-lH-berizo[d]azepine(615mg, 77%). MS (APCI+) m/z: 531 (M+H)+. Dissolve 7-chloro-6-[4-(2,2-dimemyl-propanesulfonylmethyl)-benzylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-lH-benzo[d]azepine (605 mg, 1.14 mmol) in methanol (8 mL) and add LiOH H2O (478 mg, 11.4 mmol). Stir the reaction mixture overnight. Partition the mixture between water and chloroform. Extract the aqueous phase three times with chloroform and chloroform/wo-propanol (3:1). Dry the combined organic extracts over MgSO4, filter and concentrate in vacua. Purify by chromatography on silica gel (40 g) eluting with DCM/(chloroform:methanol:concentrated NH4OH 80:18:2) (1:0 over 5 min, 19:1 over 5 min, 9:1; 50 mL/min) to obtain 7-chloro-6-[4-(2,2-dimernyl-propanesiulfonylmernyl)-benzylarmno]-2,3,4,5-tetrahydro-1H-benzo[d]azepine (467 mg, 94%). MS (APCI+) m/z: 435 (M+H)+. Dissolve 7-chloro-6-[4-(2,2-dmiethyl-propanesulfonylmethyl)-r>enzylamino]-2,3,4,5-tetrahydro-lH-benzo[d]azepine (316 mg, 0.726 mmol) in methanol (10 mL) and add succinic acid (86 mg, 0.726 mmol). Stir the mixture for 2 h. Concentrate the mixture in vacua and dry under high vacuum at 50°C to obtain the title compound (380 mg, 94%). MS (APCI+) m/z: 435 (M+H)+. Example 84 7-Chloro-6-(4-dimemylcarbamoylthio-benzylaniino)-2,3,4,5-tetrahydro-lH-benzo[d]azepine Succinate (Formula Removed) Use a method similar to the General Procedure 3-1, using 7-chloro-6-(4-dimemylcarban:toylthio-berizylammo)-2l3,4,5-terrahydro-lH-oenzo[d]azepine (56 mg, 0.14 mmol) to obtain the title compound as a solid (67 mg, 92%). MS (ES+) m/z: 390 (M+H) Example 85 7-Chloro-6-[4-(3,3-dunemyl-2-oxobutylmio)-benzylarnino]-2,3,4,5-tetrahydro-1H- benzo[d]azepine (L)-Tartrate (Formula Removed) 3-(tert-Butoxycarbonyl)-7-chloro-6-[4-(3.3-dimethyl-2-oxobutyIthio)-benzylaramino1-2.3.4.5-tetrahvdro-lH-benzo[d]nazepine: Dissolve 3-(tert-butoxycarbonyl)-7-chloro-6-(4-dimethylcarbaiinoylthio-benzylamino)-2,3,4,5-tetrahydro-lH-benzo[d]azepine (57 mg, 0.1 mmol) in methanol (5 mL). Add potassium hydroxide (65 mg, 1.1 mmol) and heat the mixture for 3 h at 65 °C. Then add l-bromo-3,3-dimethyl-2-butanone and heat at 65 °C for 2 h. Cool the mixture and dilute with EtOAc. Wash the organic phase with water, dry over MgSO4, filter and concentrate in vacua. Purify by chromatography on silica gel eluting with hexane/diethyl ether (7:3) to obtain the desired intermediate as an oil (18 mg, 30%). 7-ChIoro-6-[4-(3,3-dimethyl-2-oxobutyImio)-benzylamino1-2.3.4.5-tetrahvdro-lH-benzo[d]lazepme: Dissolve 3-(tert-butoxycarbonyl)-7-chloro-6-[4-(3,3-dimethyl-2-oxobutylthio)-lberizylarnino]-2,3,4,5-tetrahy(lro-lH-benzo[d]azepine (35 mg, 0.06 mmol) in DCM ( 0.2 mL). Add 4M hydrogen chloride in dioxane (0.3 mL, 1.3 mmol) and stir at room temperature for 1 h. Concentrate in vacua and purify by SCX chromatography to obtain the desired intermediate (26 mg, 93%). 7-Chloro-6-[4-(3,3-dimethyl-2-oxobutylthio)-benzvlarnino1-2.3.4.S-tetrahydro-1H-benzo[d]azepine (L)-Tartrate: Use a method similar to the General Procedure 3-2, using 7-chloro-6-[4H;3,3-dimethyl-2-xobutylthio)-benzylammol-2,3,4,5-tetrahydro-lfr benzo[d]azepine (26 mg, 0.06 mmol) to obtain the title compound as a white solid (35 mg,99%). MS(ES+)m/r.418(M+H)+. Example 86 7-Chloro-6-{4-[(2,2-dimethyl-propylcarbamoyl)-methylthio]-benzylamino}-2,3,4>5-tetrahydro-lH-benzo[d]azepme (L)-Tartrate (Formula Removed) tetrahydro- IH-benzorrflazepine: Dissolve 3-(tert-butoxycarbonyl)-7-chloro-6-(4-dimethylcarbainoylthio-ben2ylamino)-2,3,4,5-tetrahydro-lH-benzo[d]az.epine (270 mg, . 0.5 mmol) in methanol (20 mL). Add potassium hydroxide (308 mg, 5.5 mmol) and heat the mixture for 3 h at 65 °C. Add methyl bromoacetate (0.52 mL, 5.5 mmol) and heat at 65 °C for 3 h. Cool the mixture to room temperature and dilute with EtOAc. Wash the organic phase with water, dry over MgSO4, filter and concentrate in vacua. Purify by chromatography on silica gel eluting with hexane/EtOAc (4:1) to obtain die desired intermediate as an oil (203 mg, 75%). 3-(tert-Butoxycarbonyl)-7-choro-6-{4-[(2.2-dimethyl-propylcarbamoyl)-methylthio1-benzvlamino}-2.3.4.5-tetrahydro-lH-benzo[d]L, 0.79 mmol, IM solution in toluene). Allow the mixture warm up to room temperature and stir for 2 h. Add this complex to a solution of 3-(tert-butoxycarbonyl)-7-chloro-6-(4-methoxycaibonylmethylthio-benzylamino)_ 2,3,4,5-tetrahydro-lH-benzo[d]azepine (70 mg, 0.14 mmol) in THF (0.3 mL) and stir at room temperature overnight Dilute with EtOAc and quench with 5% aqueous KHSO4. Dry the organic phase over MgSO4, filter and concentrate in vacua. Purify the crude mixture by chromatography on silica gel eluting with hexane/EtOAc (4:1) to obtain the desired intermediate as an oil (51 mg, 65%). 7-Chloro-6-{4-[(2,2-dimethyl-propvlcarbamovl-methylthio1-benzylamino)-2.3.4.5-tetrahydro- IH-benzof rflazepine: Dissolve 3-(tert-butoxycarbonyl)-7-chloro-6-{4-[(2,2-dimemyl-propylcaibamoyl)-memylmio]-benzylammo}-23,4,5-tetrahydro-lH-benzo[4Jazepine (51 mg, 0.09 mmol) in DCM (0.2 mL). Add 4M hydrogen chloride in dioxane (0.5 mL, 1.8 mmol) and stir at room temperature for 1 h. Concentrate in vacua and purify by SCX chromatography to obtain the desired intermediate (39 mg, 93%). 7-Chloro-6-{4-[(2.2-dimethyl-prQpylcarbamoyl)-methyltfaio1-benzylaminol-2,3,4.5-tetrahydro-1H-benzorrflazepine (L)-Tartrate: Use a method similar to the General Procedure 3-2, using 7-chloro-6-{4-[(2,2-dimethyl-propylcarbamoyl)-methyltbio]-benzylamino}-2,3,4,5-tetrahydro-lH-benzo[d]azepine (39 mg, 0.08 mmol) to obtain the title compound as a white solid (51 mg, 98%). MS (ES+) m/z: 446 (M+H)+. Example 87 7-Chloro-6- {[6-(3,3-dimethyl-2-oxo-butoxy)-pyridin-3-yhnethyl]-amino} -2,3,4,5-tetrahydro-lH-benzo[d]azepine (L)-Tartrate (Formula Removed) Use a method similar to the General Procedure 1-2 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromemanesutfonyloxy-2,3,4,5-tetrahydro-lH-benzo[d]azepine (210 mg, 0.5 mmol) with 3-aminomethyl-6-(3,3-dimethyl-2-oxo-butoxy)-pyridine (220 mg, 1 mmol). Purify by chromatography on silica gel eluting with hexane/EtOAc (4:1) to give7-chloroo-6-{[6-(3,3-diraemyl-2-oxo-butoxy)-pyridm-3-ylmethyl]-arnino}-3-(2,2,2- trifluoroacetyl)-2,3,4,5-tetrahydto-lH-benzo[d]azepine(122 mg, 50%). MS (ES+) m/z: 498 (M+H)+. Use a method similar to the General Procedure 2-1, using 7-chloro-6-{[6-(3,3-dimemyl-2-oxo-butoxy)-pyridm-3-ylmethyl]-amino}-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-lH-benzo[d]azepine (122 mg, 0.2 mmol) to give 7-chloro-6-{[6-(3,3-dimethyl-2-xo-butoxy)-pyridin-3-ymiemyl]-ammo}-2,3,4,54etrahydro-lH-benzo[d]azepine(80 mg, 81%) suitable for use without further purification. Use a method similar to the General Procedure 3-2, using 7-chloro-6-{[6-(3,3-dimemyl-2-oxo-butoxy)-pyridm-3-ymiemyl]-amino}-2,3,4,5-tetrahydro-lH-benzo[d]azepine to afford the title compound as a white solid (108 mg, 99%). MS (ES+) m/z: 402 (M+H)+. Example 88 7-Chloro-6-({6-[(2,2-duriemyl-propylcarbamoyl)-memoxy]-pyridin-3-yhnemyl}-amino)-2,3,4,5-tetrahydro-lH-benzod]azepine(L)-Tartrate (Formula Removed) Use a method similar to the General Procedure 1-2 to couple 7-chloro-3-(2,2,2-ttifluoroacetyl)-6-trffluoromemanesulfonyloxy-2,3,4,5-tetrahydro-lH-benzo[rfJazepine (265 mg, 0.6 mmol) with 3-ammomethyl-6-[(2,2-dimethyl-propylcarbarnoyl)-methoxy]-pyridine (314 mg, 1.2 mmol). Purify by chromatography on silica gel eluting with hexane/EtOAc (1:1) to give 7-chloro-6-({6-[(2,2-dimethyl-propylcarbamoyl)-methoxy]-pyridin-3-ylmemyl}-armno)-3-(2,2,2-trifluoroacetyl)-2,3A5-tetrahydro-lH-benzo[djazepiiie (145 mg, 44%). MS (ES+) m/z: 527 (M+H)+. Use a method similar to the General Procedure 2-1, using 7-chloro-6-({6-[(2,2-dimemyl-propylcarbamoyl)-memoxy]-pyridin-3-yhnemyl}-amino)-3-(2,2,2-trucluoroacetyl)-2,3,4,5-tetrahydro-lH-benzo[d]azepine (145 mg, 0.2 mmol) to give 7-crdoro-6-({6-[(2,2-draiemyl-propylcarbamoyl)-memoxy]-pyridm-3-ymiemyl}-ainino)- 2,3,4,5-tetrahydro-lH-benzo[d]azepine (100 mg, 84%) suitable for use without further purification. Use a method similar to the General Procedure 3-2, using 7-chloro-6-({6-[(2,2-diraethyl-propylcarbamoyl)-memoxy]-pyridm-3-ylmemyl}-amino)-2,3,4,5-tetrahydro-lH-benzo[d]azepine (100 mg, 0.2 mmol) to give the title compound as a white solid (125 mg, 92%). MS (ES+) m/i: 431 (M+H)+. Example 89 7-Chloro-6-{4-[5-(cyclopropylmethyl-amino)-isothiazol-3-yl]-benzylamino}-2,3,4,5-tetrahydro-lH-benzo[d]azepine Succinate (Formula Removed) Use a method similar to the General Procedure 1-2 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-tTifluoromethanesulfonyloxy-2,3,415-tetrahydro-lH-benzo[d]azepine (75 mg, 0.18 mmol) with 4-[5-(cyclopropylmethyl-amino)-isothiazol-3-yl]-benzylamine (68 mg, 0.26 mmol) in toluene (3 mL). Purify the crude mixture by chromatography on silica gel (4 g) eluting with hexane/EtOAc with 2% methanol (9:1 to 4:1 gradient) to obtain 7-chloro-6- {4-[5-(cyclopropyhnethyl-amino)-isothiazol-3-yl]-benzylamino }-3-(2,2^-trifluoroacetyl)-2,3,4,5-tetrahydro-lH-benzo[6-trirluoromemanesulfonyloxy-2,3,4,5-tetrahydro-lH-benzo[d]azepine (1.29 g, 3.03 mmol), tris(dibenzylideneacetone)-dipalladium(0) (0.55 g, 0.61 mmol), BIN AP (0.75 g, 0.12 mmol) and cesium carbonate (3.45 g, 10.6 mmol) all at once. Purge the reaction mixture with nitrogen and heat at 100 °C overnight. After cooling to room temperature, filter the reaction mixture over Celite® and wash with DCM (500 mL). Concentrate in vacua, dissolve the residue in DCM and load on to an Analogix® column (150 g). Purify by preparative liquid chromatography (0:1 to 1:9 2M ammonia in methanol/DCM over 33 min, 1:9 to 1:3 2M ammonia in methanol/DCM over 33 min, 1:3 to 1:12M ammonia in methanol/DCM over 33 min; 35 mL/min) to afford 72,3,4,5-tetrahydro-lH-benzo[rfJazcpine as a yellow oil (135 mg, 59%). MS (ES+) m/z: 503 (M+H)+. Use a method similar to General Procedure 2-1, using 7-chloro-6-[4-(l-cyclopropylmethyl4^-pyimol-3-yl)-benzylaniinol-3-(2,2,2-trifluoroacetyl)-2,3,4)5- tetrahydro-lH-benzo[d]azepine (135 mg, 0.27 mmol) to give 7-chloro-6-[4-(l-cyclopropylmetiiy-1Hf-pyrazol-3-yl)-benzylaininol-2,3,4,5-tetrahydro-lH-benzo[d]azepine (97 mg, 89%) as a yellow oil. Use a method similar to the General Procedure 4-2, using 7-chloro-6-[4-(l-cyclopropylmemyl-lH-pyrazol-3-yl)-benzylainhiol-2,3,4,5-tetrahydro-lH-benzo[d]azepine (97 mg, 0.088 mmol) to give the title compound as a white solid (122 mg, 98%). MS (ES+) m/z: 407 (M+H)+. Example 104 Example 104 may be prepared essentially as described in Example 103 using 7-chloro-3-(2,2,2-itrifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-lH-benzo[d]azepine and 4-[3-(cyclopropylmethyl-amino)-pyrazol-1 -yl]-benzylamine. Overall yield and MS (ES+) data are shown in the Table below. (Table Removed) Example 105 7-CMon>6-{4-(6-(cyclopropytaerayl-ammo)-pyrirm tetrahydro-ltf-benzo[d]azepine Succinate (Formula Removed) Use a method similar to the General Procedure 1-3, using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine (260 mg, 0.6 mmol) and 4-[6-(cyclopropylmethyl-amino)-pvrimidin-4-yl]-benzylamine (300 mg, 1.18 mmol), to give 7-chloro-6-{4-[6-(cyclopropylmemyl-ammo)-pyrimidin-4-yl]-benzylammo}-3-(2,2,2-trifluoroacetyl)-23,4,5-tetrahydro-lH-benzo[rf]azepineasan off-white foam (250 mg, 78%). MS (ES+) m/z: 530 (M+H)+. Use a method similar to the General Procedure 2-1 to deprotect 7-chloro-6-{4-[6-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-benzylamino}-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-lH-benzo[d]azepine (250 mg, 0.47 mmol) to give 7-chloro-6-{4-[6-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-benzylamino} -2,3,4,5-tetrahydro-1H benzo[d]azepine (145 mg, 71%) as an off-white foam. MS (ES+) m/z: 434 (M+H)+. Use a method similar to the General Procedure 4-1, using 7-chloro-6-{4-[6-(cyclopropymiethyl-amino)-pyrinudm-4-yl]-benzylarnino}-2,3,4,5-tetrahydro-lH-benzo[d]azepine (175 mg, 0.4 mmol) to give the title compound (175 mg, 98%) as an off-white solid. MS (ES+) m/z: 434 (M+H)*. Examples 106-107 Examples 106-107 may be prepared essentially as described in Example 105 using 7-chloro-3-(2t2,2-trffluoroacetyl)-6-trirfluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H- benzo[d]azepine and the appropriate benzylamine. Overall yields and MS (ES+) data are shown in the Table below. (Table Removed) Example 108 7-Chloro-6-{4-[5-(3,3-dimethylbutyryl)-tiophen-2-yl]-benzylamino}-2,3,4,5-tetrahydro- IH-benzo[d3azepine (L)-Tartrate (Formula Removed) Use a method similar to the General Procedure 1-2 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluorornethanesulfonyloxy-2,3,4,5-tetrahydro-lH-benzo[d]azepine (93.5 mg, 0.2 mmol) with 4-[5-(3,3-dimethylbutyryl)tiophen-2-yl]-benzylamine (129 mg. 0.4 mmol) using tris(dibenzylideneacetone)dipalladium(0) (40.3 mg, 0.04 mmol), BINAP (58.3 mg, 0.08 mmol) and cesium carbonate (100 mg, 0.3 mmol) in toluene/DMF (11:1, 12 mL). Purify by chromatography on silica gel eluting with hexane/EtOAc (4:1) to give 7-chloro-6-{4-[5-(3,3-dimemylbutyrylHiophen-2-yl]-berizylarnino}-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-lflr-benzo[J]azepine as a yellow oil (77 mg, 62%). MS (ES+) m/z563 (M+H)+. Use a method similar to the General Procedure 2-1, using 7-chloro-6-{4-[5-(3,3-draeraylbutyryl)-tiophra-2-yl]-benzylainmo}-3-(2,3,4,5-tetrahydro lH-benzo[d\azepine (77 mg, 0.1 mmol) to give 7-chloro-6-{4-[5-(3,3-dimethylbutyryl)-tiophen-2-yl]-benzylarnino}-2,3,4,5-tettahydro-lH-beuzo[d]azepine (55 mg, 87%) as a yellow oil. Use a method similar to the General Procedure 3-2, using 7-chloro-6-{4-[5-(3,3-dimemylbutyiyl)-tiopheu-2-yl]-benzylanimo}-2,3,4,5-tea-ahydro-lH-berizo[d]azepine (55 mg, 0.1 mmol) to give the title compound as a white solid (70 mg, 96%). MS (ES+) m/z: 467 (M+H)+. Example 109 7-Chloro-6-{[6-(2,2-dimethylpropane-sulfonyl)-pyridin-3-yi-methyl]-amino}-2,3,4,5-tetrahydro-lH-benzo[d]azepine Succinate (Formula Removed) Under a nitrogen atmosphere, add 3-aminoraethyl-6-[(2,2-dimethylpropane)-sulfonyl]-pyridine (300 mg, 1.23 mmol), 7-diloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethansiulfonyloxy-2,3,4,5-tetrahydro-lH-benzo[d]azepine (350 mg, 822 µmol), tris(dibenzyliderieacetone)dipalladium(0) (75 mg, 82 umol), BINAP (77 mg, 123 Mmol), and cesium carbonate (402 mg, 1.23 mmol) to toluene (100 mL). Heat the mixture at 95°C overnight. Cool the mixture to room temperature, and concentrate the mixture in vacua. Purify the crude mixture by chromatography on silica gel .eluting with DCM/ (chloroform:methanol:concentrated NH4OH) (1:0 to 1:1 over 1.5 h, 80 mL/min) to provide 7-chloro-6-{[6-(2,2Hlimemylpropane-sulfonyl)-pyridm-3-yl-memyl]-amino}-3-(2,2,2-trifluoroacetyl)-2f3,4,5-tetrahydro-lH-benzo[rf]azepine (142 mg, 33%) and additional impure product (150 mg, 33%). MS (ES+) m/z: 518 (M+H)+. Dissolve 7-chloro-6-{ [6-(2,2-dunethyIpropane-sulfonyl)-pyridin-3-yl-methyl]-ammo}-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-l/f-benzo[d]azepme (142 mg, 0.27 mmol) in methanol (5 mL). Add lithium hydroxide hydrate (23 mg, 0.54 mmol) and stir for 1 h. Mix with silica gel (1 g), concentrate in vacua, and purify by chromatography on silica gel (12 g) eluting with DCM/(chloroform:methanol:concentrated NFUOH) (1:0 to 9:1 gradient) to give 7-chloro-6-{[6-(2,2-dimethylpropane-suUbnyl)-pyridm-3-yl-methyl]-amino}-2,3,4,5-itetrahydro-l/f-benzo[rflazepine (91 mg, 78%). MS (APCI) m/z: 422 (M+H)+. Dissolve 7-chloro-6-{ [6-(2,2-dimethylpropane-sulfonyl)-pyridin-3-yl-methyl]-amino}-2,3,4,5-tetrahydro-lH-benzo[d]azepine (171 mg, 0.4 mmol) hi methanol and add succinic acid (45 mg, 0.38 mmol). Stir the mixture until homogeneous. Concentrate the mixture in vacua, dissolve in water, and freeze dry the solution to provide the title compound (215 mg, 99%). MS (APCI) m/z: 422 (M+H)+. Example 110 7-Chloro-6-[4-(2,2,2-trifluoroethylthio-methylcarbonyl)-benzylainmo]-2,3,4,5-tetrah lH-benzo[d]azepine (L)-Tartrate (Formula Removed) Use a method similar to the General Procedure 1-2 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro- lH-benzo[d]azepine (173 mg, 0.4 mmol) with 4-[2-(2,2,2-trifluoroethylthio)-l,l-(ethylenedioxy)ethyl3-benzylamine (250 mg, 0.8 mmol) using tris(dibenzylideneacetone)dipalladium(0) (73.2 mg, 0.08 mmol), BINAP (106 mg, 0.16 mmol) and cesium carbonate (182 mg, 0.6 mmol) in toluene (20mL). Purify by chromatography on silica gel eluting with hexane/EtOAc (75:25) to give 7-chloro-3-(2,2,2-trffluoroarctyl)-6-{4-t2-(2t2;2-trifluoroethylthio)-l,l-(ethylenedioxy)ethyl]-beraylamino}-2,,3,4,54etrahydro-lH-benzo[d]azepine (97 mg, 41%). To a solution of 7-chloro-3-(2,2,2-trifluoroacetyl)-6-{4-[2-(2,2,2-trifluoroethylthio)-l,l-(ethylenedioxy)ethyl]-benzylamino}-2,3,4,5-tetrahydro-lH-benzo[d]azepine (97 mg, 0.16 mmol) in anhydrous dichloromethane (0.5 mL), add a solution of 4M hydrogen chloride in dioxane (1.2 mL) and reflux overnight. Dilute with dichloromethane and wash with saturated aqueous NaHCOs. Dry the organics extracts over MgSO4, filter and concentrate in vacua. Purify the crude mixture by chromatography on silica gel eluting with hexane/EtOAc (4:1) to obtain 7-chloro-3-(2,2,2-trifluoroacetyl))-6-[4-(2,2,2-trifluoroettylthio-methylcarboyl)-benzylamino]-2,3,4,5-tetrahyclro-lH-benzo[d]azepine (37 mg, 41%). MS (ES+) m/z: 539 (M+H)+. Use a method similar to the General Procedure 2-1, using 7-chloro-3-(2,2,2-trifluoroaretyl)-6-[4-(2,2,2-trifluoroernylthio-methylcarbonyl)-methylcarbonyl)-benzylamino-2,3,4,5, tetrahydro-1H-benzo|d|azepine (37 mg, 0.07 mmol) to give 7-chloro-6-[4-(2,2,2-truluoroethylthio-methylcarbonyl)-benzylamino]-2,3,4,5-tetrahydrco-lH-benzo[dlazepine (16 mg, 53%). Use a method similar to the General Procedure 3-2, using 7-chloro-6-[4-(2,2,2-trifluoroethyltIiio-methylcarbonyl)-benzylamino]-2,3,4,5,-tetrahydro-1H-benzo[d]azepine (16 mg, 0.04 mmol) to give the title compound as a white solid (21 mg, 98%). MS (ES+) m/z: 443 (M+H)'h. The compounds of the present invention are relatively selective for the 5-HT2C receptor. The compounds of the present invention are particularly relatively selective for the 5-HT2C receptor in comparison to other 5- HT receptor subtypes and specifically the 5-HT2A and 5-HT2B receptors. This selectivity is demonstrated in the following agonist activity assays and receptor binding assays. Agonist Activity Assays (G alpha q-GTPγ35S1 Binding Assays) The 5-HT2 receptors are functionally coupled to specific G-proteins. Agonist activation of 5-HT2 G-protein-coupled receptors results in the release of GDP from the a-subunit (G alpha q or G alpha i) of the G-protein and the subsequent binding of GTP. The binding of the stable analog GTPγ[3SS] is an indicator of receptor activation (i.e. agonist activity). The G alpha q-GTPγ[35S] binding assay is used to determine the hi vitro potency (ECso) and maximal efficacy (lew, normalized to the 5-HT response) of a test compound at the 5-HT2A, S-HTT2B, and S-HT2c receptors. The area under the dose response curve (AUC) is also determined for each receptor subtype and used to measure the test compound's selectivity for the 5-HT2c receptor over the 5-HT2A and 5-HT2B receptors, expressed as Selectivity Ratios (AUC 2C/2A and AUC 2C/2B, respectively). The Selectivity Ratios allow the assessment of selectivity based on both potency and efficacy. A selectivity measure that incorporates both potency and efficacy at the S-HT2c receptor, as compared to the 5-HT2A and 5-HT2B-receptors, is considered important due to the adverse events associated with 5-HT2A and 5-HT2B agonist activity (see introduction). Membrane Preparation: Grow AV12 cells stably transfected with the human 5-HT2A, 5-HT2B or 5-HT2C receptors La suspension, harvest by centrifugation, wash the cell pellet with phosphate buffered saline, pH 7.4, pellet the cells again, remove the supernatant, freeze the cell pellet on dry ice and store at -70°C. Thaw stock cell pellet and resuspend in 50mM Tris, pH 7.4, aliquot into 1-2 mL volumes and refreeze at -70°C for subsequent assays. (As is appreciated in the art, optimal cell quantities used per aliquot will vary with the individual transfected cell line used. In one embodiment, 5-HT=2A and 5-HT2C transfected cells are typically used at about 6 x 108 cells per aliquot, while 5-HT2B cells are typically used at about 7.5 x 108 cells per aliquot). On the day of assay, thaw membranes, wash the membranes with assay buffer (50 mM Tris-HCl (pH 7.4), 10 mM MgCl2,100 mM NaCl, and 0.2 mM EDTA), resuspend in assay buffer and incubate for 10 min. at 37°C to hydrolyze any residual endogenous 5-HT. Wash the membranes again with assay buffer, and resuspend in assay buffer at a concentration to provide aliquots of about l-4x!06 cell equivalents per well (typically about 1-2 x 106 cell equivalents for assays with 5-HT2A or 5-HT2C receptor assays, and about 3-4 x 106 cell equivalents for assays with 5-HT2B receptor assays). Homogenize the cells with a tissue grinder and use the homogenate directly in the assay as described below. G alpha q-GTPγ[355S] Binding Assays: The immunoadsorption scintillation proximity assay (ISPA) of [35S]-GTPγS binding to G alpha q is modified from published conditions (DeLapp et al, JPET 289 (1999) 946-955). Dissolve test compounds in DMSO and dilute hi assay buffer to provide a range of concentrations to generate a concentration response curve. In wells of a 96 well microtiter plate, mix diluted test compound, GDP (0.1µM final concentration), and [3SS]-GTP-γS (between 0.5 and 1.0 nM final concentration). Add an aliquot of membranes to the incubation mixture and mix the plates to initiate agonist stimulation of the nucleotide exchange (200µl final volume). Incubate the microtiter plates for 30 min. at room temperature. Quench the incubation with IGEPAL® CA-630 detergent (0.27% final concentration). Add affinity purified polyclonal rabbit anti-G alpha q antibody (about 1-2 fig per well), and anti-rabbit Ig scintillation proximity assay beads (Amersham; about 1.25 mg per well; 300 nl final volume). Seal the plates and incubate the mixture for 3 h at room temperature. Centrifuge the microtiter plates briefly to pellet beads. Quantitate the GTPγ[35S] binding by microtiter plate scintillation spectrometry (Wallac Trilux MicroBeta™ scintillation counter). Data Analysis: For each concentration response curve for a test compound at a given receptor, analyze the data with GraphPad Prism™ software (v3.02; GraphPad Software, San Diego, CA) running on a personal computer with Microsoft Windows OS®, using nonlinear regression analysis curve fitting to determine the EC50 and Emax (normalized to 5-HT control curves). Determine the Area Under the agonist concentration-response Curve (AUC) with GraphPad Prism™ by the trapezoidal method. To calculate the Selectivity Ratios, first, determine the AUC for the test compound for each receptor subtype as described above. Second, normalize the AUC's at each receptor subtype relative to the AUC determined for 5-HT at that receptor. The normalized AUC for a test compound at a given receptor is therefore expressed as a percentage of the AUC determined for 5-HT at that receptor. For example: 5HT2A Normalized AUC = a = (AUCtnf compound at SHT2A receptor) X 100% (AUCs-HT at SHTaA receptor) 5HT2BNormalized AUC = b=( AUCM fflrpn.mri at 5HTm receptor) X100% (AUCs-HT at 5HT2B receptor) 5HT2c Normalized AUC = c = (AUCtest ampm.nd at 5HT2C receptor) X100% (AUCs-HT at SHTjc receptor) Third, calculate the Selectivity Ratios for the test compound as follows: Selectivity Ratio for 5-HT2C receptor/5-HT2A receptor (AUC 2C/2A) = c/a Selectivity Ratio for 5-HT2c receptor/5-HT2B receptor (AUC 2C/2B) = c/b For reference purposes, the AUC 2C/2A and AUC 2C/2B for 5-HT are each 1.0. Likewise, the ratios for mCPP (meta-chlorophenylpiperazine) are tested and are found to be 2.1 and 2.1 respectively. Representative compounds of the present invention are tested in the G alpha q-GTPy[35S] assays for the 5-HT2A, 5-HT2B, and 5-HT2C receptors essentially as described above and are found to be a highly potent and selective agonists of the 5-HT2C receptor, with ECjo's typically less than or equal to 250 nM, and AUC 2C/2A and AUC 2C/2B ratios greater than 1.5. Preferred compounds are those with EC5O's less than or equal to 100 nM, and AUC 2C/2A and AUC 2C/2B ratios greater than or equal to 2.0. More preferred are those with EC5O's less than or equal to 50 nM, and AUC 2C/2A and AUC 2C/2B ratios greater than or equal to 3.0. Ligand Binding Assays The ligand binding affinity of the compounds of the present invention to the 5-HTac receptor subtype is measured essentially as described by Wainscott (Wainscott, et al., Journal of Pharmacology and Experimental Therapeutics, 276:720-727 (1996)). Data is analyzed! by nonlinear regression analysis on the concentration response curves using the four parameter logistic equation described by DeLean (DeLean, etal.. Molecular Pharmacology. 21, 5-16 (1982)). IC50 values are converted to Kivalues using the Cheng-Prusoff equation (Cheng, etal.. Biochem. Pbarmacol.. 22, 3099-3108 (1973)). Representative compounds of the present invention are tested essentially as described above and are found to have excellent affinity for the 5-HT2C receptor, with Ki' typically less than or equal to about 250 nM. Preferred compounds are those with Kj's of less than or equal to about 100 nM. More preferred are those with Kj's less than or equal to 50nM. Affinities for other receptor subtypes can readily be determined by slight modification of the above described radioligand receptor binding assay using cells transfected with the desired receptor in place of cells transfected with the 5-HT2C receptor subtype and using an appropriate radioligand. The binding affinities for representative compounds of the present invention for a variety of receptors are determined in such assays and the compounds are found to have surprisingly higher affinity for the 5-HT2C receptor. Affinity for the 5-HT2C receptor is found to be significantly higher than for other 5-HT receptor subtypes, and notably higher than the 5-HT2A and 5-HT2b receptor subtypes. Preferred compounds are those with ICso's equal to or greater than 300 nM for the alpha 1 and alpha 2 adrenergic receptors and equal to or greater than 500 nM for DI and D2 dopaminergic receptors. More preferred compounds are those with ICso's equal to or greater than 1000 nM for the alpha 1 and alpha 2 adrenergic receptors and the DI and D2 dopaminergic receptors. Still more preferred are those compounds with IC50's equal to or greater than 3000 nM for the alpha 1 and alpha 2 adrenergic receptors and the DI and DZ dopaminergic receptors. For the above in vitro assays, exemplified compounds are assayed and found to have either an ECS0 or a K1I value of equal to or less than 50 nM, and to have AUC 2C/2A and AUC 2C/2B ratios of greater than or equal to 2.0. Exemplified compounds are assayed and found to typically have alpha 1 and alpha 2 adrenergic receptor ICso's equal to or greater than 300 nM, and D1 and D2 dopaminergic receptor IC50' s equal to or greater than 500 nM. Rat feeding assays The ability of the compounds of the present invention to treat obesity is demonstrated by testing in acute and chronic rat feeding assays. Animals: Obtain male Long-Evans rats (Harlan Sprague-Dawley, Indianapolis, IN) that are approximately one hundred-days old and have been maintained on a calorie rich diet since weaning (TD 95217,40% calories from fat; Teklad, Madison, WI). House the rats individually with a 12 h:12 h light:dark cycle (lights on from about 22:00 h to about 10:00 h) and maintain rats on the same diet (TD 95217) with free access to water, for about 1-2 weeks to acclimate the rats to the environment. Dose rats orally with vehicle (10% acacia with 0.15% saccharin in water) once daily for at least 1 day (typically 1-2 days) to acclimate the rats to the procedures. Randomize the rats into groups so each group has similar mean body weights. Calorimetric Acute Feeding Assay: At approximately 8:00 h on the day of assay, weigh each rat and transfer to individual chambers of an open circuit calorimetry system (Oxymax, Columbus Instruments International Corporation; Columbus, OH), with free access to food (pre-weighed) and water, and begin measuring VO2 and VCO2. At approximately 10:00 h, dose rats orally with vehicle or test compound, return them to their calorimetry chambers, and continue measuring VO2 and VCO2 at regular time intervals (approximately hourly). At approximately 8:00 h the following day, measure rat body weight and the remaining food, assuming the difference in weight of food is equal to the mass of food consumed. Calculate the 24 h energy expenditure (EE) and respiratory quotient (RQ) essentially as described in Chen, Y. and Heiman, M. L., Regulatory Peptide, 92:113-119 (2000). EE during light photoperiod is indicative of the resting metabolic rate and RQ is indicative of the fuel source the animal utilizes (pure carbohydrate metabolism gives an RQ of about 1.0, pure fat metabolism gives an RQ of about 0.7, mixed carbohydrate and fat metabolism gives intermediate values for RQ). Calculate EE as; the product of calorific value (CV) and VO2 per body weight (kg); where CV = 3.815 + 1.232*RQ, and RQ is the ratio of CO2 produced (VCO2) to O2 consumed (VO2). Caloric intake is calculated as (mass of 24 h food intake in grams) x (physiological fuel value of the diet in kilocalorie/g) per kg of body weight. Acute Feeding Assay with a selective 5-HT2C receptor antagonist: The above calorimetric acute feeding assay is conducted with the following modifications. Open circuit calorimetry systems are not used and only the 24 h periodic food intake and body weight are measured. Three groups of rats are used with the first group receiving a subcutaneous dose of saline (0.5 mL) about 15 minutes prior to the oral dose of vehicle, the second group receiving; a subcutaneous dose of saline (0.5 mL) about 15 minutes prior to the oral dose of test compound in vehicle, and the third group receiving a subcutaneous injection of a selective 5-HT2C receptor antagonist, 6-chloro-5-methyl-N-{2-[(2-methylpyridin-3-yl-oxy)pyridm-5-yl]aminocarbonyl}-2,3-dihydroindole (3 mg/Kg, in 35% cyclodextrin, 0.5 mL), about 15 min. prior to the oral dose of test compound in vehicle. Chronic Feeding Assay: At between approximately 8:00 h and 10:00 h on day one of the assay, weigh and orally dose each rat with vehicle or test compound and return the animal to its home cage, with free access to food (pre-weighed) and water. For each of days 2-15, at between approximately 8:00 h and 10:00 h, measure rat body weight and the weight of food consumed in the last 24 h period, and administer daily oral dose of test compound or vehicle. On days -2 and 15 measure total fat mass and lean mass by nuclear magnetic resonance (NMR) using an EchoMRI™ system (Echo Medical Systems, Houston Texas). (See Frank C. Tinsley, Gersh Z. Taicher, and Mark L. Heiman, "Evaluation of a New Quantitative Magnetic Resonance (QMR) Method for Mouse Whole Body Composition Analysis", Obesity Research, submitted May 1,2003.) Representative compounds of the present invention are tested in acute and chronic feeding assays essentially as described above. In the acute assays, the compounds are found to significantly reduce 24 h food intake, which effect is blocked by pre-administration of the 5-HTic receptor antagonist. The compounds also are found to dose-dependently reduce RQ without significantly changing the energy expenditure during the light photo-period. Thus the compounds are found to reduce caloric intake and increase the proportion of fuel deriving from fat utilization, without significantly changing the resting metabolic rate. In the chronic assay, the compounds are found to significantly decrease cumulative food intake and cumulative body weight change in a dose-dependent manner compared to control animals. The decrease in body weight is found to be due to loss of adipose tissue while lean body mass is not changed. The ability of the 5-HT2c receptor agonists of the present invention to treat obsessive/compulsive disorder is demonstrated by testing in a variety of in vivo assays as follows: Marble burving assay Marble burying in mice has been used to model anxiety disorders including obsessive-compulsive disorders (OCD) due to ethological study of the behavior (e.g. Gyertyan I. "Analysis of the marble burying response: Marbles serve to measure digging rather than evoke burying", Befiavioural Pharmacology 6: 24-31, (1995)) and due to the pharmacological effects of clinical standards (c.f., Njung'E K. Handley SL. "Evaluation of marble-burying behavior as a model of anxiety", Piiarmacology, Biochemistry & Behavior. 38:63-67, (1991)); Borsini F., Podhoma L, and Marazziti, D. "Do animal models of anxiety predict anxiolytic effects of antidepressants?", Psychopharmacology 163:121-141, (2002)). Thus, drugs used in die treatment of generalized anxiety in humans (e.g. benzodiazepines) as well as compounds used to treat OCD (e.g. SSRIs like fluoxetine) decrease burying. House experimentally-naive male, Nffl Swiss mice (Harlan Sprague-Dawley, Indianapolis, IN) weighing between 28-35 g in groups of 12 for at least three days prior to testing in a vivarium with 12 h light and dark cycles. Conduct experiments during the light cycle in a dimly lit experimental testing room. Dose mice with vehicle or test compound and, after a specified pretreatment interval (generally 30 min.), place each mouse individually on a rotorod (Ugo Basile 7650) operating at a speed of 6 revolutions/min. and observe for falling. After 2 min. on the rotorod, place the mice individually in a 17 x 28 x 12 cm high plastic tub with 5 mm sawdust shavings on the floor that are covered with 20 blue marbles (1.5 cm diameter) placed in the center. After 30 min., count the number of marbles buried (2/3 covered with sawdust). Assess the test compound's effect on marble burying with Dunnett's test and the effect on rotorod performance by Fisher's exact test. Clinically effective standard compounds suppress marble burying at doses that are devoid of motor-impairing effects as measured on the rotorod. The in vivo efficacy of 5HT2C compounds at the SHTac receptor is confirmed by the prevention of effects of the SHTzc agonists on marble burying by co-administration of the 5HT2C receptor antagonist, 6^chloro-5-methyl-N-{2-[(2-memylpyridm-3-yl-oxy)pyridm-5-yl]aminocarbonyl}-2,3-dihydroindole. Representative compounds of the present invention are assayed in the marble burying assay essentially as described and are surprisingly found to reduce burying behavior in the test mice. The reduction of burying behavior is found to be blocked by co-administration of the 5-HT2c antagonist. In contrast to the compounds of the present invention, the anxiolytic compound chlordiazepoxide and the antipsychotic compound chlorpromazine decrease marble burying only at doses that also disrupt rotorod performance. Nestlet Shredding Mice naturally will construct nests of material available in their living environment, Since this behavior is obsessive in nature, it has been used to model OCD (Xia Li, Denise Morrow and Jeffrey M. Witkin, "Decreases in nestlet shredding of mice by serotonin uptake inhibitors: comparison with marble burying", Psychopharmacology, submitted July 14,2003). House experimentally-naiive male, NJH Swiss mice (Harlan Sprague-Dawley, Indianapolis, IN) weighing between 28-35 g in groups of 12 for at least three days prior to testing in a vivarium with a 12 h light/dark cycle. Conduct experiments during the light cycle in an experimental room with normal overhead fluorescent lighting. Dose mice with vehicle or test compound and after a specified pretreatment interval (generally 30 min.), place the mice individually in a 17 x 28 x 12 cm high plastic tub with about 5 mm sawdust shavings on the floor along with a pre-weighed multi-ply gauze pad (51 mm square). After 30 min., weigh the remainder of the gauze pad not removed by the mouse. Determine the weight of the gauze used for nestlet construction by subtraction. Compare the results for test compound treated mice to the results for vehicle control treated mice with Dunnett's test Clinically effective OCD treatment standard compounds suppress nestlet shredding at doses that are devoid of motor-impairing effects as measured by the rotorod test. The in vivo efficacy of 5HT2c compounds at the 5HTzc receptor is confirmed by the prevention of eiEfects of the 5HT2c agonists on nestlet shredding by co-administration of the 5HT2c receptor antagonist, 6-chloro-5-methyl-N-{2-[(2-methylpyridin-3-yl-oxy)pyridin-5-yl]aminocarbonyl}-2,3-dihydroindole. Representative compounds of the present invention are assayed essentially as described above and are surprisingly found to suppress nestlet shredding at doses that are devoid of motor-impairing effects as measured by the rotorod test. In contrast to the compounds of the present invention, the anxiolytic chlordiazepoxide and the psychomotor stimulant d-amphetamine decreases nestlet shredding only at doses that produce motoric side effects (depression or stimulation, respectively). Schedule-Induced Polvdipsia Food-deprived rats exposed to intermittent presentations of food will drink amounts of water that are far in excess of their normal daily intake and in excess of their intake when given all of their food at one time (Falk JL. "Production of polydipsia in normal rats by an intermittent food schedule", Science 133:195-196, (1961)). This excessive behavior is persistent and has been used to model OCD. Maintain Wistar rats on a food restricted diet (to maintain 85% free feeding weight), but with free access to water. Train the rats in a behavioral testing chamber to press a lever to receive a food pellet under a fixed interval schedule, such that the rats are rewarded with a 45 mg food pellet the first time they press a lever after a 120 second interval has elapsed. The fixed interval is then reset to 120 seconds and the process repeated. Thus, during a 90 min. test session, the rats can earn a maximum of 45 pellets. The behavioral chamber is also equipped with a water bottle that is weighed before and after the session to determine the amount of water consumed. Administer test compounds on Tuesdays and Fridays. Determine control day performances on Thursdays. Administer compounds either orally at 60 min. before the beginning of a test session, or subcutaneously at 20 min. before the beginning of a test session. Compare the rates of lever pressing and water consumption for each animal's performance during sessions after test compound treatment with that animal's performance during control sessions, expressed as a percent of the control rate. Average the individual percent of control rates for each dose and calculate the standard error of the mean. Clinically effective OCD treatment standard compounds (e.g. chlomipramine, fluoxetine) suppress schedule-induced polydipsia without producing notable changes in motor patterns, food intake, or behavior the following day. The in vivo efficacy of 5HT2c compounds at the SHTzc receptor is confirmed by the prevention of effects of the SHTac agonists on excessive drinking by co-administration of the 5HT2C receptor antagonist, 6-chloro-5-methyl-N-{2-[(2-methylpyridin-3-yl-oxy)pyridin-5-yl]aminocarbonyl}-2,3-dihydroindole. Representative compounds of the present invention are assayed in the schedule-induced polydipsia assay essentially as described above and are surprisingly found to suppress schedule-induced polydipsia without producing notable changes in motor patterns, food intake, or behavior the following day. The behavior suppression is blocked by co-administration of the 5-HTjc antagonist. In contrast to the compounds of the present invention, the psychomotor stimulant d-amphetamine decreases excessive drinking only at behaviorally stimulating doses and these effects are not prevented by the SHTjc receptor antagonist. While it is possible to administer compounds employed in the methods of this invention directly without any formulation, the compounds are usually administered in the form of pharmaceutical compositions comprising a phannaceutically acceptable excipient and at least one compound of Formula I or a phannaceutically acceptable salt thereof. These compositions can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular, and intranasal. The compounds employed in the methods of this invention are effective as both injectable and oral compositions. Such compositions are prepared in a manner well known in the pharmaceutical art. See, e.g. REMINGTON'S PHARMACEUTICAL SCIENCES, (16th ed. 1980). In making the compositions employed in the present invention the active ingredient is usually mixed with at least one excipient, diluted by at least one excipient, or enclosed within such a carrier which can be in the form of a capsule, sachet, paper or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing for example up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders. In preparing a formulation, it may be necessary to mill the compound to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it ordinarily is milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size is normally adjusted by milling to provide a substantially uniform distribution in the formulation, e.g. about 40 mesh. Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, macrocrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxybenzoates; sweetening agents; and flavoring agents. The compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art. The compositions are preferably formulated in a unit dosage form, each dosage containing from about 0.05 to about 100 mg, more usually about 1.0 to about 30 mg, of the active ingredient The term "unit dosage form" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desked therapeutic effect, in association with a suitable pharmaceutical excipient. The compounds are generally effective over a wide dosage range. For examples, dosages per day normally fall within the range of about 0.01 to about 30 mg/kg. In the treatment of adult humans, the range of about 0.1 to about 15 mg/kg/day, in single or divided dose, is especially preferred. However, it will be understood that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound or compounds administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms, and therefore the above dosage ranges are not intended to limit the scope of the invention in any way. In some instances dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed. Another preferred formulation employed in the methods of the present invention employs transdermal delivery devices ("patches"). Such transdennal patches may be used to provide continuous or discontinuous infusion of the compounds of the present invention in controlled amounts. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art See, e.g.. U.S. Patent 5,023,252, issued June 11,1991, herein incorporated by reference. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents. Under some circumstances, it will be desirable or necessary to introduce the pharmaceutical composition to the brain, either directly or indirectly. Direct techniques usually involve placement of a drug delivery catheter into the host's ventricular system to bypass the blood-brain barrier. One such implantable delivery system, used for the transport of biological factors to specific anatomical regions of the body, is described in U.S. Patent 5,011,472, issued April 30,1991, which is herein incorporated by reference. Indirect techniques, which are generally preferred, usually involve formulating the compositions to provide for drug latentiation by the conversion of hydrophilic drugs into lipid-soluble drugs or prodrugs. Latentiation is generally achieved through blocking of the hydroxy, carbonyl, sulfate, and primary amine groups present on the drug to render the drug more lipid soluble and amenable to transportation across the blood-brain barrier. Alternatively, the delivery of hydropbilic drugs may be enhanced by intra-arteria] infusion of hypertonic solutions which can transiently open the blood-brain barrier. The type of formulation employed for the administration of the compounds employed in the methods of the present invention may be dictated by the particular compound employed, the type of pharmacokinetic profile desired from the route of administration, and the state of die patient. WE CLAIM: 1. A compound of Formula I: (Formula Removed) where: R1 is hydrogen, R2, R3, and R4 are each hydrogen; R5 is hydrogen; R6 is-NR10R11; R7 is halo; R8 is hydrogen; R is hydrogen; R10 is Ph2-methyl or Ar1- methyl; R1 is hydrogen; Ph1 is phenyl optionally substituted with 1 to 5 independently selected halo substituents, or with 1 to 3 substituents independently selected from the group consisting of halo, cyano, -SCF3, (C1-C6)alkyl optionally further substituted with 1 to 6 fluoro substituents, and (C1-C6)alkoxy optionally further substituted with 1 to 6 fluoro substituents; Ph2 is phenyl substituted with R12 and optionally further substituted with 1 or 2 substituents independently selected from the group consisting of halo, cyano, -SCF3, methyl, -CF3, methoxy, -OCF3, nitro, and hydroxy; Ar1 is 5-R13-pyridin-2-yl or 6-R13-pyridin-3-yl optionally further substituted with one or two substituents independently selected from the group consisting of halo, cyano, methyl, -CF3, hydroxy, and methoxy; R12 is a substituent selected from the group consisting of: a) Het1-(Co-C5)alkyl optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; b) Het2-(Co-C3)alkyl optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; c) Het3-(Co-C3)alkyl optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; d) Ar2-(Co-C3)alkyl optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; e) (C1-C6)alkyl-C(R14)=C(R14)- optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; f) (R14)2C=C[(Ci-C6)alkyl]- optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; g) (C3-C7)cycloalkyl-(Co-C3)alkyl-C(R14)-C(R15)- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; h) (R15)CH=C[(C3-C7)cycIoalkyl-(Co-C3)alkyl]- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; i) (C1-C6)alkyl-C≡C- optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; j) (C3-C7)cycloalkyl-(Co-C3)alkyl-C=C- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; k) (C3-C7)cycloalkyl-(Co-C3)alkyl-C(O)-(C1-C5)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; 1) Ph1-(Co-C3)alkyl-C(O)-(C1-C5)alkyl optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; m) pyridyl-(Co-C3)alkyl-C(O)-(C1-C5)alkyl, optionally substituted on the pyridyl moiety with 1 to 3 substituents independently selected from the group consisting of halo, (C1-C3)alkyl, (C1-C3)alkoxy, -CF3, -O-CF3, nitro, cyano, and trifluoromethylthio, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; n) (C1-C6)alkyl-O-(C1-C3)alkyl-C(O)- optionally substituted on the (C1-C6)alkyl moiety with 1 to 6 fluoro substituents and independently optionally substituted on the (C1-C3)alkyl moiety with 1 to 4 fluoro substituents; o) (C3-C7)cycloalkyl-(C0-C3)alkyl-O-(C1-C3)alkyl-C(O)- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; p) Ph1-(Co-C3)alkyl-O-(C1-C3)alkyl-C(O)- optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; q) (C1-C6)alkyl-S-(C1-C3)alkyl-C(O)- optionally substituted on the (C1-C6)alkyl moiety with 1 to 6 fluoro substituents and independently optionally substituted on the (C1-C3)alkyl moiety with 1 to 4 fluoro substituents; r) (C3-C7)cycloalkyl-(Co-C3)alkyl-S-(C1-C3)alkyl-C(O)- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; s) Ph1-(C0-C3)alkyl-S-(C1-C3)alkyl-C(O)- optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; t) (C1-C6)alkyl-NR16-(C1-C3)alkyl-C(O)- optionally substituted on the (C1-C6)alkyl moiety with 1 to 6 fluoro substituents and independently optionally substituted on the (C1- C3)alkyl moiety with 1 to 4 fluoro substituents; u) (C3-C7)cycloalkyl-(Co-C3)alkyl-NR16-(C1-C3)alkyl-C(O)- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; v) Ph1-(Co-C3)alkyl-NR16-(C1-C3)alkyl-C(O)- optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; w) (C1-C6)alkyl-O-(C1-C3)alkyl-SO2- optionally substituted on the (C1-C6) alkyl moiety with 1 to 6 fluoro substituents and independently optionally substituted on the (C1-C3)alkyl moiety with 1 to 4 fluoro substituents; x) (C3-C7)cycloalkyl-(C0-C3)alkyl-O-(C1-C3)alkyl-SO2- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; y) Ph1-(C0-C3)alkyl-O-(C1-C3)alkyl-SO2- optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; z) (C1-C6)alkyl-S-(C1-C3)alkyl-SO2- optionally substituted on the (C1-C6)alkyl moiety with 1 to 6 fluoro substituents and independently optionally substituted on the (C1-C3)alkyl moiety with 1 to 4 fluoro substituents; k) (C3-C7)cycloalkyl-(Co-C3)alkyl-S-(C1-C3)alkyl-SO2- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; l) Ph'(Co-C3)alkyl-S-(C1-C3)alkyl-SO2- optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; ac) (C1-C6)alkyl-NR16-(C1-C3)alkyl-SO2- optionally substituted on the (C1-C6)alkyl moiety with 1 to 6 fluoro substituents and independently optionally substituted on the (C1-C3)alkyl moiety with 1 to 4 fluoro substituents; n) (C3-C7)cycloalkyl-(Co-C3)alkyl-NR16-(C1-C3)alkyl-SO2- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; o) Ph1-(Co-C3)alkyl-NR16-(C1-C3)alkyl-SO2- optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; p) R17R18-N-C(O)-(C1-C5)alkyl optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; q) RI7Rl8-N-C(S)-(C1-C5)alkyl optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; ah) (C3-C7)cycloalkyl-(Co-C3)alkyl-S- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; ai) (C3-C7)cycloalkyl-(Co-C3)alkyl-S-(C1-C5)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; aj) Ph'-(Co-C3)alkyl-S-(C1-C5)alkyl optionally substituted on the (C1-C5)alkyl moiety with 1 to 6 fluoro substituents and independently optionally substituted on the -(Co-C3)alkyl moiety with 1 to 4 fluoro substituents; ak) Ar3-(Co-C3)alkyl-S-(C1-C5)alkyl optionally substituted on the (C1 -C5) alkyl moiety with 1 to 6 fluoro substituents and independently optionally substituted on the -(Co-C3)alkyl moiety with 1 to 4 fluoro substituents; al) Ar3-(Co-C3)alkyl-O-(C1-C5)alkyl optionally substituted on the (C1-C5)alkyl moiety with 1 to 6 fluoro substituents and independently optionally substituted on the -(Co- C3)alkyl moiety with 1 to 4 fluoro substituents; am) Het1-(Co-C3)alkyl-S-(Co-Cs)alkyl wherein Het1 is linked through any carbon atom of Het and wherein the (Co-C5)alkyl moiety is optionally substituted with 1 to 6 fluoro substituents and independently optionally substituted on the -(Co-C3)alkyl moiety with 1 to 4 fluoro substituents; an) Het1-(Co-C3)alkyl-O-(Co-C5)alkyl wherein Het1 is linked through any carbon . atom of Het1 and wherein the (Co-C5)alkyl moiety is optionally substituted with 1 to 6 fluoro substituents and independently optionally substituted on the -(C0-C3)alkyl moiety with 1 to 4 fluoro substituents; ao) Het2-(C0-C3)alkyl-S-(Co-C5)alkyl optionally substituted on the (C0-C5)alkyl moiety with 1 to 6 fluoro substituents and independently optionally substituted on the -(Co-C3)alkyl moiety with 1 to 4 fluoro substituents; ap) R16R19-N-C(O)-S-(Co-C5)alkyl optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; aq) R16Rl9-N-C(O)-O-(C0-C5)alkyl optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; ar) R16R19-N-C(O)-NRl6-(C0-C5)alkyl optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; as) (C1-C6)alkyl-C(O)-(C1-C3)alkyl-S- optionally substituted on the (C1-C6)alkyl moiety with 1 to 6 fluoro substituents and independently optionally substituted on the (C1-C3)alkyl moiety with 1 to 4 fluoro substituents; at) (C1-C6)alkyl-SO2-(C1-C3)alkyl-S- optionally substituted on the (C1-C6)alkyl moiety with 1 to 6 fluoro substituents and independently optionally substituted on the (C1-C3)alkyl moiety with 1 to 4 fluoro substituents; au) (C3-C7)cycloalkyl-(C0-C3)alkyl-C(O)-(C1-C3)alkyl-O- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; av) (C3-C7)cycloalkyl-(C0-C3)alkyl-SO2-(C1-C3)alkyl-O- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; aw) (C3-C7)cycloalkyl-(Co-C3)alkyl-C(O)-(C1-C3)alkyl-S- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; ax) (C3-C7)cycloalkyl-(Co-C3)alkyl-SO2-(C1-C3)alkyl-S- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; ay) Ph1-(Co-C3)alkyl-SO2-(C1-C3)alkyl-O- optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; az) Ph1-(Co-C3)alkyl-C(O)-(C1-C3)alkyl-S- optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; u) Ph'-(Co-C3)alkyl-SO2-(C1-C3)alkyl-S- optionally substituted on either or both alkyl moieties independently with 1 to 4 fluoro substituents; v) Rl7Rl8N-C(O)-(C1-C3)alkyl-S- optionally substituted on the alkyl moiety with l to 4 fluoro substituents; be) R17RlsN-C(S)-(C1-C3)alkyl-S- optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; x) R17R18N-C(S)-(C 1-C3)alkyl-O- optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; y) (C3-C7)cycloalkyl-(Co-C3)alkyl-SO2-(C1-C5)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents and further optionally substituted on the (C1-C5)alkyl moiety with 1 to 6 fluoro substituents; bf) Ph1-(Co-C3)alkyl-SO2-(C1-C5)alkyl optionally substituted on the (C0-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (CrC5)alkyl moiety with 1 to 6 fluoro substituents; bg) Ar3-(Co-C3)alkyl-SO2-(C1-C5)alkyl optionally substituted on the (C0-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (C1- C5) alkyl moiety with 1 to 6 fluoro substituents; bh) Het2-(Co-C3)alkyl-SO2-(C0-C5)alkyl optionally substituted on the (C0-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (C1- C5)alkyl moiety with 1 to 6 fluoro substituents; bi) R17R18N-(C1-C3)alkyl optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; bj) (C1-C6)alkyl-C(O)-N(R16)-(C0-C5)alkyl optionally substituted on either or both alkyl moieties independently with 1 to 6 fluoro substituents; bk) (C3-C7)cycIoaIkyl-C(O)-N(R16)-(Co-C5)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; bl) Ph1-(Co-C3)alkyl-C(O)-N(R16)-(Co-C5)alkyl optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Co-C5)alkyl moiety with 1 to 6 fluoro substituents; bm) Ar3-(Co-C3)alkyl-C(O)-N(R16)-(C0-C5)alkyl optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Co-Cs)alkyl moiety with 1 to 6 fluoro substituents; bn) (C1-C6)alkyl-C(S)-N(R16)-(Co-C5)alkyl optionally substituted on either or both alkyl moieties independently with 1 to 6 fluoro substituents; bo) (C3-C7)cycloalkyl-C(S)-N(R16)-(Co-C5)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; bp) Ph1-(Co-C3)alkyl-C(S)-N(R16)-(C0-C5)alkyl optionally substituted on the (Co- C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Co-C5)alkyl moiety with 1 to 6 fluoro substituents; bq) Ar3-(Co-C3)alkyl-C(S)-N(R16)-(C0-C5)alkyl optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Co-Cs)alkyl moiety with 1 to 6 fluoro substituents; br) (Ci-C6)alkyl-O-N=C(CH3)- optionally substituted on the (Ci-C6)alkyl moiety with 1 to 6 fluoro substituents; bs) (C0-C3)alkyl-O-N=C[(C1-C6)alkyl]- optionally substituted on the (C0-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (C1-C6)alkyl moiety with 1 to 6 fluoro substituents; bt) HO-N=C[(C0-C1)alkyl-(C3-C7)cycloalkyl]- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 2 fluoro substituents; bu) CH3-O-N=C[(C0-C1)alkyl-(C3-C7)cycloalkyl]- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both alkyl moieties independently with 1 to 2 fluoro substituents; R13 is a substituent selected from the group consisting of: a) Het -(Co-C3)alkyl optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; b) Het3-(Co-C3)alkyl optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; c) Ar -(Co-C3)alkyl optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; d) (C1-C6)alkyl-C(Rl4)=C(R14)- optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; e) (R14)2C=C[(C1-C6)alkyl]- optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; f) (C3-C7)cycloalkyl-(C0-C3)alkyl-C(R14)=C(R15)- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; g) (R15)CH=C[(C3-C7)cycloalkyl-(Co-C3)alkyl]- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; h) (C1-C6)alkyl-C=C- optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents; i) (C3-C7)cycloalkyl-(Co-COalkyl-C≡C- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the alkyl moiety with 1 to 2 fluoro substituents; j) (C1-C6)HIlCyI-O-(C i-CsAlkyl optionally optionally substituted on either or both alkyl moieties independently with 1 to 6 fluoro substituents; k) (C3-C7)cycloalkyl-(Co-C3)aIkyl-O-(Co-C5)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents and further optionally substituted on the (Co-C5)alkyl moiety with 1 to 6 fluoro substituents; 1) Ph1-(Co-C3)alkyl-O-(C0-C5)alkyl optionally substituted on the (C0-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Co- C5)alkyl moiety with 1 to 6 fluoro substituents; m) Ar3-(Co-C3)alkyl-O-(Co-C5)alkyl optionally substituted on the (C0-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Co-C5)alkyl moiety with 1 to 6 fluoro substituents; n) Het2-(Co-C3)alkyl-O-(C0-C5)alkyl optionally substituted on the (C0-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Co-C5)alkyl moiety with 1 to 6 fluoro substituents; o) (C3-C7)cycloalk;yl-(C0-C3)alkyl-C(O)-(C1-C5)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents and further optionally substituted on the (C1-C5)alkyl moiety with 1 to 6 fluoro substituents; p) Phl-(C0-C3)alkyl-C(O)-(C1-C5)alkyl optionally substituted on the (C0-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (C1-C5)alkyl moiety with 1 to 6 fluoro substituents; q) pyridyl-(Co-C3)alkyl-C(O)-(C1-C5)alkyl optionally be substituted on the pyridyl moiety with 1 to 3 substituents independently selected from the group consisting of halo, (C1-C3)alkyl, (C1-C3)alkoxy, -CF3, -O-CF3, nitro, cyano, and trifluoromethylthio, and independently optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents, and independently optionally substituted on the (C1-C5)alkyl moiety with 1 to 6 fluoro substituents; r) (C1-C6)alkyl-C(O)-(C1-C3)alkyl-O- optionally substituted on the (C1-C6)alkyl moiety with 1 to 6 fluoro substituents and independently optionally substituted on the (C1-C3)alkyl moiety with 1 to 4 fluoro substituents; s) (C3-C7)cycloalkyl-(C0-C3)alkyl-C(O)-(C1-C3)alkyl-O- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both of the alkyl moieties independently with 1 to 4 fluoro substituents; t) Ph1-(C0-C3)alkyl-C(O)-(C1-C3)alkyl-O- optionally substituted on either or both of the alkyl moieties independently with 1 to 4 fluoro substituents; u) pyridyl-(Co-C3)alkyl-C(O)-(C1-C3)alkyl-O- optionally be substituted on the pyridyl moiety with 1 to 3 substituents independently selected from the group consisting of halo, (C1-C3)alkyl, (CrC3)alkoxy, -CF3, -O-CF3, nitro, cyano, and trifluoromethylthio, and independently optionally substituted on either or both of the alkyl moieties independently with 1 to 4 fluoro substituents; v) R17R18N-C(O)-(C1-C3)alkyl-O- optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; w) R17R18N-C(S)-(C1-C3)alkyl-O- optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; x) (C3-C7)cycloalkyl-(Co-C3)alkyl-S- substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both of the alkyl moieties independently with 1 to 4 fluoro substituents; y) (C1-C6)ahcyl-S-(C1-C5)alkyl optionally substituted on either or both alkyl moieties independently with 1 to 6 fluoro substituents; z) (C3-C7)cycloalkyl-(C0-C3)alkyl-S-(C1-C5)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents, and independently optionally substituted on the (C1-C5)aDcyl moiety with 1 to 6 fluoro substituents; k) Ph1-(Co-C3)alkyl-S-(C1-C5)alkyl optionally substituted on the (C0-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (C1-C5)alkyl moiety with 1 to 6 fluoro substituents; l) Ar3-(Co-C3)alkyl-S-(C1-C5)alkyl optionally substituted on the (C0-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (C1-C5)alkyl moiety with 1 to 6 fluoro substituents; m) (C1-C6)alkyl-C(O)-(C1-C3)alkyl-S- optionally substituted on the (C1-C6)alkyl moiety with 1 to 6 fluoro substituents and independently optionally substituted on the (C1-C3)alkyl moiety with 1 to 4 fluoro substituents; n) (C3-C7)cycloalkyl-(Co-C3)alkyl-C(O)-(C1-C3)alkyl-S- optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on either or both of the alkyl moieties independently with 1 to 4 fluoro substituents; ae) Ph1-(C0-C3)alkyl-C(O)-(C1-C3)alkyl-S- optionally substituted on either or both of the alkyl moieties independently with 1 to 4 fluoro substituents; p) pyridyl-(C0-C3)alkyl-C(O)-(C1-C3)alkyl-S- optionally be substituted on the pyridyl moiety with 1 to 3 substituents independently selected from the group consisting of halo, (C1-C3)alkyl, (C1 -C3) alkoxy, -CF3, -0-CF3, nitro, cyano, and trifiuorometliylthio, and independently optionally substituted on either or both of the alkyl moieties independently with 1 to 4 fluoro substituents; q) R17R18N-C(O)-(C1-C3)alkyl-S- optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; ah) R17Rl8N-C(S)-(C1-C3)alkyl-S- optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; ai) (C1-Co)alkyl-SO2-(C0-C5)alkyl optionally substituted on either or both of the alkyl moieties independently with 1 to 6 fluoro substituents; aj) (C3-C7)cycloalkyl-(C0-C3)alkyl-SO2-(C0-C5)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents, and independently optionally substituted on the (Co-Cs)alkyl moiety with 1 to 6 fluoro substituents; ak) Ph1-(Co-C3)alkyl-SO2-(C0-C5)alkyl optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Co-C5)alkyl moiety with 1 to 6 fluoro substituents; al) Ar3-(Co-C3)alkyl-SO2-(C0-C5)alkyl optionally substituted on the (Co-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Co-C5)alkyl moiety with 1 to 6 fluoro substituents; am) Het2-(Co-C3)alkyl-SO2-(C0-C5)alkyl optionally substituted on the (C0-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Co-C5)alkyl moiety with 1 to 6 fluoro substituents; an) R17R18-N-C(O)-(C1-C5)alkyl optionally substituted on the (C1-C5)alkyl moiety with 1 to 6 fluoro substituents; ao) R17R18-N-C(S)-(C1-C5)alkyl optionally substituted on the (C1-C5)alkyl moiety with 1 to 6 fluoro substituents; ap) R17R18N-(C1-C3)alkyl optionally substituted on the (C1-C3)alkyl moiety with 1 to 4 fluoro substituents; aq) (C1-C6)alkyl-C(O)-N(R16)-(C0-C5)alkyl optionally substituted on either or both of the alkyl moieties independently with 1 to 6 fluoro substituents; ar) (C3-C7)cycloalkyl-C(O)-N(R16)-(C0-C5)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the (C0-C5)alkyl moiety with 1 to 6 fluoro substituents; as) Ph,-(C0-C3)alkyl-C(O)-N(Rl6)-(C0-C5)alkyl optionally substituted on the (C0-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Co-C5)alkyl moiety with 1 to 6 fluoro substituents; at) Ar3-(C0-C3)alkyl-C(O)-N(R16)-(C0-C5)alkyl optionally substituted on the (C0-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Co-C5)alkyl moiety with 1 to 6 fluoro substituents; au) (C1-C6)alkyl-C(S)-N(R16)-(C0-C5)alkyl optionally substituted on either or both of the alkyl moieties independently with 1 to 6 fluoro substituents; av) (C3-C7)cycloalkyl-C(S)-N(R16)-(C0-C5)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents selected from the group consisting of methyl and fluoro, and independently optionally substituted on the (C0-C5)alkyl moiety with 1 to 6 fluoro substituents; aw) Ph1-(C0-C3)alkyl-C(S)-N(R16)-(C0-C5)alkyl optionally substituted on the (C0-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (C0-C5)alkyl moiety with 1 to 6 fluoro substituents; ax) Ar3-(C0-C3)alkyl-C(S)-N(R16)-(C0-C5)alkyl optionally substituted on the (C0-C3)alkyl moiety with 1 to 4 fluoro substituents and independently optionally substituted on the (Co-Cs)alkyl moiety with 1 to 6 fluoro substituents; R14 is hydro gen or (C1- C2)alkyl optionally substituted with 1 to 5 fluoro substituents; R15 is hydrogen or methyl optionally substituted with 1 to 3 fluoro substituents; R16 is hydrogen or (C1-C3)a!kyl optionally substituted with 1 to 5 fluoro substituents; R17 is (C1-C6)alkyl optionally substituted with 1 to 6 fluoro substituents, Ph1(C1- C3)alkyl optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents, or (C3-C7)cycloalkyl-(C0-C3)alkyl optionally substituted on the cycloalkyl moiety with 1 to 4 substituents independently selected from methyl and fluoro and independently optionally substituted on the alkyl moiety with 1 to 4 fluoro substituents; R18 is hydrogen or (C1-C3)alkyl, or R17 and R18 taken together with the nitrogen atom to which they are attached, form Het1, imidazolidin-2-onyl, imidazolidin-2,4-dionyl, or tetrahydropyrimidin-2-onyl optionally substituted with 1 or 2 methyl substituents; R19 is (C1-C3)alkyl optionally substituted with 1 to 5 fluoro substituents; Ar is an aromatic heterocycle substituent selected from the group consisting of pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, 1,2,3-oxadiazolyl, 1,2,4- oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, thiophenyl, thiazolyl, isothiazolyl, and 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,2,3- triazolyl, 1,2,4-triazolyl, wherein the heterocycle is substituted with R15R17N-, wherein R15 is hydrogen and R17 is (C1- C6) alkyl or (C3-C7) cycloalkyl or (C0- C3 ) alkyl R17NH-C(O)-, R17C(O)NH-, R17O-C(O)NH-, (d-C6)alkyl-C(O)-, (C3- C7)cycloalkyl-(C0-C3)alkyl-C(O)-, (C3-C7)cycloalkyl-(C0-C3)alkyl, N-linked Het1, and N-linked Het1-C(O)-, and which is optionally further substituted with a substituent selected from the group consisting of methyl, cyano, halo, and trifluoromethyl; Ar3 is an aromatic heterocycle substituent selected from the group consisting of pyrrolyl, furanyl, thiophenyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, and pyridyl, any of which may optionally be substituted with 1 to 3 substituents independently selected from the group consisting of halo, (C1-C3)alkyl, (C1- C3)alkoxy, -CF3, -O-CF3, nitro, cyano, and trifluoromethylthio; Het is a saturated, nitrogen-containing heterocycle substituent selected from the group consisting of pyrrolidinyl, piperidinyl, homopipei'idinyl, morpholinyl, thiomorpholinyl, homomorpholinyl, and homothiomorpholinyl, any of which may optionally be substituted with (C1-C6) alkyl or with 2 methyl substituents; Het2 is a saturated, oxygen-containing heterocycle substituent selected from the group consisting of tetrahydrofuranyl and tetrahydropyranyl, any of which may optionally be substituted with (C1-C6)alkyl or with 2 methyl substituents; Het3 is a nitrogen containing heterocycle selected from the group consisting of pyrrolidin- 2-onyl, piperidin-2-onyl, oxazolidin-2-onyl, pyrrolin-2-onyl, and dihydropyridin-2- onyl; or a pharmaceutically acceptable salt or solvate thereof. 2. The compound as claimed in claim 1, which is selected from: 7-Chloro-6-[4-(l-methoxyimino-ethyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(l-ethoxyimino-ethyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(l-iso-butoxyimino-ethyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo [d]azepine; 7-Chloro-6-[4-(l-hydroxyimino-3-methyl-butyl)-benzyIamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(l-methoxyimino-3-methyl-butyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(2-methylamino-thiazol-4-yl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(2-ethylamino-thiazol-4-yl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo [d] azepine; 7-Chloro-6-[4-(2-iso-propylamino-thiazol-4-yl)-benzylamino]-2,3.4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(2-n-propylamino-thiazol-4-yl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(2-piperidin-l-yl-thiazol-4-yl)-benzylamino]-2,3,4,5-tetrahydro- 1H-benzo[d]azepine; 7-Chloro-6-[4-(2-cyclopropylmethylamino-thiazol-4-yl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d] azepine; 7-Chloro-6-[4-(2-iso-butylamino-thiazol-4-yl)-benzylamino]-2,3,4,5-tetrahydro- 1H-benzo[d]azepine; 7-Chloro-6-[4-(2-methylamino-oxazol-4-yl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(cyclopentylthiomethyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(cyclohexylthiomethyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[(5-cyclopentylthiomethyl-pyridin-2-ylmethyl)-amino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[(5-cyclohexylthio-methyl-pyridin-2-ylmethyl)-amino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[(5-iso-propylthio-methyl-pyridin-2-ylmethyl)-amino]-2,3,4,5-tetrahydro- 1H-benzo[d]azepine; 7-Chloro-6-[(5-iso-butylthio-methyl-pyridin-2-ylmethyl)-amino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{6-[(2,2-dimethyl-propylthiotnethyl)-pyridin-3-ylmethyl]-amino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(3,3-dimethyl-cyclohexylthiomethyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[ d]azepine; 7-Chloro-6-[4-(3,3-dimethyl-cyclohexylthio)-benzylamino]-2,3,4,5-tetrahydro-1H- benzo[d] azepine; 7-ChIoro-6-{6-[(3,3-dimethyl-cyclohexyIthio)-pyridin-3-ylmethyl]-amino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 6-[(6-tert-Butylthiomethyl-pyridin-3-ylmethyl)-amino]-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{6-[(3,3-dimethyl-cyclohexyloxy)-pyridin-3-ylmethyl]-amino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[(6-cyclopentylthiomethyl-pyridin-3-ylmethyl)-amino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[(6-cyclohexylthiomethyl-pyridin-3-ylmethyl)-amino]-2,3,4,5-tetrahydro-1H-bcnzo[d]azepine; 7-Chloro-6-[(6-cyclohexyloxy-pyridin-3-ylmethyl)-amino]-2,3,4,5-tetrahydro- 1H-benzo[d]azepine; 7-Chloro-6-{6-[(4,4-dimethyl-cyclohexyloxy)-pyridin-3-ylmethyl]-amino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[6-(2-methyl-2-propane-sulfonylmethyl)-pyridin-3-ylmethyl]-amino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[(6-iso-propoxymethyl-pyridin-3-ylmethyl)-amino]-2,3,4,5-tetrahydro- 1H-benzo[d]azepine; 7-Chloro-6-[(2,2-dimethylpropoxymethyl-pyridin-3-ylmethyl)-amino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[(cyclopentyloxymethyl-pyridin-3-ylmethyl)-amino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[(cyclohexyloxymethyl-pyridin-3-ylmethyl)-amino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[(5-cyclohexyloxy-pyridin-2-ylmethyl)-amino]-2,3,4,5-tetrahydro-1H-benzo [d] azepine; 7-Chloro-6-[(5-cycloheptyloxy-pyridin-2-ylmethyl)-amino]-2,3,4,5-tetrahydro-1H-benzo[d] azepine; 7-Chloro-6-{5-[(3,3-dimethylcyclohexyloxy)-pyridin-2-ylmethyl]-amino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; (E)-7-Chloro-6-{6-[(2-cyclohexyl-vinyl)-pyridin-3-ylmethyl]-amino}-2,3,4,5-tetrahydro-1H-benzo[of]azepine; (E)-7-ChIoro-6-{5-[(2-cyclohexyl-vinyl)-pyridin-2-ylmethyl]-amino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; (Z)-7-Chloro-6-{6-[(2-cyclohexyl-vinyl)-pyridin-3-ylmethyl]-amino}-2,3,4,5-tetrahydro- 1H-benzo[d]azepine; (Z)-7-Chloro-6-{5-[(2-cyclohexyl-vinyl)-pyridin-2-ylmethyl]-amino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; (Z)-7-Chloro-6-[4-(2-cyclohexyl-vinyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(2-cyclohexyl-2-oxo-ethyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo [d] azepine; 7-Chloro-6-[4-(morpholin-4-ylmethyl)-benzylamino]-2,3,4,5-tetrahydro-lH-benzo[d]azepine; (R)-7-Chloro-6-{4-[(l-methyl-2,2,2-trifluoro-ethylamino)-methyl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[(2,2,2-trifluoroethylamino)-methyl]-benzylamino}-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(piperidin-l-ylmethyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(pyrrolidin-l-ylmethyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(azepan-l-ylmethyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[(l-methyl-2,2,2-trifluoro-ethylamino)-methyl]-benzylamino}-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[N-(cyclohexyl)-aminomethyl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 6-{4-[N-(iso-Butyl)-aminomethyl]-benzylamino}-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[N-(iso-propyl)-aminomethyl]-benzylatnino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[(N-methyl-iso-propylamino)-methyl]-benzylamino}-2,3,4,5-tetrahydro- 1H-benzo[d]azepine; 7-Chloro-6-{5-[(N-cyclohexyl-aminomethyl)-pyridin-2-yl-methyl]-amino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{6-[(piperidin-l-ylmethyl)-pyridin-3-yl-methyl]-amino}-2,3,4,5-tetrahydro- 1H-benzo[d] azepine; 7-Chloro-6-[4-(2,2-dimethyl-propionylamino)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]-azepine; 7-Chloro-6-[4-(cyclopropanecarbonyl-amino)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]-azepine; 7-Chloro-6-{4-[(l-methyl-cyclopropanecarbonyl)-amino]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]-azepine; 7-Chloro-6-{4-[(2,2,3,3-tetramethyl-cyclopropanecarbonyl)-amino]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]-azepine; (+)-7-Chloro-6-{4-[(2-methyl-cyclopropanecarbonyl)-amino]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]-azepine; (-)-7-Chloro-6-{4-[(2-methyl-cyclopropanecarbonyl)-amino]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]-azepine; 7-Chloro-6-[4-(N-methyl-2,2-dimethyl-propionylamino)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]-azepine; 7-Chloro-6-[4-(cyclohexanecarbonyl-amino)-benzylamino]-2,3,4,5-tetrahydro-1H-benzol -azepine; 7-Chloro-6-[4-(cyclopentanecarbonyl-amino)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]-azepine; 7-Chloro-6-[4-(cycloheptanecarbonyl-amino)-benzylamino]-2,3,4,5-tetrahydro- 1H-benzo[d]-azepine; 7-Chloro-6-{4-[(2,2-dimethyl-propionylamino)-methyl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[(cyclopropanecarbonyl-amino)-methyl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d] azepine; 7-Chloro-6-{4-[2-(2,2-dimethyl-propionylamino)-ethyl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d] azepine; 7-Chloro-6-[4-(iso-propylcarbamoyl-methyl)-benzylamino]-2,3,4,5-tetrahydro- lH-benzo[d] azepine; 7-Chloro-6-{4-[(2,2-dimethylpropyl-carbamoyl)-methyl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(2-oxo-2-pyrrolidin-l-yl-ethyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; (±)-7-Chloro-6-{4-[l-(2,2-dimethylpropyl-carbamoyl)-ethyl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[(cyclohexylmethyl-carbamoyl)-methyl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[(3,3-dimethylbutyl-carbamoyl)-methyl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; (R)-7-Chloro-6-{4-[(l-methyI-2,2,2-trifluoro-ethylcarbamoyl)-methyl]-benzylamino}-2,3,4,5-tetrahydro-lH-benzo[d]azepine; 6-{4-[2-(tert-Butylcarbamoyl)-ethyl]-benzylamino}-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[2-(2,2-dimethylpropyl-carbamoyl)-ethyl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{6-[(2,2-dimethyl-propanesulfonylmethyl)-pyridin-3-ylmethyl]-amino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[(6-cyclohexanesulfonylmethyl-pyridin-3-ylmethyl)-amino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(2,2-dimethyl-propanesulfonylmethyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-(4-dimethylcarbamoylthio-benzylamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(3,3-dimethyl-2-oxobutyIthio)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[(2,2-dimethyl-propylcarbamoyl)-methylthio]-benzylamino}-2,3,4,5-tetrahydro-1 H-benzo[d]azepine; 7-Chloro-6-{[6-(3,3-dimethyl-2-oxo-butoxy)-pyridin-3-ylmethyl]-amino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-({6-[(2,2-dimethyl-propylcarbamoyl)-methoxy]-pyridin-3-ylmethyl}-amino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[5-(cycIopropylmethyl-amino)-isothiazol-3-yl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[2-(2,2,2-trifluoroethylamino-thiazol-4-yl)]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[2-(3-methyl-butylamino)-thiazol-4-yl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[2-(2,2-dimethyl-propylamino)-thiazol-4-yl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(2-cyclopentylmethylamino-thiazol-4-yl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(2-cyclohexylmethylamino-thiazol-4-yl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(2-cyclopropylmethylamino-5-methyl-thiazol-4-yl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; (R)-7-Chloro-6-{4-[2-(l-methyl-2,2,2-trifluoroethyl-amino)-thiazol-4-yl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; (S)-7-Chloro-6-{4-[2-(l-methyl-2,2,2-trifluoroethy[-amino)-thiazol-4-yl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 6-[4-(2-Benzylamino-thiazol-4-yl)-benzylamino]-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[2-(3,3,3-trifluoropropylamino)-thiazol-4-yl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{[5-(2-cyclopropylmethylamino-thiazol-4-yl)-pyridin-2-ylmethyl]-amino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{[6-(2-cyclopropylmethylamino-thiazol-4-yl)-pyridin-3-ylmethyl]-amino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[2-(cyclopropanecarbonyl-amino)-thiazol-4-yl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-[4-(l-cyclopropylmethyl-1H-pyrazol-3-yl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{[4-(3-cyclopropylmethylamino)-pyrazol-l-yl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[6-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[4-(cyclopropylmethyl-amino)-pyrimidin-2-yl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 7-Chloro-6-{4-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-benzylamino}-2,3,4,5-tetrahydro-lH-benzo[d]azepine; 7-Chloro-6-{4-[5-(3,3-dimethylbutyryl)-thiophen-2-yl]-benzylamino}-2,3,4,5-tetrahydro-1H-benzo[of]azepine; 7-Chloro-6-{[6-(2,2-dimethylpropane-sulfonyl)-pyridin-3-yl-methyl]-amino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine; and 7-Chloro-6-[4-(2,2,2-trifluoroethylthio-methylcarbonyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine; or a pharmaceutically acceptable salt thereof. 3. The compound as claimed in claim 1 which is 7-Chloro-6-[4-(2-cyclopropylmethylamino-thiazol-4-yl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine, or a pharmaceutically acceptable salt thereof. 4. The compound as claimed in claim 1 which is 7-Chloro-6-{6-[(3,3-dimethyl-cyclohexyloxy)-pyridin-3-ylmethyl]-amino}-2,3,4,5-tetrahydro-1H-benzo[d]azepine, or a pharmaceutically acceptable salt thereof. 5.The compound as claimed in claim 1 which is 7-Chloro-6-[4-(piperidin-l-ylmethyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine, or a pharmaceutically acceptable salt thereof. 6.A pharmaceutical composition comprising a compound as claimed in any one of claims 1-5, or a pharmaceutically acceptable salt thereof, as an active ingredient in association with a pharmaceutically acceptable carrier, diluent or excipient.